Form 10-Q

Large accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Accelerated filer

Emerging growth company

0001193125-17-164160.txt : 20170509 0001193125-17-164160.hdr.sgml : 20170509 20170509160550 ACCESSION NUMBER: 0001193125-17-164160 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170509 DATE AS OF CHANGE: 20170509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORASURE TECHNOLOGIES INC CENTRAL INDEX KEY: 0001116463 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 364370966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16537 FILM NUMBER: 17826380 BUSINESS ADDRESS: STREET 1: 150 WEBSTER ST CITY: BETHLEHEM STATE: PA ZIP: 18015 BUSINESS PHONE: 5036416115 MAIL ADDRESS: STREET 1: 150 WEBSTER ST CITY: BETHLEHEM STATE: PA ZIP: 18015 10-Q 1 d377587d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017.

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number 001-16537

ORASURE TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

36-4370966

(State or Other Jurisdiction of

Incorporation or Organization)

(IRS Employer

Identification No.)


220 East First Street, Bethlehem, Pennsylvania		18015
(Address of Principal Executive Offices)		(Zip code)

(610) 882-1820

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company, ” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of shares of Common Stock, par value $.000001 per share, outstanding as of May 4, 2017: 57,762,761 shares.

PART I. FINANCIAL INFORMATION


	Page No.

Item 1. Financial Statements (unaudited)

Consolidated Balance Sheets at March 31, 2017 and December 31, 2016		3

Consolidated Statements of Income for the three months ended March 31, 2017 and 2016		4

Consolidated Statements of Comprehensive Income for the three months ended March 31, 2017 and 2016		5

Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and 2016		6

Notes to the Consolidated Financial Statements		7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		19

Item 3. Quantitative and Qualitative Disclosures About Market Risk		28

Item 4. Controls and Procedures		28

PART II. OTHER INFORMATION

Item 1. Legal Proceedings		29

Item 1A. Risk Factors		30

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		31

Item 3. Defaults Upon Senior Securities		31

Item 4. Mine Safety Disclosures		31

Item 5. Other Information		31

Item 6. Exhibits		31

Signatures		32

- 2-

Item 1.

FINANCIAL STATEMENTS

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except per share amounts)


	March 31, 2017			December 31, 2016
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	120,851		$	107,959
Restricted cash		1,831			1,831
Short-term investments		18,776			11,160
Accounts receivable, net of allowance for doubtful accounts of $588 and $484		24,005			19,827
Inventories		12,707			11,799
Prepaid expenses		1,732			1,722
Other current assets		633			2,143

Total current assets		180,535			156,441

PROPERTY AND EQUIPMENT, net		20,134			20,033

INTANGIBLE ASSETS, net		9,779			10,337

GOODWILL		18,971			18,793

OTHER ASSETS		3,173			2,331

	$	232,592		$	207,935

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:
Accounts payable	$	7,286		$	4,633
Deferred revenue		1,306			1,388
Accrued expenses		9,685			11,314

Total current liabilities		18,277			17,335

OTHER LIABILITIES		3,160			2,304

DEFERRED INCOME TAXES		2,330			2,446

COMMITMENTS AND CONTINGENCIES (Note 7)

STOCKHOLDERS’ EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued		—			—
Common stock, par value $.000001, 120,000 shares authorized, 57,664 and 56,001 shares issued and outstanding		—			—
Additional paid-in capital		360,612			350,528
Accumulated other comprehensive loss		(13,770	)		(14,220	)
Accumulated deficit		(138,017	)		(150,458	)

Total stockholders’ equity		208,825			185,850

	$	232,592		$	207,935

See accompanying notes to the consolidated financial statements.

- 3-

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(in thousands, except per share amounts)


	Three Months Ended March 31,
	2017			2016
NET REVENUES:
Product	$	31,482		$	25,245
Other		1,064			3,844

		32,546			29,089

COST OF PRODUCTS SOLD		12,236			8,776

Gross profit		20,310			20,313

OPERATING EXPENSES:
Research and development		2,970			2,366
Sales and marketing		6,877			8,706
General and administrative		7,092			6,542
Gain on litigation settlement		(12,500	)		—

		4,439			17,614

Operating income		15,871			2,699

OTHER INCOME (EXPENSE)		467			(192	)

Income before income taxes		16,338			2,507

INCOME TAX EXPENSE		3,897			61

NET INCOME	$	12,441		$	2,446

EARNINGS PER SHARE:
BASIC	$	0.22		$	0.04

DILUTED	$	0.21		$	0.04

SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC		56,929			55,451

DILUTED		58,772			56,079

See accompanying notes to the consolidated financial statements.

- 4-

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(in thousands)


	Three Months Ended March 31,
	2017		2016
NET INCOME	$	12,441	$	2,446

OTHER COMPREHENSIVE INCOME

Currency translation adjustments		450		2,867

COMPREHENSIVE INCOME	$	12,891	$	5,313

See accompanying notes to the consolidated financial statements.

- 5-

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)


	Three Months Ended March 31,
	2017			2016
OPERATING ACTIVITIES:
Net income	$	12,441		$	2,446
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation		1,518			1,452
Depreciation and amortization		1,408			1,354
Amortization of lease incentives		(20	)		(19	)
Amortization of debt issue costs		31			—
Unrealized foreign currency (gain) loss		(1	)		141
Deferred income taxes		(139	)		(18	)
Changes in assets and liabilities
Accounts receivable		(4,143	)		2,489
Inventories		(893	)		990
Prepaid expenses and other assets		1,505			26
Accounts payable		2,619			758
Deferred revenue		(84	)		(2,504	)
Accrued expenses and other liabilities		(1,623	)		(2,371	)

Net cash provided by operating activities		12,619			4,744

INVESTING ACTIVITIES:
Purchases of short-term investments		(7,514	)		(7,689	)
Proceeds from maturities of short-term investments		—			7,689
Purchases of property and equipment		(878	)		(1,593	)

Net cash used in investing activities		(8,392	)		(1,593	)

FINANCING ACTIVITIES:
Proceeds from exercise of stock options		9,417			—
Repurchase of common stock		(851	)		(3,187	)

Net cash provided by (used in) financing activities		8,566			(3,187	)

EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH		99			500

NET INCREASE IN CASH AND CASH EQUIVALENTS		12,892			464

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		107,959			94,094

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	120,851		$	94,558

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	$	1,949		$	84

Noncash investing activities (accrued property and equipment purchases)	$	297		$	444

See accompanying notes to the consolidated financial statements.

- 6-

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(Unaudited)

(in thousands, except per share amounts, unless otherwise indicated)

1.	The Company

We develop, manufacture, market and sell diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care, tests that are processed in a laboratory, and include a rapid point-of-care HIV in-home test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market and a rapid point-of-care HIV self-test used in certain international markets. We also manufacture and sell devices used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomic, personalized medicine, microbiome and animal genetic markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet.

2.	Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies, accruals, and performance- based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

- 7-

Our available-for-sale securities as of March 31, 2017 and December 31, 2016 consisted of guaranteed investment certificates with amortized cost and fair value of $18,776 and $11,160, respectively.

Fair Value of Financial Instruments. As of March 31, 2017 and December 31, 2016, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Included in cash and cash equivalents at March 31, 2017 and December 31, 2016, was $82,142 and $83,704 invested in government money market funds. These funds have investments in government securities and are Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2017 and December 31, 2016 was $2,828 and $1,980, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

All of our available-for-sale securities are measured as Level 1 instruments as of March 31, 2017 and December 31, 2016.

In 2017, we purchased certificates of deposit (“CD”) from a commercial bank. The CDs bear interest at an annual rate ranging from 0.28% to 0.44% and mature monthly through February 28, 2018. The carrying values of the CDs approximate their fair value. These CDs serve as collateral for certain standby letters of credit and are reported as restricted cash on the accompanying consolidated balance sheets. Also see Note 7 – Commitments and Contingencies.

Inventories. Inventories are stated at the lower of cost and net realizable value determined on a first-in, first-out basis and are comprised of the following:


	March 31, 2017		December 31, 2016
Raw materials	$	5,024	$	5,399
Work in process		1,035		1,034
Finished goods		6,648		5,366

	$	12,707	$	11,799

- 8-

forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income. Accumulated depreciation of property and equipment as of March 31, 2017 and December 31, 2016 was $36,856 and $36,067, respectively.

Intangible Assets. Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of seven to fifteen years. Accumulated amortization of intangible assets as of March 31, 2017 and December 31, 2016 was $15,944 and $15,197, respectively. The change in intangibles from $10,337 as of December 31, 2016 to $9,779 as of March 31, 2017 is a result of $637 in amortization expense and $79 in foreign currency translation gains.

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with the respective carrying values.

We performed our last annual impairment assessment as of July 31, 2016 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2017, we believe no indicators of impairment exist.

The change in goodwill from $18,793 as of December 31, 2016 to $18,971 as of March 31, 2017 is a result of foreign currency translation.

Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for sales of our OraQuick^® In-Home HIV test to the retail trade, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

Our net revenues recorded on sales of the OraQuick^® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate. Other customer allowances are at contractual rates and are recorded as a reduction of gross revenue when recognized in our consolidated statements of income.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

- 9-

States. On June 30, 2016, we mutually agreed to terminate our agreement with AbbVie effective December 31, 2016. Following the termination of the agreement, AbbVie was relieved of its co-promotion obligations, including its obligation to detail the OraQuick^® HCV Rapid Test into physician offices, and has no further financial obligations to us. We are no longer obligated to compensate AbbVie for product detailing activities and are free to pursue arrangements with other pharmaceutical companies to market and promote our OraQuick^® HCV Rapid Antibody Test in the U.S. Accordingly, during the first quarter of 2017 we did not record any revenue from this co-promotion agreement. During the first quarter of 2016, $3,362 in exclusivity revenue was recognized and was recorded as other revenue in our consolidated statements of income.

On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick^® Ebola Rapid Antigen test. The three-year, multi-phased grant includes an initial commitment of $1,800 and options for up to an additional $8,600 to fund certain clinical and regulatory activities. In September 2015, BARDA exercised an option to provide $7,200 in additional funding for the development of our OraQuick^® Ebola Rapid Antigen test. Amounts related to this grant are recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the first quarters of 2017 and 2016, $420 and $482, respectively, was recognized in connection with this grant.

In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The six-year, multi-phased contract includes an initial commitment of $7,000 and options for up to an additional $9,600 to fund the evaluation of additional product enhancements, and clinical and regulatory activities. Funding received under this contract is recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the first quarter of 2017, $644 was recognized in connection with this grant.

Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick^® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick^® In-Home HIV product revenues in our consolidated statements of income. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2017 and December 31, 2016, the reserve for sales returns and allowances was $235 and $217, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March 31, 2017 and December 31, 2016 includes customer prepayments of $1,306 and $1,388, respectively.

Customer and Vendor Concentrations. One of our customers accounted for 22% of our accounts receivable as of March 31, 2017. Another customer accounted for 15% of our accounts receivable as of December 31, 2016. We had no significant concentrations in net consolidated revenues for the three months ended March 31, 2017. One of our customers accounted for approximately 12% of our net consolidated revenues for the three months ended March 31, 2016.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

- 10-

include shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock, and performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings per share are as follows:


	Three Months Ended March 31,
	2017		2016
Net income	$	12,441	$	2,446

Weighted average shares of common stock outstanding:
Basic		56,929		55,451
Dilutive effect of stock options and restricted stock		1,843		628

Diluted		58,772		56,079

Earnings per share:
Basic	$	0.22	$	0.04

Diluted	$	0.21	$	0.04

For the three-month periods ended March 31, 2017 and 2016, outstanding common stock options, unvested restricted stock, and unvested performance units representing 666 and 4,843 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange losses resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $(200) and $(346) for the three months ended March 31, 2017 and 2016, respectively.

Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive income (loss) separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheet.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $450 and $2,867 currency translation adjustments recorded in the first three months of 2017 and 2016, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars.

Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09, Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, at which point we plan to adopt the standard.

- 11-

The FASB allows two adoption methods under ASU 2014-09. We plan to adopt the standard using the “modified retrospective method.” Under that method, we will apply the rules to all contracts existing as of January 1, 2018, recognizing in beginning retained earnings an adjustment for the cumulative effective of the change and providing additional disclosures comparing results to previous accounting standards.

Upon initial evaluation, we believe the key changes in the standard that impact our revenue recognition relate to the allocation of the transaction price to performance obligations related to our device and lab services for drug testing. This revenue stream amounts to less than 1% of total consolidated revenues. We will continue to evaluate the impact that the adoption of ASU 2014-09 will have on our consolidated financial statements and related disclosures, but do not anticipate the adoption to have a material impact on our financial results.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory, which requires an entity that uses the first-in, first-out method for inventory measurement to report inventory cost at the lower of cost and net realizable value versus the current measurement principle of lower of cost or market. The ASU requires prospective adoption for inventory measurements for fiscal years beginning after December 15, 2016. We adopted ASU 2015-11 on January 1, 2017. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to begin recording assets and liabilities from leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, using a modified retrospective approach. Early adoption is permitted. We are evaluating the effect that ASU 2016-02 may have on our consolidated financial statements and related disclosures.

In March 2016, the FASB issued authoritative guidance under ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 provides for simplification of several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted ASU 2016-09 on January 1, 2017. Since we have a full valuation allowance against our net deferred tax assets, the adoption of this standard for recognition of tax effects of deductions for employee share awards in excess of compensation costs (‘windfall”) did not have a material impact on our consolidated financial statements and related disclosures. See Note 6 – Income Taxes, for additional information. Should the full valuation allowance be reversed in future periods the adoption of this new guidance will introduce more volatility to our effective tax rate depending on the Company’s share price at exercise or vesting of share-based awards compared to grant date. The other provisions of ASU 2016-09 did not have a material impact on our consolidated financial statements and related disclosures.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides guidance related to cash flows presentation and is effective for annual reporting periods beginning after December 15, 2017, subject to early adoption. The majority of the guidance in ASU 2016-15 is consistent with our current cash flow classifications and we do not expect the adoption of this standard will have a material impact on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which requires an entity to no longer perform a hypothetical purchase price allocation to measure goodwill impairment. Instead, impairment will be measured using the difference between the carrying amount and the fair value of the reporting unit. This update will be effective for annual and interim periods in fiscal years beginning after December 15, 2019. Early adoption is permitted. We are currently assessing the impact of the future adoption of this standard on our consolidated financial statements and related disclosures.

- 12-

3.	Accrued Expenses


	March 31, 2017		December 31, 2016
Payroll and related benefits	$	3,905	$	7,685
Income taxes payable		2,045		(39	)
Royalties		688		982
Professional fees		686		715
Other		2,361		1,971

	$	9,685	$	11,314

4.	Credit Facility

On September 30, 2016, we entered into a credit agreement (the “Credit Agreement”) with a commercial bank. The Credit Agreement provides for revolving extensions of credit in an initial aggregate amount of up to $10,000 (inclusive of a letter of credit subfacility of $2,500), with an option to request, prior to the second anniversary of the closing date, that the lender, at its election, provide up to $5,000 of additional revolving commitments. Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets. There were no borrowings outstanding under the Credit Agreement at March 31, 2017 and December 31, 2016.

Borrowings under the Credit Agreement are subject to compliance with borrowing base limitations tied to eligibility of accounts receivable. Interest under the Credit Agreement is payable at the London Interbank Offered Rate for one, two, three or six-month loans, as selected by the Company, plus 2.50% per year. The Credit Agreement is subject to an unused line fee of 0.375% per year on the unused portion of the commitment under the Credit Agreement during the revolving period. The maturity date of the Credit Agreement is September 30, 2019.

In connection with the Credit Agreement, under certain circumstances, we must comply with a minimum fixed charge coverage ratio of 1.10 to 1.00, measured as of the last day of each fiscal month and for the twelve-fiscal month period ending on such date. As of March 31, 2017 and December 31, 2016, we were in compliance with all applicable covenants in the Credit Agreement.

5.	Stockholders’ Equity

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options or to issue restricted stock, or redeem performance-based restricted stock units, we issue new shares rather than purchase shares on the open market.

Total compensation cost related to stock options for the three months ended March 31, 2017 and 2016 was $502 and $733, respectively. Net cash proceeds from the exercise of stock options were $9,417 and $0 for the three months ended March 31, 2017 and 2016, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.

- 13-

The following table summarizes the stock option activity for the first three months ended March, 31, 2017:


	Options
Outstanding on January 1, 2017		5,456
Granted		191
Exercised		(1,462	)
Expired		(27	)
Forfeited		(19	)

Outstanding on March 31, 2017		4,139

Compensation cost of $655 and $719 related to restricted shares was recognized during the three months ended March 31, 2017 and 2016, respectively. In connection with the vesting of restricted shares and exercise of stock options during the three months ended March 31, 2017 and 2016, we purchased and immediately retired 96 and 98 shares with aggregate values of $851 and $527, respectively, in satisfaction of minimum tax withholding and exercise obligations.

The following table summarizes restricted stock award activity for the three months ended March 31, 2017:


	Shares
Issued and unvested, January 1, 2017		750
Granted		288
Vested		(297	)
Forfeited		(4	)

Issued and unvested, March 31, 2017		737

Commencing in 2016, we granted to certain executives performance-based restricted stock units (“PSUs”). Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also remain in our service for three years from the grant date. Performance during the one-year period will be based on a one-year earnings per share target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested. Upon grant of the PSUs, we recognize compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate.

Compensation cost of $361 related to PSUs was recognized during the three months ended March 31, 2017. No compensation cost related to the PSUs was recognized during the three months ended March, 31, 2016.

The following table summarizes PSU activity for the three months ended March 31, 2017:


	Units
Issued and unvested, January 1, 2017		456
Granted		229
Vested		—
Forfeited		—

Issued and unvested, March 31, 2017		685

- 14-

Stock Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the three months ended March 31, 2017. During the three months ended March 31, 2016, we purchased and retired 423 shares of common stock at an average price of $6.29 per share for a total cost of $2,660, respectively.

6.	Income Taxes

During the three months ended March 31, 2017 and 2016, we recorded tax expense of $3,897 and $61, respectively.

Tax expense reflects taxes due to state and Canadian taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of March 31, 2017 relate to the tax effects of the basis difference between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes. Tax expense in the first quarter of 2017 reflects the additional Canadian taxes due as a result of the $12,500 gain from the settlement of the Ancestry litigation.

In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate as of both March 31, 2017 and December 31, 2016 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state deferred income tax expense or benefit was recorded for the three-month periods ended March 31, 2017 and 2016.

The new accounting guidance under ASU 2016-09 allows for the recognition of excess tax benefits regardless of whether the deduction reduces taxes payable. On January 1, 2017, we recorded a cumulative-effect adjustment to retained earnings of $3,391 to recognize the increase in our net operating loss carryforwards from the cumulative excess tax benefits not recognized in periods prior to January 1, 2017. A corresponding $3,391 increase to our valuation allowance associated with this tax benefit was also recorded to retained earnings thereby recording a net impact to retained earnings of $0.

7.	Commitments and Contingencies

Standby Letters of Credit

In 2016, we established four standby letters of credit in the aggregate amount of $1,831, naming international customers as the beneficiaries. These letters of credit were required as a performance guarantee of our obligations under our product supply contracts with those customers and are collateralized by certificates of deposit maintained at a commercial bank.

Litigation

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

In May 2015, our subsidiary DNAG filed a complaint in the United States District Court for the District of Delaware against Ancestry.com DNA LLC (“Ancestry”) relating to the manufacture and sale by Ancestry of its oral fluid DNA collection device (the “Ancestry Device”). Ancestry previously purchased DNAG’s patented oral fluid DNA collection devices. The complaint alleged that the manufacture and sale by Ancestry of the Ancestry Device infringes U.S. Patent No. 8,221,381 B2, which is owned by DNAG. In addition, the complaint alleged that Ancestry has breached the terms of agreements under which Ancestry previously purchased DNAG products. The complaint also included an action to quiet title to the Ancestry Device and related patent applications. DNAG requested the court to grant injunctive relief and damages.

On October 20, 2015, Ancestry filed with the United States Patent and Trademark Office (“USPTO”) a Petition for Inter Partes Review (“IPR”) of some, but not all, claims of U.S. Patent No. 8,221,381 B2. On April 8, 2016, the USPTO instituted an IPR of some, but not all, of the claims raised in Ancestry’s petition. On June 3, 2016, Ancestry filed a second Petition for IPR of some, but not all, of the claims of U.S. Patent No. 8,221,381 B2.

- 15-

In July 2015, DNAG filed a complaint in the United States District Court for the District of Delaware against Spectrum DNA, Spectrum Solutions L.L.C. and Spectrum Packaging L.L.C. (collectively “Spectrum”) relating to the manufacture and sale by Spectrum of an oral fluid DNA collection device (the “Spectrum Device”). The Spectrum Device is the same as the Ancestry device mentioned above and Spectrum is the manufacturer of the Ancestry Device for Ancestry. The complaint alleged that the manufacture and sale by Spectrum of the Spectrum Device infringes U.S. patent number 8,221,381 B-2, which is owned by DNAG. DNAG requested the court to grant injunctive relief and damages. Spectrum filed a motion to dismiss this lawsuit on the grounds that the Delaware District Court lacked jurisdiction over Spectrum. The Court granted Spectrum’s motion to dismiss for lack of personal jurisdiction.

On June 20, 2016, DNAG filed a complaint in the United States District Court for the Southern District of California against Spectrum relating to the manufacture and sale of the Spectrum Device. The complaint alleged that the manufacture and sale by Spectrum of the Spectrum Device infringes U.S. Patent No. 9,207,164, which is owned by DNAG. DNAG requested the court to grant injunctive relief and damages. On June 21, 2016, DNAG filed a motion for preliminary injunction. On July 21, 2016, Spectrum filed a motion to stay the case pending resolution by the PTO of a Petition for IPR of U.S. Patent No. 9,207,164, which was filed by Ancestry in July 2016. On October 6, 2016, the Court issued an order denying DNAG’s motion for preliminary injunction and on October 7, 2016, the Court issued an order staying the case pending resolution of the IPR of U.S. Patent No. 9,207,164.

Effective February 6, 2017, DNAG settled the foregoing litigation with Ancestry and Spectrum. Under a Settlement and License Agreement executed by the parties, Ancestry agreed to pay DNAG a settlement fee of $12,500. This settlement amount has been recorded as a separate line item and a reduction of our operating expenses in our consolidated statements of income. In addition, DNAG granted Ancestry a royalty-bearing, non-exclusive, worldwide license to certain patents and patent applications related to the collection of DNA in human saliva. The license granted to Ancestry is limited to saliva DNA collection kits sold or used as part of Ancestry’s genetic testing service offerings and does not cover the sale or use of collection kits outside of Ancestry’s business. The Settlement and License Agreement also provides DNAG with a royalty-free, non-exclusive license to patents related to Ancestry’s existing saliva DNA collection kit and certain modifications thereto.

The parties have each agreed to a mutual release of claims and other provisions typical for settlement agreements of this type. Pursuant to the terms of the Settlement and License Agreement, the pending federal lawsuits in the District of Delaware and the Southern District of California have been dismissed and the IPR proceedings before the USPTO involving the DNAG patents asserted in the litigation have been terminated.

8.	Business Segment Information

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of diagnostic products, specimen collection devices and medical devices; and our molecular collection systems or “DNAG” business, which primarily consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet. OSUR also derives other revenues, including exclusivity payments for co-promotion rights and other licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of customers engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, microbiome, and animal genetic testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals.

- 16-

policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the three months ended March 31, 2017 and 2016, and asset information as of March 31, 2017 and December 31, 2016:


	Three Months Ended March 31,
	2017			2016
Net revenues:
OSUR	$	21,840		$	22,199
DNAG		10,706			6,890

Total	$	32,546		$	29,089

Operating income (loss):
OSUR	$	(219	)	$	1,608
DNAG		16,090			1,091

Total	$	15,871		$	2,699

Depreciation and amortization:
OSUR	$	625		$	639
DNAG		783			715

Total	$	1,408		$	1,354

Capital expenditures:
OSUR	$	784		$	447
DNAG		94			1,146

Total	$	878		$	1,593


	March 31, 2017			December 31, 2016
Total assets:
OSUR	$	161,730		$	151,719
DNAG		70,862			56,216

Total	$	232,592		$	207,935

Our products are sold principally in the United States and Europe.

The following table represents total net revenues by geographic area, based on the location of the customer:


	Three Months Ended March 31,
	2017		2016
United States	$	20,854	$	22,170
Europe		3,125		3,879
Other regions		8,567		3,040

	$	32,546	$	29,089

- 17-

The following table represents total long-lived assets by geographic area:


	March 31, 2017		December 31, 2016
United States	$	15,886	$	15,737
Canada		4,238		4,286
Other regions		10		10

	$	20,134	$	20,033

- 18-

Item 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements below regarding future events or performance are “forward-looking statements” within the meaning of the Federal securities laws. These may include statements about our expected revenues, earnings/loss per share, net income (loss), expenses, cash flow or other financial performance or developments, clinical trial or development activities, expected regulatory filings and approvals, planned business transactions, views of future industry, competitive or market conditions, and other factors that could affect our future operations, results of operations or financial position. These statements often include the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “may,” “will,” “should,” “could,” or similar expressions. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; impact of increased reliance on U.S. government contracts; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of negative economic conditions, high unemployment levels and poor credit conditions; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; history of losses and ability to achieve sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to meet financial covenants in credit agreements; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in our Securities and Exchange Commission (“SEC”) filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2016, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this Report, and we undertake no duty to update these statements.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, we have a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of OraSure.

- 19-

The following discussion should be read in conjunction with our consolidated financial statements contained herein and the notes thereto, along with the Section entitled “Critical Accounting Policies and Estimates,” set forth below.

Overview

We develop, manufacture, market and sell diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care, tests that are processed in a laboratory, a rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market and a rapid point-of-care HIV self-test used in certain interational markets. We also manufacture and sell collection devices used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomic, personalized medicine, microbiome and animal genetic markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet.

Recent Developments

Litigation Settlement

Effective February 6, 2017, we settled our patent infringement and breach of contract litigation against Ancestry.com DNA LLC (“Ancestry”) and its contract manufacturer. Under a Settlement and License Agreement executed by the parties, Ancestry agreed to pay a settlement fee of $12.5 million which we received in the first quarter of 2017 and recorded as a gain on litigation settlement in our consolidated statements of income. In addition, we granted Ancestry a royalty-bearing, non-exclusive, worldwide license to certain patents and patent applications related to the collection of DNA in human saliva. The license granted to Ancestry is limited to saliva DNA collection kits sold or used as part of Ancestry’s genetic testing service offerings and does not cover the sale or use of collection kits outside of Ancestry’s business. The Settlement and License Agreement also provides us with a royalty-free, non-exclusive license to patents related to Ancestry’s existing saliva DNA collection kit and certain modifications thereto.

New Genomics Contract

We recently entered into a contract to supply over $20 million of our DNA saliva collection kits over a period greater than 12 months with one of our genomics customers. This is the largest product supply contract in the history of our molecular business.

Current Consolidated Financial Results

During the three months ended March 31, 2017, our consolidated net revenues were $32.5 million, compared to $29.1 million for the three months ended March 31, 2016. Net product revenues during the three months ended March 31, 2017 increased 25% when compared to the first three months of 2016, primarily due to higher sales of our molecular products and higher international sales of our professional OraQuick^® HIV self-test and OraQuick^® HCV product, partially offset by lower domestic sales of our OraQuick^® HIV and HCV products and our cryosurgical products. Other revenues for the first three months of 2017 were $1.1 million compared to $3.8 million in the same period of 2016. Other revenues in the first quarter of 2017 represent revenue recognized in connection with funding received from the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) for our Ebola and Zika products. Other revenues in the first quarter of 2016 included $482,000 of BARDA funding and $3.4 million of exclusivity revenues recognized under our HCV co-promotion agreement with AbbVie, which terminated effective December 31, 2016.

- 20-

Our consolidated net income for the three months ended March 31, 2017 was $12.4 million, or $0.21 per share on a fully-diluted basis, compared to consolidated net income of $2.4 million, or $0.04 per share on a fully-diluted basis, for the three months ended March 31, 2016. Results for the current quarter include a pre-tax gain of $12.5 million associated with the Ancestry settlement, as described above.

Cash provided by operating activities for the three months ended March 31, 2017 was $12.6 million and included the $12.5 million litigation settlement noted above. Cash provided by operating activities during the three months ended March 31, 2016 was $4.7 million. As of March 31, 2017, we had $141.5 million in cash (including restricted cash), cash equivalents, and short-term investments compared to $120.9 million at December 31, 2016.

Business Segments

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices, and our “DNAG” or molecular collection systems business, which consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold into the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies, mass merchandisers and consumers over the internet. DNAG revenues result from products sold into the commercial market, which consists of customers engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, microbiome and animal genetic testing, as well as products sold into the academic research market which consists of research laboratories, universities and hospitals.

Results of Operations

Three months ended March 31, 2017 compared to March 31, 2016

CONSOLIDATED NET REVENUES

The table below shows a breakdown of total consolidated net revenues (dollars in thousands) generated by each of our business segments for the three months ended March 31, 2017 and 2016.


	Three Months Ended March 31,
	Dollars							Percentage of Total Net Revenues
	2017		2016		% Change			2017			2016
OSUR	$	20,776	$	18,355		13	%		64	%		63	%
DNAG		10,706		6,890		55			33			24

Net product revenues		31,482		25,245		25			97			87
Other		1,064		3,844		(72	)		3			13

Net revenues	$	32,546	$	29,089		12	%		100	%		100	%

Consolidated net product revenues increased 25% to $31.5 million in the first quarter of 2017 from $25.2 million in the comparable period of 2016. Higher sales of our molecular products and increased international sales of our OraQuick^® HIV self-test and OraQuick^®HCV product, were partially offset by lower domestic sales of our OraQuick^® HIV and HCV products and lower sales of our cryosurgical products. In the first quarter of 2017, we recognized $1.1 million as other revenues in connection with funding from BARDA related to our Ebola and Zika products. Other revenues in the first quarter of 2016 were $3.8 million and included $3.4 million in exclusivity payments received under our HCV co-promotion agreement with AbbVie and $482,000 recognized in connection with funding from BARDA. Our co-promotion agreement with AbbVie was terminated effective as of December 31, 2016 and no further revenues under this agreement will be recognized.

- 21-

Consolidated net revenues derived from products sold to customers outside of the United States were $11.7 million and $6.9 million, or 36% and 24% of total net revenues, in the first quarters of 2017 and 2016, respectively. Because the majority of our international sales are denominated in U.S. dollars, the impact of fluctuating foreign currency exchange rates was not material to our total consolidated net revenues.

Net Revenues by Segment

OSUR Segment

The table below shows a breakdown of total net revenues (dollars in thousands) generated by our OSUR segment.


	Three Months Ended March 31,
	Dollars							Percentage of Total Net Revenues
Market	2017		2016		% Change			2017			2016
Infectious disease testing	$	14,583	$	11,368		28	%		67	%		51	%
Risk assessment testing		3,130		3,105		1			14			14
Cryosurgical		3,063		3,882		(21	)		14			18

Net product revenues		20,776		18,355		13			95			83
Other		1,064		3,844		(72	)		5			17

Net revenues	$	21,840	$	22,199		(2	)%		100	%		100	%

Infectious Disease Testing Market

Sales to the infectious disease testing market increased 28% to $14.6 million in the first quarter of 2017 from $11.4 million in the first quarter of 2016. This increase resulted from higher international sales of our OraQuick^® HIV self-test and OraQuick^®HCV product, partially offset by a decline in domestic sales of our OraQuick^® HIV and HCV products.

The table below shows a breakdown of our total net OraQuick^® HIV and HCV product revenues (dollars in thousands) during the first quarters of 2017 and 2016.


	Three Months Ended March 31,
Market	2017		2016		% Change
Domestic HIV	$	3,812	$	5,703		(33	)%
International HIV		2,644		854		210
Domestic OTC HIV		1,542		1,523		1

Net HIV revenues		7,998		8,080		(1	)

Domestic HCV		1,709		1,900		(10	)
International HCV		4,402		1,001		340

Net HCV revenues		6,111		2,901		111

Net OraQuick^® HIV and HCV product revenues	$	14,109	$	10,981		28	%

Domestic OraQuick^® HIV sales decreased 33% to $3.8 million for the three months ended March 31, 2017 from $5.7 million for the three months ended March 31, 2016. This decrease was primarily the result of customer ordering patterns and continued price and product competition. We anticipate that future domestic sales of our professional HIV product will continue to be negatively affected as a result of Centers for Disease Control and Prevention (“CDC”) testing guidelines recommending the use of competing fourth generation automated HIV immunoassays performed in a laboratory, changes in government funding and continued product and price

- 22-

competition. International sales of our OraQuick^® HIV test during the first quarter of 2017 rose 210% to $2.6 million from $854,000 in the first quarter of 2016. This increase was largely due to the continued shipment of product in support of a HIV self-testing program in Africa, higher sales into the Middle East, and customer ordering patterns.

Sales of our OraQuick^® In-Home HIV test remained consistent at $1.5 million during the first quarters of 2017 and 2016.

Domestic OraQuick^® HCV sales decreased 10% to $1.7 million in the first quarter of 2017 from $1.9 million in the first quarter of 2016 primarily due to customer ordering patterns. International OraQuick^® HCV sales increased 340% to $4.4 million in the first quarter of 2017 from $1.0 million in the first quarter of 2016, largely due to continued shipments of product to a foreign government to support a nationwide HCV testing and treatment program that began in November 2016, and increased sales in Africa.

International orders for both our HIV and HCV products can be sporadic in nature and are often predicated upon the availability of governmental funding, the impact of competition and other factors. As such, there is no assurance that such sales will continue at the same levels in future periods.

Risk Assessment Market

Sales to the risk assessment market remained consistent at $3.1 million in the first quarters of 2017 and 2016.

Cryosurgical Market

Sales of our cryosurgical products (which includes sales in both the physicians’ office and OTC markets) decreased 21% to $3.1 million in the first quarter of 2017 from $3.9 million in the first quarter of 2016.

The table below shows a breakdown of our total net cryosurgical revenues (dollars in thousands) generated in each market during the first quarters of 2017 and 2016.


	Three Months Ended March 31,
Market	2017		2016		% Change
Domestic professional	$	1,496	$	1,554		(4	)%
International professional		130		235		(45	)
Domestic OTC		285		378		(25	)
International OTC		1,152		1,715		(33	)

Net cryosurgical revenues	$	3,063	$	3,882		(21	)%

Sales of our Histofreezer^® product to physicians’ offices in the United States decreased 4% to $1.5 million in the first quarter of 2017 from $1.6 million in the first quarter of 2016, primarily due to distributor ordering patterns. International sales of Histofreezer^® decreased to $130,000 in the first quarter of 2017 from $235,000 in the same period of the prior year largely due to lower sales into Asia and Europe.

Sales of our private-label wart removal product in the U.S. retail market decreased to $285,000 in the first quarter of 2017 from $378,000 in the first quarter of 2016. Sales volume in the first quarter of 2016 was at a higher level as a result of inventory stocking at a new large pharmacy chain in that period. Sales levels in the first quarter of 2017 are more reflective of typical quarterly sales of the product in the U.S. retail market.

Sales of our international OTC cryosurgical products during the first quarter of 2017 decreased 33% to $1.2 million compared to $1.7 million in the first quarter of 2016, largely due to lower sales into Europe and Latin America.

- 23-

Other revenues

Other revenues in the first quarter of 2017 decreased 72% to $1.1 million from $3.8 million in the first quarter of 2016.

Other revenues in the first quarter of 2016 included AbbVie exclusivity revenues of $3.4 million. There are no similar revenues in the first quarter of 2017 due to the termination of our co-promotion agreement with AbbVie on December 31, 2016. Funding from BARDA increased to $1.1 million in the first quarter of 2017 compared to $482,000 in the first quarter of 2016.

DNAG Segment

Molecular Market

Net molecular revenues increased 55% to $10.7 million in the first quarter of 2017 from $6.9 million in the first quarter of 2016. Sales of our Oragene^® product in the commercial market rose 119% in the first quarter of 2017 compared to the first quarter of 2016, primarily as a result of higher customer demand and increased sales from new customer accounts won in the second half of 2016. Sales of our Oragene^® product in the academic market decreased 20% in the first quarter of 2017 compared to the first quarter of 2016, largely due to ordering patterns of existing customers and the absence of a one-time order which occurred in the first quarter of 2016 and did not repeat in 2017. The higher revenues in the first quarter of 2017 also included $767,000 in sales of our microbiome product compared to $162,000 in the same period of 2016. We believe interest in our microbiome product offering continues to grow with both new and existing customers.

CONSOLIDATED OPERATING RESULTS

Consolidated gross margin was 62% for the first quarter of 2017 compared to 70% for the first quarter of 2016. Gross margin in the first quarter of 2017 was negatively impacted by the absence of exclusivity revenues under our HCV co-promotion agreement with AbbVie, increased scrap and spoilage costs, and an increase in lower margin product sales in the first quarter of 2017 compared to the first quarter of 2016.

Consolidated operating income for the first quarter of 2017 was $15.9 million, a $13.2 million improvement from $2.7 million of operating income reported in the first quarter of 2016. The operating income for the first quarter of 2017 benefited from the Ancestry litigation settlement gain and lower sales and marketing costs, partially offset by higher research and development and general and administrative expenses.

OPERATING INCOME (LOSS) BY SEGMENT

OSUR Segment

OSUR’s gross margin was 60% in the first quarter of 2017 compared to 69% in the first quarter of 2016. OSUR’s gross margin in the first quarter of 2017 was negatively impacted by the absence of exclusivity revenues under our HCV co-promotion agreement with AbbVie ($3.4 million was recorded in the first quarter of 2016 and none in 2017), increased scrap and spoilage costs, and an increase in lower margin product sales in the first quarter of 2017 compared to the first quarter of 2016.

Research and development expenses increased 36% to $2.4 million in the first quarter of 2017 from $1.7 million in the first quarter of 2016, largely due to higher supply costs associated with the development of our Ebola and Zika products and increased staffing expenses. Sales and marketing expenses decreased 28% to $4.7 million in the first quarter of 2017 from $6.5 million in the first quarter of 2016. This decrease was primarily the result of the termination of our OraQuick^® HCV co-promotion agreement with AbbVie on December 31, 2016 and lower staffing costs. General and administrative expenses increased 14% to $6.3 million in the first quarter of 2017 from $5.5 million in the first quarter of 2016 due to increased staffing costs.

- 24-

All of the above contributed to OSUR’s first quarter 2017 operating loss of $219,000, which included non-cash charges of $625,000 for depreciation and amortization and $1.4 million for stock-based compensation.

DNAG Segment

DNAG’s gross margin was 67% in the first quarter of 2017 compared to 73% in the first quarter of 2016. This decline was attributable to an increase in lower margin sales in the first quarter of 2017 compared to the first quarter of 2016.

Research and development expenses decreased 4% to $603,000 in the first quarter of 2017 from $627,000 in the first quarter of 2016, largely due to lower supply costs. Sales and marketing expenses remained consistent at $2.2 million in the first quarters of each of 2017 and 2016. General and administrative expenses decreased 22% to $831,000 in the first quarter of 2017 compared to $1.1 million in the first quarter of 2016 primarily due to lower legal costs. Operating expenses in the first quarter of 2017 were offset by the $12.5 million pre-tax gain associated with the settlement of our Ancestry litigation.

All of the above contributed to DNAG’s first quarter 2017 operating income of $16.1 million, which included non-cash charges of $783,000 for depreciation and amortization and $97,000 for stock-based compensation.

CONSOLIDATED INCOME TAXES

We continue to believe the full valuation allowance established in 2008 against OSUR’s total U.S. deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed. For the three months ended March 31, 2017, state income tax expense of $31,000 was recorded compared to $0 in the three months ended March 31, 2016. Canadian income tax expense of $3.9 million and $61,000 was recorded in the first quarters of 2017 and 2016, respectively. Taxes in the first quarter of 2017 included the additional taxes due as a result of the $12.5 million Ancestry litigation settlement payment.

Liquidity and Capital Resources


	March 31,		December 31,
	2017		2016
	(In thousands)
Cash and cash equivalents	$	122,682	$	109,790
Short-term investments		18,776		11,160
Working capital		162,258		139,106

Our cash, cash equivalents, and short-term investment balances increased to $141.5 million at March 31, 2017 from $120.9 million at December 31, 2016. Our working capital increased to $162.2 million at March 31, 2017 from $139.1 million at December 31, 2016.

During the first three months of 2017, we generated $12.6 million in cash from operating activities. Our net income of $12.4 million benefitted from non-cash stock-based compensation expense of $1.5 million and depreciation and amortization expense of $1.4 million, partially offset by a net reduction of other non-cash charges of $129,000. Additional sources of cash included an increase in accounts payable of $2.6 million largely due to consulting services and inventory purchases that were invoiced at the end of the quarter, and a decrease in prepaid and other assets of $1.5 million largely due to the receipt of $1.4 million as payment of a claim from one of our raw material suppliers. This settlement was recorded as a receivable at December 31, 2016. Uses of cash in operating activities during the period include an increase in accounts receivable of $4.1 million largely resulting from longer collection periods associated with our international contracts, a decrease in accrued expenses and other liabilities of $1.6 million associated with payment of our 2016 management incentive bonuses partially offset by an increase in our Canadian income taxes payable, an increase in inventory balances of $893,000 required to meet expected demand, and a decrease in deferred revenue of $84,000.

- 25-

Net cash used in investing activities was $8.4 million for the three months ended March 31, 2017, which reflects $7.5 million used to purchase short-term investments and $878,000 to acquire property and equipment.

Net cash provided by financing activities was $8.6 million for the three months ended March 31, 2017, which resulted from $9.4 million in proceeds received from the exercise of stock options partially offset by $851,000 used for the repurchase of common stock to satisfy withholding taxes related to the vesting of restricted shares.

On September 30, 2016, we entered into a credit agreement (the “Credit Agreement”) with a commercial bank. The Credit Agreement provides for revolving extensions of credit in an initial aggregate amount of up to $10,000,000 (inclusive of a letter of credit subfacility of $2,500,000), with an option to request, prior to the second anniversary of the closing date, that lenders, at their election, provide up to $5,000,000 of additional revolving commitments. Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets. There were no borrowings outstanding at March 31, 2017 or December 31, 2016.

Borrowings under the Credit Agreement are subject to compliance with borrowing base limitations tied to eligibility of accounts receivable. Interest under the Credit Agreement is payable at the London Interbank Offered Rate for one, two, three or six-month loans, as selected by the Company, plus 2.50% per annum. The Credit Agreement will be subject to an unused line fee of 0.375% per annum on the unused portion of the commitment under the Credit Agreement during the revolving period. The maturity date of the Credit Agreement is September 30, 2019.

Our current cash and cash equivalents balance and available borrowing capacity are expected to be sufficient to fund our current operating and capital needs for the foreseeable future. Our cash requirements, however, may vary materially from those now planned due to many factors, including, but not limited to, the scope and timing of future strategic acquisitions, the progress of our research and development programs, the scope and results of clinical testing, the cost of any future litigation, the magnitude of capital expenditures, changes in existing and potential relationships with business partners, the timing and cost of obtaining regulatory approvals, the timing and cost of future stock purchases, the costs involved in obtaining and enforcing patents, proprietary rights and any necessary licenses, the cost and timing of expansion of sales and marketing activities, market acceptance of new products, competing technological and market developments, the impact of the current economic environment and other factors.

Summary of Contractual Obligations

A summary of our obligations to make future payments under contracts existing at December 31, 2016 is included in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2016. As of March 31, 2017, there were no significant changes to this information, including the absence of any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our judgments and estimates, including those related to the valuation of accounts receivable, inventories and intangible assets, as well as calculations related to contingencies and accruals. We base our judgments and estimates on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

- 26-

A more detailed review of our critical accounting policies is contained in our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC. During the first three months of 2017, there were no material changes in our critical accounting policies.

Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not hold any amounts of derivative financial instruments or derivative commodity instruments and, accordingly, we have no material derivative risk to report under this Item.

As of March 31, 2017, we did not have any foreign currency exchange contracts or purchase currency options to hedge local currency cash flows. Sales denominated in foreign currencies comprised 5.2% of our total revenues for the three months ended March 31, 2017. We do have foreign currency exchange risk related to our operating subsidiary in Canada. While the majority of this subsidiary’s revenues are recorded in U.S. dollars, almost all of this subsidiary’s operating expenses are denominated in Canadian dollars. Fluctuations in the exchange rate between the U.S. dollar and the Canadian dollar could affect year-to-year comparability of operating results and cash flows. Our Canadian subsidiary had net assets, subject to translation, of $78.4 million CDN ($58.9 million USD), which are included in the Company’s consolidated balance sheet as of March 31, 2017. A 10% unfavorable change in the Canadian-to-U.S. dollar exchange rate would have decreased our comprehensive income by $5.9 million in the three months ended March 31, 2017.

Item 4.

CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of March 31, 2017. Based on that evaluation, the Company’s management, including such officers, concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2017 to provide reasonable assurance that material information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 was accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure and was recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission.

(b) Changes in Internal Control Over Financial Reporting. There was no change in the Company’s internal control over financial reporting that occurred during the three months ended March 31, 2017 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

- 27-

PART II. OTHER INFORMATION

Item 1.

LEGAL PROCEEDINGS

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected, individually or in the aggregate, to have a material adverse effect on our future financial position or results of operations.

In July 2015, DNAG filed a complaint in the United States District Court for the District of Delaware against Spectrum DNA, Spectrum Solutions L.L.C. and Spectrum Packaging L.L.C. (collectively “Spectrum”) relating to the manufacture and sale by Spectrum of an oral fluid DNA collection device (the “Spectrum Device”). The Spectrum Device is the same as the Ancestry device mentioned above and Spectrum is the manufacturer of the Ancestry Device for Ancestry. The complaint alleged that the manufacture and sale by Spectrum of the Spectrum Device infringes U.S. patent number 8,221,381 B-2, which is owned by DNAG. DNAG is requesting the court to grant injunctive relief and damages. Spectrum filed a motion to dismiss this lawsuit on the grounds that the Delaware District Court lacked jurisdiction over Spectrum. The Court granted Spectrum’s motion to dismiss for lack of personal jurisdiction.

Effective February 6, 2017, DNAG settled the foregoing litigation with Ancestry and Spectrum. Under a Settlement and License Agreement executed by the parties, Ancestry agreed to pay DNAG a settlement fee of $12.5 million. This settlement amount has been recorded as a separate line item and a reduction of our operating expenses in our statements of income in 2017. In addition, DNAG granted Ancestry a royalty-bearing, non-exclusive, worldwide license to certain patents and patent applications related to the collection of DNA in human saliva. The license granted to Ancestry is limited to saliva DNA collection kits sold or used as part of Ancestry’s genetic testing service offerings and does not cover the sale or use of collection kits outside of Ancestry’s business. The Settlement and License Agreement also provides DNAG with a royalty-free, non-exclusive license to patents related to Ancestry’s existing saliva DNA collection kit and certain modifications thereto.

- 28-

Item 1A.

RISK FACTORS

There have been no material changes to the factors disclosed in Item 1A., entitled “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2016.

- 29-

Item 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS


Period	Total number of shares purchased			Average price paid per Share		Total number of shares purchased as part of publicly announced plans or programs		Maximum number (or approximate dollar value) of shares that may yet be repurchased under the plans or programs ^{(2, 3)}
January 1, 2017 - January 31, 2017		—			—		—		11,984,720
February 1, 2017 - February 28, 2017		—			—		—		11,984,720
March 1, 2017 - March 31, 2017		96,105	⁽¹⁾	$	8.85		N/A		11,984,720

		96,105					—

⁽¹⁾	Pursuant to the OraSure Technologies, Inc. Stock Award Plan, and in connection with the vesting of restricted shares, these shares were retired to satisfy minimum tax withholdings.

⁽²⁾	On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25.0 million of outstanding shares. This share repurchase program may be discontinued at any time.

⁽³⁾	This column represents the amount that remains available under the $25.0 million repurchase plan, as of the period indicated. We have made no commitment to purchase any shares under this plan.

Item 3.

DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable

ITEM 5.

OTHER INFORMATION

None

Item 6.

EXHIBITS

Exhibits are listed on the Exhibit Index following the signature page of this Report.

- 30-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


				ORASURE TECHNOLOGIES, INC.

				/s/ Ronald H. Spair
Date: May 9, 2017				Ronald H. Spair
				Chief Operating Officer and
				Chief Financial Officer
				(Principal Financial Officer)

				/s/Mark L. Kuna
Date: May 9, 2017				Mark L. Kuna
				Senior Vice President, Finance and Controller
				(Principal Accounting Officer)

- 31-

EXHIBIT INDEX


Exhibit Number		Exhibit

10.1		Description of the OraSure Technologies, Inc. 2017 Management Incentive Plan is incorporated by reference to Item 5.02 to the Company’s Current Report on Form 8-K filed February 24, 2017.*

10.2		Description of Long-Term Incentive Policy, as amended, is incorporated by reference to Item 5.02 to the Company’s Current Report on Form 8-K filed February 24, 2017.*

10.3		Description of Non-Employee Director Compensation Policy, as amended, is incorporated by reference to Item 5.02 to the Company’s Current Report on Form 8-K filed February 24, 2017. *

31.1		Certification of Douglas A. Michels required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2		Certification of Ronald H. Spair required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certification of Douglas A. Michels required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Ronald H. Spair required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Taxonomy Extension Labels Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

*	Management contract or compensatory plan or arrangement.

- 32-

EX-31.1 2 d377587dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification

I, Douglas A. Michels, certify that:

1.	I have reviewed this report on Form 10-Q of OraSure Technologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d –15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within the entity, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2017

/s/ Douglas A. Michels

Douglas A. Michels

President and Chief Executive Officer

(Principal Executive Officer)

- 33-

EX-31.2 3 d377587dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification

I, Ronald H. Spair, certify that:

1.	I have reviewed this report on Form 10-Q of OraSure Technologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2017

/s/ Ronald H. Spair

Ronald H. Spair

Chief Operating Officer and

Chief Financial Officer

(Principal Financial Officer)

- 34-

EX-32.1 4 d377587dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of OraSure Technologies, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Douglas A. Michels, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Douglas A. Michels

Douglas A. Michels

President and Chief Executive Officer

May 9, 2017

- 35-

EX-32.2 5 d377587dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of OraSure Technologies, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ronald H. Spair, Chief Operating Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Ronald H. Spair

Ronald H. Spair

Chief Operating Officer and Chief Financial Officer

May 9, 2017

- 36-

EX-101.INS 6 osur-20170331.xml XBRL INSTANCE DOCUMENT

25000000

57762761

94558000

2867000

6.29

3905000

0.000001

36856000

57664000

232592000

180535000

688000

120000000

360612000

588000

120851000

24005000

7286000

2828000

1306000

686000

450000

-13770000

2330000

9685000

5024000

0.000001

25000000

15944000

633000

9779000

12707000

232592000

9779000

18971000

1035000

3160000

18277000

1732000

2361000

10000000

6648000

3173000

20134000

18776000

208825000

2045000

-138017000

1831000

4139000

82142000

18776000

11160000

1.10

2500000

1831000

737000

685000

1306000

5000000 2

161730000

70862000

4238000

15886000

10000

94094000

7685000

0.000001

36067000

56001000

207935000

156441000

982000

120000000

350528000

484000

107959000

19827000

4633000

1980000

1388000

715000

-14220000

2446000

11314000

5399000

0.000001

25000000

15197000

2143000

10337000

11799000

207935000

10337000

18793000

1034000

2304000

17335000

1722000

1971000

5366000

2331000

20033000

11160000

185850000

-39000

-150458000

1831000

5456000

83704000

18776000

11160000

750000

456000

1388000

151719000

56216000

4286000

15737000

10000

3391000

12500000

P3Y 8600000 1800000 10400000

0.15

3391000

7200000 P6Y 9600000 7000000 16600000

217000

31000

ORASURE TECHNOLOGIES INC 10-Q 0001116463

2017-03-31

12892000

99000

2017 false --12-31

7092000

0.22

1408000

<div> Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted average number of shares outstanding is increased to include shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock, and performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. The computations of basic and diluted earnings per share are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net income </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,441</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,446</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Weighted average shares of common stock outstanding: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,929</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,451</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Dilutive effect of stock options and restricted stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,843</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">628</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,772</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,079</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings per share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.22</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.21</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> For the three-month periods ended March 31, 2017 and 2016, outstanding common stock options, unvested restricted stock, and unvested performance units representing 666 and 4,843 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. </div>

0.21

12891000

<div> Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive income (loss) separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheet. We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $450 and $2,867 currency translation adjustments recorded in the first three months of 2017 and 2016, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars. </div>

Accelerated Filer

637000

12236000

-200000

<div> Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated. The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results of operations expected for the full year. </div>

<div> Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange losses resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $(200) and $(346) for the three months ended March 31, 2017 and 2016, respectively. </div>

1000

<div> Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with the respective carrying values. We performed our last annual impairment assessment as of July 31, 2016 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2017, we believe no indicators of impairment exist. The change in goodwill from $18,793 as of December 31, 2016 to $18,971 as of March 31, 2017 is a result of foreign currency translation. </div>

-139000

<div> Fair Value of Financial Instruments. As of March 31, 2017 and December 31, 2016, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). Included in cash and cash equivalents at March 31, 2017 and December 31, 2016, was $82,142 and $83,704 invested in government money market funds. These funds have investments in government securities and are Level 1 instruments. We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2017 and December 31, 2016 was $2,828 and $1,980, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets. All of our available-for-sale securities are measured as Level 1 instruments as of March 31, 2017 and December 31, 2016. In 2017, we purchased certificates of deposit (“CD”) from a commercial bank. The CDs bear interest at an annual rate ranging from 0.28% to 0.44% and mature monthly through February 28, 2018. The carrying values of the CDs approximate their fair value. These CDs serve as collateral for certain standby letters of credit and are reported as restricted cash on the accompanying consolidated balance sheets. Also see Note 7 – Commitments and Contingencies. </div>

32546000

<div> Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.   Our available-for-sale securities as of March 31, 2017 and December 31, 2016 consisted of guaranteed investment certificates with amortized cost and fair value of $18,776 and $11,160, respectively. </div>

467000

-1623000

20310000

1949000

4439000

12441000

16338000

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Inventories. Inventories are stated at the lower of cost and net realizable value determined on a first-in, first-out basis and are comprised of the following: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,024</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,399</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,035</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,034</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,648</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,366</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,707</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,799</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-8392000

0.00375

450000

79000

<div> Intangible Assets. Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of seven to fifteen years. Accumulated amortization of intangible assets as of March 31, 2017 and December 31, 2016 was $15,944 and $15,197, respectively. The change in intangibles from $10,337 as of December 31, 2016 to $9,779 as of March 31, 2017 is a result of $637 in amortization expense and $79 in foreign currency translation gains. </div>

4143000

Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.

2019-09-30

12500000

851000

<div> Customer and Vendor Concentrations. One of our customers accounted for 22% of our accounts receivable as of March 31, 2017. Another customer accounted for 15% of our accounts receivable as of December 31, 2016. We had no significant concentrations in net consolidated revenues for the three months ended March 31, 2017. One of our customers accounted for approximately 12% of our net consolidated revenues for the three months ended March 31, 2016. We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations. </div>

2619000

-1505000

<div> Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09, Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, at which point we plan to adopt the standard.   The FASB allows two adoption methods under ASU 2014-09. We plan to adopt the standard using the “modified retrospective method.” Under that method, we will apply the rules to all contracts existing as of January 1, 2018, recognizing in beginning retained earnings an adjustment for the cumulative effective of the change and providing additional disclosures comparing results to previous accounting standards. Upon initial evaluation, we believe the key changes in the standard that impact our revenue recognition relate to the allocation of the transaction price to performance obligations related to our device and lab services for drug testing. This revenue stream amounts to less than 1% of total consolidated revenues. We will continue to evaluate the impact that the adoption of ASU 2014-09 will have on our consolidated financial statements and related disclosures, but do not anticipate the adoption to have a material impact on our financial results. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory, which requires an entity that uses the first-in, first-out method for inventory measurement to report inventory cost at the lower of cost and net realizable value versus the current measurement principle of lower of cost or market. The ASU requires prospective adoption for inventory measurements for fiscal years beginning after December 15, 2016.    We adopted ASU 2015-11 on January 1, 2017. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to begin recording assets and liabilities from leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, using a modified retrospective approach. Early adoption is permitted. We are evaluating the effect that ASU 2016-02 may have on our consolidated financial statements and related disclosures. In March 2016, the FASB issued authoritative guidance under ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 provides for simplification of several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted ASU 2016-09 on January 1, 2017. Since we have a full valuation allowance against our net deferred tax assets, the adoption of this standard for recognition of tax effects of deductions for employee share awards in excess of compensation costs (‘windfall”) did not have a material impact on our consolidated financial statements and related disclosures. See Note 6 – Income Taxes, for additional information. Should the full valuation allowance be reversed in future periods the adoption of this new guidance will introduce more volatility to our effective tax rate depending on the Company’s share price at exercise or vesting of share-based awards compared to grant date. The other provisions of ASU 2016-09 did not have a material impact on our consolidated financial statements and related disclosures. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides guidance related to cash flows presentation and is effective for annual reporting periods beginning after December 15, 2017, subject to early adoption. The majority of the guidance in ASU 2016-15 is consistent with our current cash flow classifications and we do not expect the adoption of this standard will have a material impact on our consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which requires an entity to no longer perform a hypothetical purchase price allocation to measure goodwill impairment. Instead, impairment will be measured using the difference between the carrying amount and the fair value of the reporting unit. This update will be effective for annual and interim periods in fiscal years beginning after December 15, 2019. Early adoption is permitted. We are currently assessing the impact of the future adoption of this standard on our consolidated financial statements and related disclosures. </div>

893000

1843000

15871000

8566000

7514000

-84000

1064000

3897000

12619000

878000

1462000

<div> Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies, accruals, and performance- based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods. </div>

31482000

<div> The following table represents total net revenues by geographic area, based on the location of the customer:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,854</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,170</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,125</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,879</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,567</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,040</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,546</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,089</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following table represents total long-lived assets by geographic area:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,886</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,737</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Canada </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,238</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,286</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,134</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,033</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

58772000

<div> Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income. Accumulated depreciation of property and equipment as of March 31, 2017 and December 31, 2016 was $36,856 and $36,067, respectively. </div>

235000

<div> The following table summarizes restricted stock award activity for the three months ended March 31, 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="90%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Issued and unvested, January 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">750</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">288</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(297</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Issued and unvested, March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">737</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The computations of basic and diluted earnings per share are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net income </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,441</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,446</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Weighted average shares of common stock outstanding: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,929</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,451</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Dilutive effect of stock options and restricted stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,843</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">628</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,772</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,079</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings per share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.22</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.21</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Inventories are stated at the lower of cost and net realizable value determined on a first-in, first-out basis and are comprised of the following: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,024</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,399</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,035</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,034</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,648</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,366</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,707</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,799</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes PSU activity for the three months ended March 31, 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="92%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Units</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Issued and unvested, January 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">456</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Issued and unvested, March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">685</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of income. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2017 and December 31, 2016, the reserve for sales returns and allowances was $235 and $217, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected. </div>

56929000

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="4%" align="left">2.</td> <td valign="top" align="left">Summary of Significant Accounting Policies</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results of operations expected for the full year.     <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies, accruals, and performance- based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Our available-for-sale securities as of March 31, 2017 and December 31, 2016 consisted of guaranteed investment certificates with amortized cost and fair value of $18,776 and $11,160, respectively. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Fair Value of Financial Instruments. As of March 31, 2017 and December 31, 2016, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Included in cash and cash equivalents at March 31, 2017 and December 31, 2016, was $82,142 and $83,704 invested in government money market funds. These funds have investments in government securities and are Level 1 instruments. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2017 and December 31, 2016 was $2,828 and $1,980, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> All of our available-for-sale securities are measured as Level 1 instruments as of March 31, 2017 and December 31, 2016. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In 2017, we purchased certificates of deposit (“CD”) from a commercial bank. The CDs bear interest at an annual rate ranging from 0.28% to 0.44% and mature monthly through February 28, 2018. The carrying values of the CDs approximate their fair value. These CDs serve as collateral for certain standby letters of credit and are reported as restricted cash on the accompanying consolidated balance sheets. Also see Note 7 – Commitments and Contingencies. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Inventories. Inventories are stated at the lower of cost and net realizable value determined on a first-in, first-out basis and are comprised of the following: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,024</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,399</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,035</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,034</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,648</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,366</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,707</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,799</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income. Accumulated depreciation of property and equipment as of March 31, 2017 and December 31, 2016 was $36,856 and $36,067, respectively. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Intangible Assets. Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of seven to fifteen years. Accumulated amortization of intangible assets as of March 31, 2017 and December 31, 2016 was $15,944 and $15,197, respectively. The change in intangibles from $10,337 as of December 31, 2016 to $9,779 as of March 31, 2017 is a result of $637 in amortization expense and $79 in foreign currency translation gains. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with the respective carrying values. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> We performed our last annual impairment assessment as of July 31, 2016 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2017, we believe no indicators of impairment exist. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The change in goodwill from $18,793 as of December 31, 2016 to $18,971 as of March 31, 2017 is a result of foreign currency translation. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for sales of our OraQuick® In-Home HIV test to the retail trade, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate. Other customer allowances are at contractual rates and are recorded as a reduction of gross revenue when recognized in our consolidated statements of income. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In June 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick® HCV test in the United States. On June 30, 2016, we mutually agreed to terminate our agreement with AbbVie effective December 31, 2016. Following the termination of the agreement, AbbVie was relieved of its co-promotion obligations, including its obligation to detail the OraQuick® HCV Rapid Test into physician offices, and has no further financial obligations to us. We are no longer obligated to compensate AbbVie for product detailing activities and are free to pursue arrangements with other pharmaceutical companies to market and promote our OraQuick® HCV Rapid Antibody Test in the U.S. Accordingly, during the first quarter of 2017 we did not record any revenue from this co-promotion agreement. During the first quarter of 2016, $3,362 in exclusivity revenue was recognized and was recorded as other revenue in our consolidated statements of income. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick® Ebola Rapid Antigen test. The three-year, multi-phased grant includes an initial commitment of $1,800 and options for up to an additional $8,600 to fund certain clinical and regulatory activities. In September 2015, BARDA exercised an option to provide $7,200 in additional funding for the development of our OraQuick® Ebola Rapid Antigen test. Amounts related to this grant are recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the first quarters of 2017 and 2016, $420 and $482, respectively, was recognized in connection with this grant. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The six-year, multi-phased contract includes an initial commitment of $7,000 and options for up to an additional $9,600 to fund the evaluation of additional product enhancements, and clinical and regulatory activities. Funding received under this contract is recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the first quarter of 2017, $644 was recognized in connection with this grant. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of income. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2017 and December 31, 2016, the reserve for sales returns and allowances was $235 and $217, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March 31, 2017 and December 31, 2016 includes customer prepayments of $1,306 and $1,388, respectively. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Customer and Vendor Concentrations. One of our customers accounted for 22% of our accounts receivable as of March 31, 2017. Another customer accounted for 15% of our accounts receivable as of December 31, 2016. We had no significant concentrations in net consolidated revenues for the three months ended March 31, 2017. One of our customers accounted for approximately 12% of our net consolidated revenues for the three months ended March 31, 2016. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted average number of shares outstanding is increased to include shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock, and performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The computations of basic and diluted earnings per share are as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net income </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,441</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,446</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Weighted average shares of common stock outstanding: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,929</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55,451</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Dilutive effect of stock options and restricted stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,843</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">628</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,772</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,079</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Earnings per share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.22</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.21</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> For the three-month periods ended March 31, 2017 and 2016, outstanding common stock options, unvested restricted stock, and unvested performance units representing 666 and 4,843 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive.     <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange losses resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $(200) and $(346) for the three months ended March 31, 2017 and 2016, respectively. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive income (loss) separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheet. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $450 and $2,867 currency translation adjustments recorded in the first three months of 2017 and 2016, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09, Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, at which point we plan to adopt the standard. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The FASB allows two adoption methods under ASU 2014-09. We plan to adopt the standard using the “modified retrospective method.” Under that method, we will apply the rules to all contracts existing as of January 1, 2018, recognizing in beginning retained earnings an adjustment for the cumulative effective of the change and providing additional disclosures comparing results to previous accounting standards. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Upon initial evaluation, we believe the key changes in the standard that impact our revenue recognition relate to the allocation of the transaction price to performance obligations related to our device and lab services for drug testing. This revenue stream amounts to less than 1% of total consolidated revenues. We will continue to evaluate the impact that the adoption of ASU 2014-09 will have on our consolidated financial statements and related disclosures, but do not anticipate the adoption to have a material impact on our financial results. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory, which requires an entity that uses the first-in, first-out method for inventory measurement to report inventory cost at the lower of cost and net realizable value versus the current measurement principle of lower of cost or market. The ASU requires prospective adoption for inventory measurements for fiscal years beginning after December 15, 2016.    We adopted ASU 2015-11 on January 1, 2017. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to begin recording assets and liabilities from leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, using a modified retrospective approach. Early adoption is permitted. We are evaluating the effect that ASU 2016-02 may have on our consolidated financial statements and related disclosures. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In March 2016, the FASB issued authoritative guidance under ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 provides for simplification of several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted ASU 2016-09 on January 1, 2017. Since we have a full valuation allowance against our net deferred tax assets, the adoption of this standard for recognition of tax effects of deductions for employee share awards in excess of compensation costs (‘windfall”) did not have a material impact on our consolidated financial statements and related disclosures. See Note 6 – Income Taxes, for additional information. Should the full valuation allowance be reversed in future periods the adoption of this new guidance will introduce more volatility to our effective tax rate depending on the Company’s share price at exercise or vesting of share-based awards compared to grant date. The other provisions of ASU 2016-09 did not have a material impact on our consolidated financial statements and related disclosures. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides guidance related to cash flows presentation and is effective for annual reporting periods beginning after December 15, 2017, subject to early adoption. The majority of the guidance in ASU 2016-15 is consistent with our current cash flow classifications and we do not expect the adoption of this standard will have a material impact on our consolidated financial statements. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which requires an entity to no longer perform a hypothetical purchase price allocation to measure goodwill impairment. Instead, impairment will be measured using the difference between the carrying amount and the fair value of the reporting unit. This update will be effective for annual and interim periods in fiscal years beginning after December 15, 2019. Early adoption is permitted. We are currently assessing the impact of the future adoption of this standard on our consolidated financial statements and related disclosures. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">   </div>

OSUR

2970000

<div> Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March 31, 2017 and December 31, 2016 includes customer prepayments of $1,306 and $1,388, respectively. </div>

9417000

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Payroll and related benefits </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,905</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,685</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Income taxes payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,045</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(39</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Royalties </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">688</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">982</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Professional fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">686</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">715</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,361</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,971</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,685</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,314</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">8.</td> <td valign="top" align="left">Business Segment Information</td> </tr> </table> We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of diagnostic products, specimen collection devices and medical devices; and our molecular collection systems or “DNAG” business, which primarily consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet. OSUR also derives other revenues, including exclusivity payments for co-promotion rights and other licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of customers engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, microbiome, and animal genetic testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals. We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated. The following table summarizes operating segment information for the three months ended March 31, 2017 and 2016, and asset information as of March 31, 2017 and December 31, 2016:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,840</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,199</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,706</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,890</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,546</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,089</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss): </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(219</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,608</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,090</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,091</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,871</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,699</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">625</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">639</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">783</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">715</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,408</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,354</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Capital expenditures: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">784</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">447</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">94</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,146</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">878</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,593</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">161,730</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">151,719</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70,862</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,216</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">232,592</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">207,935</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Our products are sold principally in the United States and Europe. The following table represents total net revenues by geographic area, based on the location of the customer:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,854</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,170</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,125</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,879</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,567</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,040</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,546</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,089</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following table represents total long-lived assets by geographic area:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,886</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,737</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Canada </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,238</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,286</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,134</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,033</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes operating segment information for the three months ended March 31, 2017 and 2016, and asset information as of March 31, 2017 and December 31, 2016:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,840</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,199</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,706</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,890</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,546</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,089</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss): </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(219</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,608</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,090</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,091</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,871</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,699</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">625</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">639</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">783</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">715</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,408</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,354</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Capital expenditures: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">784</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">447</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">94</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,146</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">878</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,593</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">161,730</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">151,719</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70,862</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,216</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">232,592</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">207,935</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes the stock option activity for the first three months ended March, 31, 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Options</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding on January 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,456</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">191</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,462</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(27</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Outstanding on March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,139</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

191000

<div> Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for sales of our OraQuick® In-Home HIV test to the retail trade, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred. Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate. Other customer allowances are at contractual rates and are recorded as a reduction of gross revenue when recognized in our consolidated statements of income. We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. In June 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick® HCV test in the United States. On June 30, 2016, we mutually agreed to terminate our agreement with AbbVie effective December 31, 2016. Following the termination of the agreement, AbbVie was relieved of its co-promotion obligations, including its obligation to detail the OraQuick® HCV Rapid Test into physician offices, and has no further financial obligations to us. We are no longer obligated to compensate AbbVie for product detailing activities and are free to pursue arrangements with other pharmaceutical companies to market and promote our OraQuick® HCV Rapid Antibody Test in the U.S. Accordingly, during the first quarter of 2017 we did not record any revenue from this co-promotion agreement. During the first quarter of 2016, $3,362 in exclusivity revenue was recognized and was recorded as other revenue in our consolidated statements of income. On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick® Ebola Rapid Antigen test. The three-year, multi-phased grant includes an initial commitment of $1,800 and options for up to an additional $8,600 to fund certain clinical and regulatory activities. In September 2015, BARDA exercised an option to provide $7,200 in additional funding for the development of our OraQuick® Ebola Rapid Antigen test. Amounts related to this grant are recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the first quarters of 2017 and 2016, $420 and $482, respectively, was recognized in connection with this grant. In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The six-year, multi-phased contract includes an initial commitment of $7,000 and options for up to an additional $9,600 to fund the evaluation of additional product enhancements, and clinical and regulatory activities. Funding received under this contract is recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the first quarter of 2017, $644 was recognized in connection with this grant. </div>

6877000

19000

1518000

27000

297000

644000 -20000

0.22

0.00

0.01

666000

0.0250

9417000

502000

851000

297000

4000

288000

655000

96000

361000

229000

P1Y

P3Y

P7Y

P2Y

P20Y

P2Y

0.0028

P15Y

P10Y

P40Y

P10Y

0.0044 420000 2018-02-28 2016-12-31

625000

21840000

-219000

784000

783000

10706000

16090000

94000

3125000

20854000

8567000

464000

500000

6542000

0.04

1354000

0.04

5313000

8776000

3362000

-346000

-141000

-18000

29089000

-192000

-2371000

20313000

84000

17614000

2446000

2507000

-1593000

2867000

7689000

-2489000

3187000

758000

-26000

-990000

628000

2699000

-3187000

7689000

-2504000

3844000

61000

4744000

1593000

25245000

56079000

55451000

2366000

8706000

1452000

444000

-19000

0.12

4843000

733000

527000

719000

98000

423

2660000

482000

639000

22199000

1608000

447000

715000

6890000

1091000

1146000

3879000

22170000

3040000

0001116463 osur:OtherForeignCountriesMember 2016-01-01 2016-03-31 0001116463 country:US 2016-01-01 2016-03-31 0001116463 us-gaap:EuropeMember 2016-01-01 2016-03-31 0001116463 osur:DNAGMember 2016-01-01 2016-03-31 0001116463 osur:OSURMember 2016-01-01 2016-03-31 0001116463 us-gaap:OtherIncomeMember 2016-01-01 2016-03-31 0001116463 osur:PerformanceBasedRestrictedStockUnitMember 2016-01-01 2016-03-31 0001116463 osur:StockRepurchaseProgramMember 2016-01-01 2016-03-31 0001116463 us-gaap:RestrictedStockMember 2016-01-01 2016-03-31 0001116463 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001116463 osur:CommonStockOptionsUnvestedRestrictedStockAndUnvestedPerformanceUnitsMember 2016-01-01 2016-03-31 0001116463 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberosur:CustomerOneMember 2016-01-01 2016-03-31 0001116463 2016-01-01 2016-03-31 0001116463 osur:OtherForeignCountriesMember 2017-01-01 2017-03-31 0001116463 country:US 2017-01-01 2017-03-31 0001116463 us-gaap:EuropeMember 2017-01-01 2017-03-31 0001116463 osur:DNAGMember 2017-01-01 2017-03-31 0001116463 osur:OSURMember 2017-01-01 2017-03-31 0001116463 osur:AbbVieMemberus-gaap:CollaborativeArrangementCopromotionMember 2017-01-01 2017-03-31 0001116463 us-gaap:CertificatesOfDepositMember 2017-01-01 2017-03-31 0001116463 us-gaap:OtherIncomeMember 2017-01-01 2017-03-31 0001116463 us-gaap:CertificatesOfDepositMemberus-gaap:MaximumMember 2017-01-01 2017-03-31 0001116463 us-gaap:FurnitureAndFixturesMemberus-gaap:MaximumMember 2017-01-01 2017-03-31 0001116463 us-gaap:MachineryAndEquipmentMemberus-gaap:MaximumMember 2017-01-01 2017-03-31 0001116463 us-gaap:BuildingMemberus-gaap:MaximumMember 2017-01-01 2017-03-31 0001116463 us-gaap:ComputerEquipmentMemberus-gaap:MaximumMember 2017-01-01 2017-03-31 0001116463 us-gaap:MaximumMember 2017-01-01 2017-03-31 0001116463 us-gaap:CertificatesOfDepositMemberus-gaap:MinimumMember 2017-01-01 2017-03-31 0001116463 us-gaap:FurnitureAndFixturesMemberus-gaap:MinimumMember 2017-01-01 2017-03-31 0001116463 us-gaap:MachineryAndEquipmentMemberus-gaap:MinimumMember 2017-01-01 2017-03-31 0001116463 us-gaap:BuildingMemberus-gaap:MinimumMember 2017-01-01 2017-03-31 0001116463 us-gaap:ComputerEquipmentMemberus-gaap:MinimumMember 2017-01-01 2017-03-31 0001116463 us-gaap:MinimumMember 2017-01-01 2017-03-31 0001116463 osur:PerformanceBasedRestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-03-31 0001116463 osur:PerformanceBasedRestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-03-31 0001116463 osur:PerformanceBasedRestrictedStockMember 2017-01-01 2017-03-31 0001116463 osur:PerformanceBasedRestrictedStockUnitMember 2017-01-01 2017-03-31 0001116463 osur:StockRepurchaseProgramMember 2017-01-01 2017-03-31 0001116463 us-gaap:RestrictedStockMember 2017-01-01 2017-03-31 0001116463 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001116463 us-gaap:LineOfCreditMemberus-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-03-31 0001116463 osur:CommonStockOptionsUnvestedRestrictedStockAndUnvestedPerformanceUnitsMember 2017-01-01 2017-03-31 0001116463 us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:MaximumMember 2017-01-01 2017-03-31 0001116463 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-03-31 0001116463 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberosur:CustomerOneMember 2017-01-01 2017-03-31 0001116463 2017-01-01 2017-03-31 0001116463 2016-01-01 2016-12-31 0001116463 2016-08-01 2016-08-31 0001116463 2015-09-01 2015-09-30 0001116463 osur:AccountingStandardsUpdateTwoThousandSixteenZeroNineMemberus-gaap:ValuationAllowanceOperatingLossCarryforwardsMember 2017-01-01 2017-01-01 0001116463 osur:AccountingStandardsUpdateTwoThousandSixteenZeroNineMember 2017-01-01 2017-01-01 0001116463 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2016-12-31 2016-12-31 0001116463 2015-06-12 2015-06-12 0001116463 osur:DNAGenotekMember 2017-02-06 2017-02-06 0001116463 osur:AccountingStandardsUpdateTwoThousandSixteenZeroNineMember 2017-01-01 0001116463 osur:OtherForeignCountriesMember 2016-12-31 0001116463 country:US 2016-12-31 0001116463 country:CA 2016-12-31 0001116463 osur:DNAGMember 2016-12-31 0001116463 osur:OSURMember 2016-12-31 0001116463 us-gaap:UpFrontPaymentArrangementMember 2016-12-31 0001116463 osur:PerformanceBasedRestrictedStockMember 2016-12-31 0001116463 us-gaap:RestrictedStockMember 2016-12-31 0001116463 us-gaap:FairValueInputsLevel1Memberosur:GuaranteedInvestmentCertificatesMember 2016-12-31 0001116463 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2016-12-31 0001116463 2016-12-31 0001116463 2015-12-31 0001116463 osur:OtherForeignCountriesMember 2017-03-31 0001116463 country:US 2017-03-31 0001116463 country:CA 2017-03-31 0001116463 osur:DNAGMember 2017-03-31 0001116463 osur:OSURMember 2017-03-31 0001116463 osur:DNAGenotekMember 2017-03-31 0001116463 us-gaap:MaximumMember 2017-03-31 0001116463 us-gaap:UpFrontPaymentArrangementMember 2017-03-31 0001116463 osur:PerformanceBasedRestrictedStockMember 2017-03-31 0001116463 us-gaap:RestrictedStockMember 2017-03-31 0001116463 us-gaap:StandbyLettersOfCreditMember 2017-03-31 0001116463 us-gaap:LetterOfCreditMember 2017-03-31 0001116463 us-gaap:LineOfCreditMember 2017-03-31 0001116463 us-gaap:FairValueInputsLevel1Memberosur:GuaranteedInvestmentCertificatesMember 2017-03-31 0001116463 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2017-03-31 0001116463 2017-03-31 0001116463 osur:StockRepurchaseProgramMember 2016-03-31 0001116463 2016-03-31 0001116463 2017-05-04 0001116463 2008-08-05 iso4217:USD shares iso4217:USD shares pure osur:Debt_Instruments osur:Supplier osur:Segment

EX-101.SCH 7 osur-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Income link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - The Company link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Credit Facility link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Business Segment Information link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Business Segment Information (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Summary of Significant Accounting Policies - Schedule of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Credit Facility - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Stockholders' Equity - Summary of PSU Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Business Segment Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Business Segment Information - Summary of Operating Segment and Asset Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Business Segment Information - Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 osur-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 osur-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 osur-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE AbbVie. AbbVie [Member] AbbVie [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Accounting Standards Update Two Thousand Sixteen Zero Nine. Accounting Standards Update Two Thousand Sixteen Zero Nine [Member] Accounting Standards Update Two Thousand Sixteen Zero Nine [Member] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accounts Payable, Current Accounts payable Accounts Receivable [Member] Accounts Receivable [Member] Accounts Receivable, Net, Current Accounts receivable, net of allowance for doubtful accounts of $588 and $484 Accrued Liabilities, Current Accrued expenses Accrued Expenses, Total Accrued Liabilities, Current [Abstract] Accrued Liabilities, Current [Abstract] Accrued Professional Fees, Current Professional fees Accrued Royalties, Current Royalties Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation of property and equipment Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Accumulated foreign currency adjustments included in other comprehensive loss amounted Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional contract revenue from clinical and regulatory activities. Additional Contract Revenue From Clinical And Regulatory Activities Additional contract revenue from clinical and regulatory activities Additional Paid in Capital, Common Stock Additional paid-in capital Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Adjustments Related to Tax Withholding for Share-based Compensation Restricted shares of common stock and stock options, aggregate values Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Allowance for Doubtful Accounts Receivable, Current Allowance for doubtful accounts Amendment Flag Amendment Flag Amount of amortization (accretion) of lease incentive costs incurred by the lessor for the benefit of the lessee. Amortization Accretion of Lease Incentives Amortization of lease incentives Amortization of Debt Issuance Costs Amortization of debt issue costs Amortization of Intangible Assets Intangible Assets, Accumulated Amortization Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of anti-dilutive securities excluded from EPS computation Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets TOTAL ASSETS Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] CURRENT ASSETS: Available-for-sale Securities, Amortized Cost Basis Available-for-sale securities, amortized cost Award Type [Axis] Award Type [Axis] Basis of Accounting, Policy [Policy Text Block] Principles of Consolidation and Basis of Presentation Building [Member] Buildings [Member] CANADA Canada [Member] Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, END OF PERIOD CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD Cash and cash equivalents Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents, Period Increase (Decrease) NET INCREASE IN CASH AND CASH EQUIVALENTS Certificates of Deposit [Member] Certificates of Deposit [Member] Collaborative Arrangement, Co-promotion [Member] Collaborative Arrangement Co-promotion [Member] Commitments and Contingencies COMMITMENTS AND CONTINGENCIES (Note 7) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common stock options unvested restricted stock and unvested performance units. Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member] Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member] Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, par value $.000001, 120,000 shares authorized, 57,664 and 56,001 shares issued and outstanding Comprehensive Income (Loss), Net of Tax, Attributable to Parent COMPREHENSIVE INCOME Comprehensive Income, Policy [Policy Text Block] Accumulated Other Comprehensive Income (Loss) Computer Equipment [Member] Computer Equipment [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk, Percentage Percentage of concentration risk Concentration Risk Type [Domain] Concentration Risk Type [Domain] Contract expiration period. Contract Expiration Period Period of grant Contract revenues from clinical and regulatory activities. Contract Revenues From Clinical And Regulatory Activities Contract revenues from clinical and regulatory activities Contracts Revenue Revenue recognized Contractual Obligation Fiscal Year Maturity [Line Items] Contractual Obligation Fiscal Year Maturity [Line Items] Contractual Obligation Fiscal Year Maturity [Line Items] Contractual Obligation Fiscal Year Maturity [Table] Contractual Obligation Fiscal Year Maturity [Table] Contractual Obligation Fiscal Year Maturity [Table] Cost of Goods Sold COST OF PRODUCTS SOLD Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Cumulative Effect on Retained Earnings, Tax Net impact of cumulative-effect adjustment to retained earnings Current Fiscal Year End Date Current Fiscal Year End Date Customer Concentration Risk [Member] Customer Concentration Risk [Member] Customer One [Member] Customer One [Member] Customer One [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Credit Facility Debt Instrument, Basis Spread on Variable Rate Line of credit, interest rate Debt instrument covenant terms minimum fixed charge coverage ratio. Debt Instrument Covenant Terms Minimum Fixed Charge Coverage Ratio Minimum fixed charge coverage ratio Debt instrument number of instruments held. Debt Instrument Number Of Instruments Held Debt instrument, number of letters of credit Deferred Compensation Plan Assets Fair value of plan assets Deferred Federal, State and Local, Tax Expense (Benefit) U.S. federal or state deferred income tax expense or benefits Deferred Income Tax Expense (Benefit) Deferred income taxes Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] Deferred Revenue [Domain] Deferred Revenue, Current Deferred revenue Deferred Tax Expense from Stock Options Exercised Income tax benefit realized from stock option exercises during period Deferred Tax Liabilities, Net, Noncurrent DEFERRED INCOME TAXES Depreciation, Depletion and Amortization Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] DNA Genotek. DNA Genotek [Member] DNA Genotek [Member] DNAG. DNAG [Member] DNAG [Member] Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] EARNINGS PER SHARE: Earnings Per Share, Basic BASIC Earnings Per Share, Diluted DILUTED Earnings Per Share, Policy [Policy Text Block] Earnings Per Share Effect of Exchange Rate on Cash and Cash Equivalents EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH Employee-related Liabilities, Current Payroll and related benefits Employee Stock Option [Member] Stock Options [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Europe [Member] Europe [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Level I Instruments [Member] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization of intangible assets Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Intangible Assets, Foreign currency translation gains Finite-Lived Intangible Assets, Net INTANGIBLE ASSETS, net Finite-Lived Intangible Asset, Useful Life Useful life of Intangible assets Foreign Currency Transaction Gain (Loss), before Tax Net foreign exchange losses Foreign Currency Transaction Gain (Loss), Unrealized Unrealized foreign currency (gain) loss Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation Furniture and Fixtures [Member] Furniture and Fixtures [Member] Gain (Loss) Related to Litigation Settlement Gain from settlement of Ancestry litigation Gain on litigation settlement General and Administrative Expense General and administrative Goodwill Amount of goodwill at period end GOODWILL Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill Gross Profit Gross profit Guaranteed Investment Certificates [Member] Guaranteed Investment Certificates [Member] Guaranteed Investment Certificates [Member] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes Paid Cash paid for income taxes Income Taxes [Table] Income Taxes [Table] Income Taxes [Table] Income Tax Expense (Benefit) INCOME TAX EXPENSE Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Accrued Liabilities Accrued expenses and other liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Inventories Inventories Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Dilutive effect of stock options and restricted stock Initial contract revenue from clinical and regulatory activities. Initial Contract Revenue From Clinical And Regulatory Activities Initial grant revenue from clinical and regulatory activities Intangible Assets, Finite-Lived, Policy [Policy Text Block] Intangible Assets Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net Inventory, Finished Goods, Net of Reserves Finished goods Inventory, Net Inventories Inventories Inventory, Net [Abstract] Inventory, Net [Abstract] Inventory, Policy [Policy Text Block] Inventories Inventory, Raw Materials, Net of Reserves Raw materials Inventory, Work in Process, Gross Work in process Investment Interest Rate Interest rate on certificates of deposit Investment Maturity Date Certificates of deposit maturity date Investment, Policy [Policy Text Block] Short-Term Investments Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Legal Entity [Axis] Legal Entity [Axis] Letter of Credit [Member] Letter of Credit [Member] Letters of Credit Outstanding, Amount Standby letters of credit Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] CURRENT LIABILITIES: Long-term Line of Credit Borrowings Line of credit additional borrowing capacity. Line Of Credit Additional Borrowing Capacity Additional revolving commitments Line of Credit Facility [Abstract] Line of Credit Facility [Abstract] Line of Credit Facility, Collateral Line of credit facility, collateral Line of Credit Facility, Expiration Date Maturity date of credit facility Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line of Credit Facility, Maximum Borrowing Capacity Current borrowing capacity Line of Credit Facility [Table] Line of Credit Facility [Table] Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Unused capacity commitment fee Line of Credit [Member] Line of Credit [Member] Litigation Settlement, Amount Settlement fee London Interbank Offered Rate (LIBOR) [Member] London Interbank Offered Rate (LIBOR) [Member] Machinery and Equipment [Member] Machinery and Equipment [Member] Customer [Axis] Customer [Axis] Major Customers, Policy [Policy Text Block] Customer and Vendor Concentrations Maximum contract revenue from clinical and regulatory activities. Maximum Contract Revenue From Clinical And Regulatory Activities Maximum value of grant revenue from clinical and regulatory activities Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Money Market Funds [Member] Money Market Fund [Member] Customer [Domain] Customer [Domain] Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] FINANCING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] INVESTING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] OPERATING ACTIVITIES: Net Income (Loss) Attributable to Parent NET INCOME NET INCOME New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets Cumulative-effect adjustment to retained earnings New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification Cumulative-effect adjustment to retained earnings New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] EX-101.PRE 11 osur-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 04, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		57,762,761

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 120,851	$ 107,959
Restricted cash	1,831	1,831
Short-term investments	18,776	11,160
Accounts receivable, net of allowance for doubtful accounts of $588 and $484	24,005	19,827
Inventories	12,707	11,799
Prepaid expenses	1,732	1,722
Other current assets	633	2,143
Total current assets	180,535	156,441
PROPERTY AND EQUIPMENT, net	20,134	20,033
INTANGIBLE ASSETS, net	9,779	10,337
GOODWILL	18,971	18,793
OTHER ASSETS	3,173	2,331
TOTAL ASSETS	232,592	207,935
CURRENT LIABILITIES:
Accounts payable	7,286	4,633
Deferred revenue	1,306	1,388
Accrued expenses	9,685	11,314
Total current liabilities	18,277	17,335
OTHER LIABILITIES	3,160	2,304
DEFERRED INCOME TAXES	2,330	2,446
COMMITMENTS AND CONTINGENCIES (Note 7)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 57,664 and 56,001 shares issued and outstanding	0	0
Additional paid-in capital	360,612	350,528
Accumulated other comprehensive loss	(13,770)	(14,220)
Accumulated deficit	(138,017)	(150,458)
Total stockholders' equity	208,825	185,850
Total liabilities and stockholders' equity	$ 232,592	$ 207,935

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 588	$ 484
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	57,664,000	56,001,000
Common stock, shares outstanding	57,664,000	56,001,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
NET REVENUES:
Product	$ 31,482	$ 25,245
Other	1,064	3,844
Total revenue	32,546	29,089
COST OF PRODUCTS SOLD	12,236	8,776
Gross profit	20,310	20,313
OPERATING EXPENSES:
Research and development	2,970	2,366
Sales and marketing	6,877	8,706
General and administrative	7,092	6,542
Gain on litigation settlement	(12,500)
Total operating expenses	4,439	17,614
Operating income	15,871	2,699
OTHER INCOME (EXPENSE)	467	(192)
Income before income taxes	16,338	2,507
INCOME TAX EXPENSE	3,897	61
NET INCOME	$ 12,441	$ 2,446
EARNINGS PER SHARE:
BASIC	$ 0.22	$ 0.04
DILUTED	$ 0.21	$ 0.04
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC	56,929	55,451
DILUTED	58,772	56,079

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement of Comprehensive Income [Abstract]
NET INCOME	$ 12,441	$ 2,446
OTHER COMPREHENSIVE INCOME
Currency translation adjustments	450	2,867
COMPREHENSIVE INCOME	$ 12,891	$ 5,313

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
OPERATING ACTIVITIES:
NET INCOME	$ 12,441	$ 2,446
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	1,518	1,452
Depreciation and amortization	1,408	1,354
Amortization of lease incentives	(20)	(19)
Amortization of debt issue costs	31
Unrealized foreign currency (gain) loss	(1)	141
Deferred income taxes	(139)	(18)
Changes in assets and liabilities
Accounts receivable	(4,143)	2,489
Inventories	(893)	990
Prepaid expenses and other assets	1,505	26
Accounts payable	2,619	758
Deferred revenue	(84)	(2,504)
Accrued expenses and other liabilities	(1,623)	(2,371)
Net cash provided by operating activities	12,619	4,744
INVESTING ACTIVITIES:
Purchases of short-term investments	(7,514)	(7,689)
Proceeds from maturities of short-term investments		7,689
Purchases of property and equipment	(878)	(1,593)
Net cash used in investing activities	(8,392)	(1,593)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	9,417
Repurchase of common stock	(851)	(3,187)
Net cash provided by (used in) financing activities	8,566	(3,187)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	99	500
NET INCREASE IN CASH AND CASH EQUIVALENTS	12,892	464
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	107,959	94,094
CASH AND CASH EQUIVALENTS, END OF PERIOD	120,851	94,558
Cash paid for income taxes	1,949	84
Noncash investing activities (accrued property and equipment purchases)	$ 297	$ 444

XML 18 R7.htm IDEA: XBRL DOCUMENT

The Company

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

1.	The Company

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Our available-for-sale securities as of March 31, 2017 and December 31, 2016 consisted of guaranteed investment certificates with amortized cost and fair value of $18,776 and $11,160, respectively.

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale securities are measured as Level 1 instruments as of March 31, 2017 and December 31, 2016.

Inventories. Inventories are stated at the lower of cost and net realizable value determined on a first-in, first-out basis and are comprised of the following:


	March 31, 2017		December 31, 2016
Raw materials	$	5,024	$	5,399
Work in process		1,035		1,034
Finished goods		6,648		5,366

	$	12,707	$	11,799

Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income. Accumulated depreciation of property and equipment as of March 31, 2017 and December 31, 2016 was $36,856 and $36,067, respectively.

The change in goodwill from $18,793 as of December 31, 2016 to $18,971 as of March 31, 2017 is a result of foreign currency translation.

In June 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick^® HCV test in the United States. On June 30, 2016, we mutually agreed to terminate our agreement with AbbVie effective December 31, 2016. Following the termination of the agreement, AbbVie was relieved of its co-promotion obligations, including its obligation to detail the OraQuick^® HCV Rapid Test into physician offices, and has no further financial obligations to us. We are no longer obligated to compensate AbbVie for product detailing activities and are free to pursue arrangements with other pharmaceutical companies to market and promote our OraQuick^® HCV Rapid Antibody Test in the U.S. Accordingly, during the first quarter of 2017 we did not record any revenue from this co-promotion agreement. During the first quarter of 2016, $3,362 in exclusivity revenue was recognized and was recorded as other revenue in our consolidated statements of income.

Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted average number of shares outstanding is increased to include shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock, and performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings per share are as follows:


	Three Months Ended March 31,
	2017		2016
Net income	$	12,441	$	2,446

Weighted average shares of common stock outstanding:
Basic		56,929		55,451
Dilutive effect of stock options and restricted stock		1,843		628

Diluted		58,772		56,079

Earnings per share:
Basic	$	0.22	$	0.04

Diluted	$	0.21	$	0.04

XML 20 R9.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Accrued Expenses

3.	Accrued Expenses


	March 31, 2017		December 31, 2016
Payroll and related benefits	$	3,905	$	7,685
Income taxes payable		2,045		(39	)
Royalties		688		982
Professional fees		686		715
Other		2,361		1,971

	$	9,685	$	11,314

XML 21 R10.htm IDEA: XBRL DOCUMENT

Credit Facility

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Credit Facility

4.	Credit Facility

XML 22 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Stockholders' Equity

5.	Stockholders’ Equity

Stock-Based Awards

The following table summarizes the stock option activity for the first three months ended March, 31, 2017:


	Options
Outstanding on January 1, 2017		5,456
Granted		191
Exercised		(1,462	)
Expired		(27	)
Forfeited		(19	)

Outstanding on March 31, 2017		4,139

The following table summarizes restricted stock award activity for the three months ended March 31, 2017:


	Shares
Issued and unvested, January 1, 2017		750
Granted		288
Vested		(297	)
Forfeited		(4	)

Issued and unvested, March 31, 2017		737

The following table summarizes PSU activity for the three months ended March 31, 2017:


	Units
Issued and unvested, January 1, 2017		456
Granted		229
Vested		—
Forfeited		—

Issued and unvested, March 31, 2017		685

Stock Repurchase Program

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

6.	Income Taxes

During the three months ended March 31, 2017 and 2016, we recorded tax expense of $3,897 and $61, respectively.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

7.	Commitments and Contingencies

Standby Letters of Credit

Litigation

XML 25 R14.htm IDEA: XBRL DOCUMENT

Business Segment Information

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Business Segment Information

8.	Business Segment Information

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the three months ended March 31, 2017 and 2016, and asset information as of March 31, 2017 and December 31, 2016:


	Three Months Ended March 31,
	2017			2016
Net revenues:
OSUR	$	21,840		$	22,199
DNAG		10,706			6,890

Total	$	32,546		$	29,089

Operating income (loss):
OSUR	$	(219	)	$	1,608
DNAG		16,090			1,091

Total	$	15,871		$	2,699

Depreciation and amortization:
OSUR	$	625		$	639
DNAG		783			715

Total	$	1,408		$	1,354

Capital expenditures:
OSUR	$	784		$	447
DNAG		94			1,146

Total	$	878		$	1,593


	March 31, 2017			December 31, 2016
Total assets:
OSUR	$	161,730		$	151,719
DNAG		70,862			56,216

Total	$	232,592		$	207,935

Our products are sold principally in the United States and Europe.

The following table represents total net revenues by geographic area, based on the location of the customer:


	Three Months Ended March 31,
	2017		2016
United States	$	20,854	$	22,170
Europe		3,125		3,879
Other regions		8,567		3,040

	$	32,546	$	29,089

The following table represents total long-lived assets by geographic area:


	March 31, 2017		December 31, 2016
United States	$	15,886	$	15,737
Canada		4,238		4,286
Other regions		10		10

	$	20,134	$	20,033

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Use of Estimates

Short-Term Investments

Our available-for-sale securities as of March 31, 2017 and December 31, 2016 consisted of guaranteed investment certificates with amortized cost and fair value of $18,776 and $11,160, respectively.

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale securities are measured as Level 1 instruments as of March 31, 2017 and December 31, 2016.

Inventories

Inventories. Inventories are stated at the lower of cost and net realizable value determined on a first-in, first-out basis and are comprised of the following:


	March 31, 2017		December 31, 2016
Raw materials	$	5,024	$	5,399
Work in process		1,035		1,034
Finished goods		6,648		5,366

	$	12,707	$	11,799

Property and Equipment

Intangible Assets

Goodwill

The change in goodwill from $18,793 as of December 31, 2016 to $18,971 as of March 31, 2017 is a result of foreign currency translation.

Revenue Recognition

Customer Sales Returns and Allowances

Deferred Revenue

Customer and Vendor Concentrations

Earnings Per Share

The computations of basic and diluted earnings per share are as follows:


	Three Months Ended March 31,
	2017		2016
Net income	$	12,441	$	2,446

Weighted average shares of common stock outstanding:
Basic		56,929		55,451
Dilutive effect of stock options and restricted stock		1,843		628

Diluted		58,772		56,079

Earnings per share:
Basic	$	0.22	$	0.04

Diluted	$	0.21	$	0.04

Foreign Currency Translation

Accumulated Other Comprehensive Income (Loss)

Recent Accounting Pronouncements

XML 27 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost and net realizable value determined on a first-in, first-out basis and are comprised of the following:


	March 31, 2017		December 31, 2016
Raw materials	$	5,024	$	5,399
Work in process		1,035		1,034
Finished goods		6,648		5,366

	$	12,707	$	11,799

Computations of Basic and Diluted Earnings Per Share

The computations of basic and diluted earnings per share are as follows:


	Three Months Ended March 31,
	2017		2016
Net income	$	12,441	$	2,446

Weighted average shares of common stock outstanding:
Basic		56,929		55,451
Dilutive effect of stock options and restricted stock		1,843		628

Diluted		58,772		56,079

Earnings per share:
Basic	$	0.22	$	0.04

Diluted	$	0.21	$	0.04

XML 28 R17.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Schedule of Accrued Expenses


	March 31, 2017		December 31, 2016
Payroll and related benefits	$	3,905	$	7,685
Income taxes payable		2,045		(39	)
Royalties		688		982
Professional fees		686		715
Other		2,361		1,971

	$	9,685	$	11,314

XML 29 R18.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity for the first three months ended March, 31, 2017:


	Options
Outstanding on January 1, 2017		5,456
Granted		191
Exercised		(1,462	)
Expired		(27	)
Forfeited		(19	)

Outstanding on March 31, 2017		4,139

Summary of Restricted Stock Award Activity

The following table summarizes restricted stock award activity for the three months ended March 31, 2017:


	Shares
Issued and unvested, January 1, 2017		750
Granted		288
Vested		(297	)
Forfeited		(4	)

Issued and unvested, March 31, 2017		737

Summary of PSU Activity

The following table summarizes PSU activity for the three months ended March 31, 2017:


	Units
Issued and unvested, January 1, 2017		456
Granted		229
Vested		—
Forfeited		—

Issued and unvested, March 31, 2017		685

XML 30 R19.htm IDEA: XBRL DOCUMENT

Business Segment Information (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the three months ended March 31, 2017 and 2016, and asset information as of March 31, 2017 and December 31, 2016:


	Three Months Ended March 31,
	2017			2016
Net revenues:
OSUR	$	21,840		$	22,199
DNAG		10,706			6,890

Total	$	32,546		$	29,089

Operating income (loss):
OSUR	$	(219	)	$	1,608
DNAG		16,090			1,091

Total	$	15,871		$	2,699

Depreciation and amortization:
OSUR	$	625		$	639
DNAG		783			715

Total	$	1,408		$	1,354

Capital expenditures:
OSUR	$	784		$	447
DNAG		94			1,146

Total	$	878		$	1,593


	March 31, 2017			December 31, 2016
Total assets:
OSUR	$	161,730		$	151,719
DNAG		70,862			56,216

Total	$	232,592		$	207,935

Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area

The following table represents total net revenues by geographic area, based on the location of the customer:


	Three Months Ended March 31,
	2017		2016
United States	$	20,854	$	22,170
Europe		3,125		3,879
Other regions		8,567		3,040

	$	32,546	$	29,089

The following table represents total long-lived assets by geographic area:


	March 31, 2017		December 31, 2016
United States	$	15,886	$	15,737
Canada		4,238		4,286
Other regions		10		10

	$	20,134	$	20,033

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) shares in Thousands			1 Months Ended		3 Months Ended		12 Months Ended
	Dec. 31, 2016 USD ($)	Jun. 12, 2015 USD ($)	Aug. 31, 2016 USD ($)	Sep. 30, 2015 USD ($)	Mar. 31, 2017 USD ($) Supplier shares	Mar. 31, 2016 USD ($) shares	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Available-for-sale securities, fair values	$ 11,160,000				$ 18,776,000		$ 11,160,000
Cash and cash equivalents	107,959,000				120,851,000	$ 94,558,000	107,959,000	$ 94,094,000
Fair value of plan assets	1,980,000				2,828,000		1,980,000
Accumulated depreciation of property and equipment	36,067,000				36,856,000		36,067,000
Intangible Assets, Net	10,337,000				9,779,000		10,337,000
Intangible Assets, Accumulated Amortization					637,000
Intangible Assets, Foreign currency translation gains					79,000
Accumulated amortization of intangible assets	15,197,000				15,944,000		15,197,000
Amount of goodwill at period end	18,793,000				18,971,000		18,793,000
Revenue recognized					0	3,362,000
Maximum value of grant revenue from clinical and regulatory activities		$ 10,400,000	$ 16,600,000
Initial grant revenue from clinical and regulatory activities		1,800,000	7,000,000
Remaining grant revenue from clinical and regulatory activities		$ 8,600,000	$ 9,600,000
Period of grant		3 years	6 years
Additional contract revenue from clinical and regulatory activities				$ 7,200,000
Contract revenues from clinical and regulatory activities					644,000
Reserve for sales return and allowances					235,000		217,000
Deferred revenue	1,388,000				1,306,000		1,388,000
Net foreign exchange losses					(200,000)	(346,000)
Accumulated foreign currency adjustments included in other comprehensive loss amounted					450,000	$ 2,867,000
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 83,704,000				$ 82,142,000		83,704,000
Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation \| shares					666	4,843
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	15.00%
Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk					0.00%
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	$ 1,388,000				$ 1,306,000		1,388,000
AbbVie [Member] \| Collaborative Arrangement Co-promotion [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Expiration date of rights agreement					Dec. 31, 2016
Customer One [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk					22.00%
Customer One [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk						12.00%
Guaranteed Investment Certificates [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Available-for-sale securities, amortized cost	18,776,000				$ 18,776,000		18,776,000
Available-for-sale securities, fair values	$ 11,160,000				11,160,000		$ 11,160,000
Other [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contract revenues from clinical and regulatory activities					$ 420,000	$ 482,000
Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Certificates of deposit maturity date					Feb. 28, 2018
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets					15 years
Maximum [Member] \| Net Consolidated Revenue [Member] \| Revenue from Rights Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk					1.00%
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					10 years
Maximum [Member] \| Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificates of deposit					0.44%
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets					7 years
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets					2 years
Minimum [Member] \| Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificates of deposit					0.28%
DNA Genotek [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier					2

XML 32 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory, Net [Abstract]
Raw materials	$ 5,024	$ 5,399
Work in process	1,035	1,034
Finished goods	6,648	5,366
Inventories	$ 12,707	$ 11,799

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
NET INCOME	$ 12,441	$ 2,446
Weighted average shares of common stock outstanding:
BASIC	56,929	55,451
Dilutive effect of stock options and restricted stock	1,843	628
Diluted	58,772	56,079
BASIC	$ 0.22	$ 0.04
DILUTED	$ 0.21	$ 0.04

XML 34 R23.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 3,905	$ 7,685
Income taxes payable	2,045	(39)
Royalties	688	982
Professional fees	686	715
Other	2,361	1,971
Accrued Expenses, Total	$ 9,685	$ 11,314

XML 35 R24.htm IDEA: XBRL DOCUMENT

Credit Facility - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 10,000,000
Line of credit facility, collateral	Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
Borrowings	$ 0	$ 0
Unused capacity commitment fee	0.375%
Maturity date of credit facility	Sep. 30, 2019
Maximum [Member]
Line of Credit Facility [Line Items]
Additional revolving commitments	$ 5,000,000
Line of Credit [Member]
Line of Credit Facility [Line Items]
Minimum fixed charge coverage ratio	110.00%
Line of Credit [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Line of credit, interest rate	2.50%
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 2,500,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of stock options	$ 9,417,000
Income tax benefit realized from stock option exercises during period	0	$ 0
Total compensation cost	$ 1,518,000	$ 1,452,000
Amount share repurchase program of common shares			$ 25,000,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	423
Average price of common stock		$ 6.29
Total cost of common stock purchased and retired		$ 2,660,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of stock options	$ 9,417,000	0
Total compensation cost	502,000	733,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 655,000	$ 719,000
Vesting of restricted shares and exercise of stock options, withholding and exercise obligations	96,000	98,000
Restricted shares of common stock and stock options, aggregate values	$ 851,000	$ 527,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 361,000	$ 0

XML 37 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2017 shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding, Beginning Balance	5,456
Options, Granted	191
Options, Exercised	(1,462)
Options, Expired	(27)
Options, Forfeited	(19)
Options, Outstanding, Ending Balance	4,139

XML 38 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail) - Restricted Stock [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2017 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	750
Shares, Granted	288
Shares, Vested	(297)
Shares, Forfeited	(4)
Shares, Issued and unvested, Ending Balance	737

XML 39 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of PSU Activity (Detail) - Performance Based Restricted Stock [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2017 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	456
Shares, Granted	229
Shares, Vested	0
Shares, Forfeited	0
Shares, Issued and unvested, Ending Balance	685

XML 40 R29.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($)		3 Months Ended
	Jan. 01, 2017	Mar. 31, 2017	Mar. 31, 2016
Income Taxes [Line Items]
INCOME TAX EXPENSE		$ 3,897,000	$ 61,000
Gain from settlement of Ancestry litigation		12,500,000
U.S. federal or state deferred income tax expense or benefits		$ 0	$ 0
Accounting Standards Update Two Thousand Sixteen Zero Nine [Member]
Income Taxes [Line Items]
Cumulative-effect adjustment to retained earnings	$ 3,391,000
Net impact of cumulative-effect adjustment to retained earnings	0
Accounting Standards Update Two Thousand Sixteen Zero Nine [Member] \| Valuation Allowance, Operating Loss Carryforwards [Member]
Income Taxes [Line Items]
Cumulative-effect adjustment to retained earnings	$ 3,391,000

- Definition

Amount of cumulative effect of the change in accounting principle or new accounting pronouncement on retained earnings or other components of equity or net assets in the statement of financial position as of the beginning of the earliest period presented.

+ References + Details

XML 41 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Feb. 06, 2017 USD ($)	Mar. 31, 2017 USD ($) Debt_Instruments
DNA Genotek [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Settlement fee	$ 12,500
Standby Letters of Credit [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Standby letters of credit		$ 1,831
Debt instrument, number of letters of credit \| Debt_Instruments		4

XML 42 R31.htm IDEA: XBRL DOCUMENT

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

XML 43 R32.htm IDEA: XBRL DOCUMENT

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Segment Reporting Information [Line Items]
Net revenues	$ 32,546	$ 29,089
Operating income (loss)	15,871	2,699
Depreciation and amortization	1,408	1,354
Capital expenditures	878	1,593
Total assets	232,592		$ 207,935
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues	21,840	22,199
Operating income (loss)	(219)	1,608
Depreciation and amortization	625	639
Capital expenditures	784	447
Total assets	161,730		151,719
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues	10,706	6,890
Operating income (loss)	16,090	1,091
Depreciation and amortization	783	715
Capital expenditures	94	$ 1,146
Total assets	$ 70,862		$ 56,216

XML 44 R33.htm IDEA: XBRL DOCUMENT

Business Segment Information - Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 32,546	$ 29,089
Long-lived assets	20,134		$ 20,033
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	20,854	22,170
Long-lived assets	15,886		15,737
Europe [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	3,125	3,879
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	8,567	$ 3,040
Long-lived assets	10		10
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 4,238		$ 4,286

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 46 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 87 190 1 false 40 0 false 7 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.orasure.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Consolidated Balance Sheets Sheet http://www.orasure.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.orasure.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Consolidated Statements of Income Sheet http://www.orasure.com/taxonomy/role/StatementOfIncome Consolidated Statements of Income Statements 4 false false R5.htm 106 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.orasure.com/taxonomy/role/StatementOfOtherComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 107 - Statement - Consolidated Statements of Cash Flows Sheet http://www.orasure.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows Statements 6 false false R7.htm 108 - Disclosure - The Company Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock The Company Notes 7 false false R8.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 8 false false R9.htm 110 - Disclosure - Accrued Expenses Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses Notes 9 false false R10.htm 111 - Disclosure - Credit Facility Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Credit Facility Notes 10 false false R11.htm 112 - Disclosure - Stockholders' Equity Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity Notes 11 false false R12.htm 113 - Disclosure - Income Taxes Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 12 false false R13.htm 114 - Disclosure - Commitments and Contingencies Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 13 false false R14.htm 115 - Disclosure - Business Segment Information Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Business Segment Information Notes 14 false false R15.htm 116 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 15 false false R16.htm 117 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) Tables http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 16 false false R17.htm 118 - Disclosure - Accrued Expenses (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) Tables http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock 17 false false R18.htm 119 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) Tables http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock 18 false false R19.htm 120 - Disclosure - Business Segment Information (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Business Segment Information (Tables) Tables http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 19 false false R20.htm 121 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) Details 20 false false R21.htm 122 - Disclosure - Summary of Significant Accounting Policies - Schedule of Inventories (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfInventories Summary of Significant Accounting Policies - Schedule of Inventories (Detail) Details 21 false false R22.htm 123 - Disclosure - Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationsOfBasicAndDilutedEarningsPerShare Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) Details 22 false false R23.htm 124 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 23 false false R24.htm 125 - Disclosure - Credit Facility - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureCreditFacilityAdditionalInformation Credit Facility - Additional Information (Detail) Details 24 false false R25.htm 126 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysStockOptionActivity Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) Details 26 false false R27.htm 128 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockAwardActivity Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail) Details 27 false false R28.htm 129 - Disclosure - Stockholders' Equity - Summary of PSU Activity (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfPSUActivity Stockholders' Equity - Summary of PSU Activity (Detail) Details 28 false false R29.htm 130 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 30 false false R31.htm 132 - Disclosure - Business Segment Information - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureBusinessSegmentInformationAdditionalInformation Business Segment Information - Additional Information (Detail) Details 31 false false R32.htm 133 - Disclosure - Business Segment Information - Summary of Operating Segment and Asset Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfOperatingSegmentAndAssetInformation Business Segment Information - Summary of Operating Segment and Asset Information (Detail) Details 32 false false R33.htm 134 - Disclosure - Business Segment Information - Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureBusinessSegmentInformationPresentationOfTotalNetRevenuesAndLongLivedAssetsByGeographicArea Business Segment Information - Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area (Detail) Details 33 false false All Reports Book All Reports osur-20170331.xml osur-20170331.xsd osur-20170331_cal.xml osur-20170331_def.xml osur-20170331_lab.xml osur-20170331_pre.xml true true ZIP 51 0001193125-17-164160-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-17-164160-xbrl.zip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

U_ M7F>?8(;XKPSOCZ4T>PC9S^^'IU\NY8N3_S?X**G*+/LDT0=#[_>3S__[4?I/ M?SK[]*]YG'VZ#*:@YL%1E<[CJ1^57WR2_CP][\L79U[OY,NO'R5E=O])ZL)' M@W.Y=_KYLW=V 6./XC#T9RG[!'+Z?R_ERW/OR\7P]/SWCU(41_#IZ?G9;_#1 M1TF#\4[ZIW_R/S\/+B]AG&+P*$Y@OXM!3K[T!U\NQ1OE.W;U-%,'?WDM7<3)F"7Y> M95N2\^PJ8?Y7.8C28,P^2OYM'(QK/QQ+MWX87$<_O\_B63&T 0.+CT,VR>@) M_/D5_F$GEY^CLR,Y>1%PK-;R>7 UK80;FL+9+4+B[TOC\')[_^=ED^#=)V>OY1 M2JZO?E0Z\+\_Y1.]_-_/E9OG63P)0P'*( M,5;0"6DY8NW[$6R3_*MA(=TP"9<1@ M\:4@RF+)ET9<$/SKA-$Y4OHQNV&XM/QI>*R7"XN7_Z;\KO_I)Y#:[ 8'BJ=3 MEHS LY2N_.CKL71YPR3^) Q7/"O-DO@6MD,*Q"12PF[C\!91Y8 C6.L?@P,4 M3_)9!9'D1U+ '588Q;^&88 K3/)Y#!U^.I])0,@/*JRCHD@_PHDWG"-F '[G M2R'A^9=#PB#I_&HBQ!X__T'KF(KR4T?0$4G\B(R#)NQ?PN]N2*KQ";+L MQ3AA[$F@(/9;09Q0D#_B5I5O M]K9U[@AA$D8(Y2Q(X$2)YF7$4G*0IG-*! ;=\9#[-E/>/0H,YSW6)E#_*/@) M;R"%JH%Z98%L83,JW 3JL0(^UY3Y*5E=/\T%+_1A\+%/NH7YHQL8,AV1;T,; MELP4J@'\;7;'PELF\U^([[EL@Q-'QA!(3>"23:R?AROA3* M4S A#"4?6SR,2*.-1'.M%#V%=FM6%5W6U7HTHC:O59+S^0,G$3BE8(A@4>B_]S'HA>@]*N::K)"" MWTY5 V)>7$4-[D=T7X6&[S1J'V\O^6&]_Z4! ;(.28LR/:3M_;]@$H?PR?-I M?J94ZURJZ_+"-T>BDE$%PRP1@P$XWA&58GMZS7'G@ MN*9L8+I85S&[LM:WX;]=W=)L7!47[Y<:ZN$),MISR8=LC \1"A@\^3D&1EWZ M]^*9+@PY6:<:@/%-F 5\E.?V##/QU-BIZ$<15Y$#G_6]=-@M%&2E^"[M22_K+C\",:J'&M:11VV$=%<\J>;+>RC M\L>B;4-I5@\\3' M^D#OZLM"_R\XW33.-(L'AVH(/,ACSG/$^>,!*R1B#?D,,Z+P'3Q<_KCN/Q, MXEN%Y0/@,9/$'-X3I.3-SL4Y%P@-R'N.&,:Y$%E4''_!_0VN;^!GLL]=>RFB MVA<8 ]QJOFLHE$@XRL A7*UJ<*IR'!6'4*D?A',>YEJ<6VUF&.N$PRJ<8>#; M8!J$/D4#D&>U,Z48^11@RYID6188\/ PAF-^SKM4' A1%@JG%HPG?DC.KUC0E,^ M#QZG**CG5**K ,QL5@#XF3^NA29+]8!PUKX^%PLH#\"1S-A MRR15B$DN'5,_^2[0X3H@![:#<2F,=]7 M;?N"_A^7>!(CF'_Z\?G3IS!'=8)*17W5XG*U\=>X.%U@Q](;T96O)FVKO$ < MT77/THO*^M5A_KS[M_=/7B]>Q5D63XMWFLL?V=3GK_;J^@5H>;M;65CGZ74] M\WX=R-WS@?<_\LF7BY/^X/$+84%D/7"["EL:3SS^K*!$R%R^#?Z#YXM)*EB7 M%)R3\?L%WH-0@B3"!U93U&K7S)<8PR[G\#O&L-+Z9?-5(GVH3(H^A[,1&U<> M6PAHK7@'OB(3#PO\R )KCRXP^I^;78S])]C:N?2M8C>6BI]T=0VTQ:#\_P/. M.(/A$$4E.V:^,^#X24\P*8+-K5Q9R##;_*Y?"F\] 4SNU'!:7GVAY7,D/AG M@LXW/:9J'<-05WJ67]K]_+YR>;?%O;$Y$I%":QL4KK(99O?OS:72UY-LBI7N7E37>F+1YS"MCJNY;\.M>C&M9L)A# 0R/[ MY@)O=&)OYTQR6(^#)[>: 6/C-V>23*=CV]KW89/ ;U7LK?BMWX-9.H1F#BNR MGROR;9^DU@R6#1;2, ZQL/V8\\&#VL-8V#.OW3#1]FTX3<\F4#$.GM(^6+_] MG=G!4]JWF7W?GM(;.;(_W^1\VZDL!Y.S+VID?V=V,#G[-K/U=M\F0:M6KE\8 MYF7\F ,M5\OW4ZS?9^-'"_6I)!]&J=:AU--.5BND.7I7_J!:A<*K3Q(L7DL9 MH05+EF71JPV\+Q39+C@%^*\9 BOA8%8@%%X(FRNF65U[QH_55J MKXWWO_Q=;:N\KLSI\=)!X4SL>8FH2R6BZO*E$F0TT>&G()PWB IVRTXH YA: M:5_Z]SNM#?6&ENEYL)A63_5DH^_U91=K0VW-,0;]7M>TNQ8O^$:H1Y?M(H]-,TF#Q(0<:FE.$7TPM&M1>(6M$? M0WR!*!D-L#@T(K@:499&,":,5]I59GSEAZ1WV\>&0>JCIVSF)_!@^,!5;'6H ML6@,C.\K8>($SU;!AYKYP5@.(N)"C@XEC?Q9@ 62',\%1DLK[9J%D4(DI$\Y MRELJP'8$VAL()MT*5ZG%46X8RUZG@! 6E@P*\BMBO+*RYT?^./ C<$5"K+#E MIDB:S*.10-OC;9I'#[QL%BDKGFD'M$,8K?GHIB-*)]-YF)$(<:0_;-LDZA?1 M]"&V;LJ7D0 8_SB^.!9S0?2AFV!T@Y6IM2I,&*4R*4X&1^GBA:X_&*9",_E! MZSB67?XX?QF\'0WJ^)_SO*=GPD98$#C.T7L($5 @CI&G0A0L."-U3P#I"1$* M*7RHT)Y/L?)R(2(P0,'*@BU5R4J+74)2DRZR:!4_8%55VH0/'@8A2WJP--=Q MLG/P8' %0+^Q$+D"RT)SJ6((UR;W&(SV203>(N$UKMO<;P.FLJ_80UWM6K+7 M[[FRX6J&W+6!6$4U++,_=%VCJ_VE(Y"+U>CN]C@135N9@@G]-09'^@+4TSZ" MHB!0A(:M;NO.0&W>"[UP"&H^%;CJNP4Z\92>8I@#$Z1T:,F&H@_EKN<8LFYJ M/0>63>V:W@+027/*=8+@^,/@[-@3RN@2U8%/2O97/XC02'<9G$;8KMTYQ3-T M8S PY*&&OKD+GAPX;:IL=[6N:ZO&T+1$TR,Y[QSR#)+JO,!+IO1T4NG,LE7? MSK;LKMHW^_+0-'4X?JB.[+I#3^[V!@Y\/^RY]E+,[VT99NLQUZYH5$-FIU=X M$F@[T/X0_[A!/N/G56X[5G3R!)1 Q3^9<*A^Q(- >!XRBMP'(P0,X;QQM%N8 MT6GB7Z"'=\E&-U$$< &V!4'W?BQ-6.^3^&7Y$2(D(PF$]0#>5/@@QW?H MC32<"1CH5Q;%&?O*!ZX/B]Y&;K!'? M= K$ Q..I7-$*F+\!_ '^@)Q&8:A%]^Q3O6]M>_FZ?+OP-S7O^3!D,;HPHVI M_7#*P#W(&9YSKK9X%0RKYUKU>@ M6=+"@+0&TSP(1LYKRI;MQ?2&0D)7Z%?ZY*@"8?\4?GJ)\-G.4(I[X6XB5SIA M);H-C81D>%$TAZ?.R(=&M1$+-O#-%-U0;8'0,,I^P.AZH\ #>O-[2&KCWH M[U<41/!,RIDF5=C49@_Y$9%#K(M]$08^ 5P'W-S2GA:CKG!:A0'$80P!A4:B M\SL3V)<(A8N81P7@;>U$)W#Q^302[C7R(AO&4?$67@NOR,LO&Z_@>JH*M<5W M$H$85U6,O#IZPB<"\)IS;:F"E+>B#X9C*P=PO(C/TNSB"<8_>%85#R\,E MKV2,RBTE78./RIF--+%4J 'D%X68:OR5^-\4P8AJK@6XUU$L7 C2REP029B( M?QD\60FH5*,7A'G6T,-UTU[J<([;A2$Q6J=RH?%!OAYT[\#G',,R)F!2$"TB M%^:"($YOH?@*BO,?U@,F.9T$ ]:8,;*#B,RC=4)N?UJ9FB.!V?7#CW"ZX*[A M#S_JAO53J\I?JO"/WC6B,[78S"H*^]G*=R%PG;>D0+3;F'0_EX=MMC4"]6SV M34>3X3!G@.*&<[CK]5S94H>JU3,MW?&,#;0UV@(ZUTJ-@YZ1ZK)2]R![0]V# MRD47RKRV\(^]XY4N9MN.GQ=XKWKU('VF'C'\Z$DHYO73Y$Z4=F5^)U&E64^* M# K >*);ACU5Q)S#LM\/?>QF1SO ('SCQ=:UN"G MLR0>ST?@=,]GL_ !+48>6LH=?;Q2J$XA\?=I&4K=(JS47'* ?HH M*H*@JW@N14+&V,ZIK :/Q 709$[W>RT'7VIAU7*8>AUO#UCZN_^ VL/L-#HP MT7T54!"B^//F#K@?\I7Z(Q*A!T*K3J5^P%-)0*_/DZQP38J/@=@^"_T[RN8@ MQY):/V H*4L>CF%\?*'T^7.O'L?*?U&/CU$K*/+;\PY;0.9\ LN5()ZG(%VS.7AB!)A;#\FAV,Z =1&=(VJS(G66STO,*JV\*,FW,P%\V"(.UG6"@!Y:3KM#.:'HPQI>X\G:GHVEJ1W=4J:M5 MSCD\1GG%Y:;R\Y.HN'+.M^>2N1>S 79)V AQ="/N8&&W346(@!%(&%@L."EF0A[QXKYB1Z!'Q=GEZ>- MR+ATQC*N2OEYOC"(U"(+QDXRX4_R2/XY+ T05AOWY.R\/BK:B1A-U]4\0Z6/ M@A:&'4SS"'AZ1V5#+-\.Q\@@;Y8$8?5[?O*R^'4_D22A^@LR2L0"*8/I+,R MO[]L;L4GDOB$'PTZ>%$ODD(1O*&)_/<\JB"IZIWB4KZQ3G[>GK#*V4_C M-;FSALC>UT46_]V0R?L5#$N MSU5\R^H\"M)%7R)99BIQL0KO1:J9$:X\EMKDFD6NLBJK4$57 &TV69@5 55? M;J]5KR&ZLM:I7T,LL>#2RTU4513R33&-9'F/O^L$ MSJ%C'E$32UGLA(:G&8)DP\C_G,-98AR(!+-;:L&0O[QA[_ES1 KE[^N2!>F M>?2.EAS?AFL%?GM*1^'J>U_-)M;S9+T1 MN-(4K.&E!7"*%18G[X6"C@VU4&[S(];A\QWX_WPBU3-+P"VMX$2=7PM.J=6I M^%Q#YS["GL=E9V9V5W;-1WKZ'+H+@6$ I..70^%L*ZLQ\%"J: MH"^F2&.(-K0_J-3O&XT\]JVMO)L'2^FTRBM0BB19OW;O1TUM,5&27BF)'_PP>Y"OF(_*K[.RSQ#%D4SU M.WB_V?0>XB0YLY2_+R83G2T61\C[-%)Y"#4;/-7W/KQ@-2C$;%#8Y]7D5#R?VN;8'$+D!>:QGF[^)2+A6A/FXO"!'[\3#FHBT&Y^/F2 MTW8H%K>=(G8OTHZ6+I'8X+DX3>,QC]2+^U9*U'F]K"VA57A8F)KSEEH%;.@\ MPWPAX *U:L5%YP=F3A._%J;E23DY#[, $X'0ZE353!GQ(HL0T"^I>^_9/$GG MZ%J([9/'R;C/\X2 =(27DEN>">\^F+OB19_>]N-HE#LY3[F'92*A\*1%_RMA MVGA8#GM7T?:YHG386J0D;])-Y[BRH>FV;%CP'U[?Z\J*X@Y=Q]6Z3G_/>A?FC%@Y*3E_H"S"Y3$/;.N7 MIF5<+@]\BSYM=ZBH@K%4F")*U+SUPWEQ",/&AODJB3L#L!D17HM2ZD-0K&&1 M&#;*[W Q/:B2'U;V_A,.#/TRO_V:\"V, 88)1G1MEY+EI;=&_/(.E27V] L2TG3P+W@0:9C0:2S*,*-Q@CRXPC/7+>/' M1Y'D&//+Z*?)GZ;\:3])Z(S" MO5QQ=1-1RW=*L\577%7N\M'R\WM\HFA5GR*[BV58T5G=G?@76K6<8Y75P=7' MQ3G-<[<[^4MS"_&R]S9>1>*8YSD?"Z//*]_PV7SW;(]6VD5TB\[[?OI%Q\5R M20N#+QQKW*3U!891R._#=2US/8H5IE'R!''\()<_$CD1RJC]N%6*4 NQ\6(E M(GY9=_O*N5.N0%5LQ$U$E;NT$+2;QHS;2J9#L?'+3@Z!;^,][#$:HC*"%MPOD4@>W6E1\\?(^FYU;C#74!.Y=0? M4X4!QG]Q_? H..4YS%3;"^9/] ( E5@TC&W5Q#B[^K1HRV%($\\!/(DD3Q<1 M^2@\UPGK-9#3)#7+LF*6SJS#R9GZ#YPD/#Z0I8JJ"PH^1'+-BH+??#;%F8X7 MZ);*8LA_T5!A*-D@]B/RI.?TKJN*1)&W(6QY45I,]1!PTDG&*!_@XR<=M.QI M'&.O8]S9$APUKJ_IS(TQDUNR_2*CUZ.=N:3DH5-U!:*XX@CPB,."*_!JATN1 MB@Q,*70'Y2#_H#H=V]5%QOSR0A&N,_'7KJV*7R^K Z$\];(:NYGFC!NP3.]= MY1BULO_?;/,^8?#*<=GU'M/++C!1_I2+[J!HHKS3>/E15US5D5>UV9<-6 M++GK#6U9L^$<9:I&UW&QW%6ME;NN04VC0%M4$I[Y#ZABL#?\:)3,V?ASZ6AO M,U>ZJW?5OHTEZ*9IR<;0ZLI=7?%DSS#LX=#1NJ[C;2!7F@3Q7_,X^]38&.47 MGZ0_3\_[Y$N=?/E59 8L3:D6('J7Y]Z7B^'I^>_H?47PZ>GYV6_PT4=)@_%. M^J=_\C\_#RXO89QB<%[TUD#BHS?*=^SJ:Y#)R%UPX9+X*Y,I>YJ^WVPF-V8^ M?96#",.!&TKBUC>3Q"V$4!+"O).L;>V94E-WP?FZMHA2N[S0^_XOVNZJKY>V_3MO_M9;;57DKO5E>IK M-ITN=M.E^MCCO'E9_I:F^I$<$^+]) M'.8P! (6C0J-LG3Q$+*?:,%ZQU7,E1Y]JWC(=L=RMD+ACC?0F]\N L\P\^_Q M)H*?'7>^3=9[HJU1O&*\D?WR4E)_U)_=Y.NG/=HWWZ#A.:?\F+PP^2UM'\O9 M2C_3_2/4=;;2V.9@<]9TT9)XPM*4UX5/V)O<,=;WL6-L]5OPTKY!:T/9#&]N MWV@=W7HCC5Y>2JJ*5VBOM7?>:LN76O!FSSI3;VMNNQ?M?:%\G^>V9Q;L<7NU MQX$>=UN!GKVA4%4[NGIH[O7\?;M_W:2V-KDWI>L/Z[)D)SX_,^&9-Y&'S(3- M9"8LYIP],VNJ/0.-Q]++S*TNOW;:Q[(=Y_TOLJJ[M] M!IY 4,:DW7_D2;L%BZ0*CT@B5ZGA\41J]&.=_);G='9$R7@M+?R($E='?GK# MTZ;Q#ZS*@&]Q:IVR,4$" \/'L#E$(R+Q!8P@KHNPB"")[REM&-\5)-5\]&KR M^Q4A:W&\#NIIE=[$":J"9"K:6[U.ZNRPS+#F^?UE[21"WY>0?"7"=;5^Z>A= M">-[Q9#)8I2QN(7&;&U.N%_-YKZBAA-^PM'2RYJ8JZ)76""&R!M^<3SCJ*C! MFL1A&-_QA&:.Z#OBW7M@5A]WP4H>NS+^MA3J\3.[915D*_6C]$?$P;(9)FK' M!'N&)6=4.^ISF4%P+Y:5X,A'A*"-(6,2-X'D4:X4(7[SLBZJ0!OY(7:L+%M5 MX@!\Z1"/I5RYG< _KI98Z4LM NZZ1^S/ MT6/M)SI4@O.#HW540^-@Y([>L14#RZIX;2:58U]CM6E$W)R"DGO(^3-!7*>B MD0>!/%$)"G^:J^KF "EV(!'5I0+'MZF*"%%/V.)7*Y,B% @P"^"J4UD3J?RQ M\,2HH@Q<,"ZZL]#G\#("V0 &8. @DTYDTUD8/S!![906HNB[T(W]A(I$^[3C MXX0SLZ(4^>ZF%R"G;EA8-.V+$!RMWA"0H(UIJP3)6$9 @X>*CHOD$*P0P Y<^'#?G!75D*.H\%ZJD^4#";7BTGN:I7<0W MD=9Q-(?O(;7C.DH=DI^[:'>$95>4D8TE! 'A18G"XHJ-)>Q+5;F7735BPAA" MRYKF?:"JVZW.IJJ_DF+ASY@[)8UM6/I%Z>/;L<%-[JY6>1FD]1X/9-^:99$< MV(_6^>A=R^^K->B"HJ5-E6" >M_(UU$9N!!B6^,K5RDA7O5W_JT?A&BX9-B2 M,F+/$(5YT7'M'Y6%1362L)67]O%=%X6 )43P,A#X&FYLKU_^ MJ__I)U1XU&IW 1J>1+[71SP3/^'@^5C%C+HVRDMG497B80&+X_+^(LJQYOP- M%:9R;!A_X]N,MPJF[A[DRB7Q_/H&#SH+8%N:0WQU!!YE_918Z'V85>601ZH? MCWGE!LVM,_X2_1]JOUX"YU?-5MY= $99Q/K/;75Q9O+3:L=Y\DKB GA]:0.T MQDZ%79/&,"\F?0'U)]D5V% =E[?1::+>9V*E-B>K1$/J 93SO#'1'C86U=__ MHFNF46\LFD^X3L9)812VU3T+.X7K UV5%0N>-@9*7W;[IB+;GJ[W0'+=H;YG M("T7%-6XQ'-3R9[5PSU_\C:2 0'7$:)')4Q2-<(\5+ G9D"X0"FKV?R$@W$F M5'V+,"5YJXYQA9*C1C\-LM^EFB5MQL>K5=^#C\? \QS[#_3R3?/!>Y$Y1$T: M\"X@5>@*'@&;ST"'M;EB':*=SI$%Z%.SHU8.4]$IE22=!9[JI$[X@D4[,8IM M-;N2X4(L]"7[)B&X3_?+?WKJ8/#8L2!'=ACS(''K#FO97R58TBA.N>%%0841 MBO,+H0;8ECAMJ!W54M;O +;40-3M".6S?8FC M:2WT*(*XA]-)(J6$G#JC<8 M?YR*IN4<(2((@Z6E_SZ)%J^>]O'J2#7Q[LC2]!KEJU#3@'M+0+E@*O".;\A6 M7%Z@4E-TM=Z;NS+GA<7D=V;;A5C0^X8U5.3^<.#" O5=V5-A@1RS!R/H \_H M.@>(A;<#L6!M!F)!E'!=8@G78P-NKRG>VT]BL/8LB:$_+W#$5NK4V>S3> ^#$T*"R/7C .\F&*(PPSDS MN^-XY=E-?G&-)XC6^W 2O.N(G$L,_!1W T=51#5Z/[P;#GJSF,XU^ FBBA;> M$YT_BA_R$-&1 !:$@>_\1-P+U>[IBC-.<0&2Q9D?EI%_&.RH;%#]\(3[S8O( M"[CD&K=J_"CYE;.+XP NQT$M6@AR(/D*Z&F-;8\P[1@%XJA @"_AT!!O4N"@ M(7&"DEQ>,- MT-]I5:J2(B3)K\-[X2,"U9Y.I#SVR&=? 9YN=KXIT94/BF6_ M%0N%N!5GH2&LS[, *C"+F')"T=6\OQ1NL;QI>V6/<7$_AHV50PWF('IIF5U0 MC'OTKC(R-DW("/D2H\XSF'7&Q#:E:_EGWZ&E 0[/K_%'0G.-@F0TGV)4>D2G M<8[>2@"3P@27$Z-[9\R]X$A[8T(.S/=)!^_T!2-R9/0X$0JYX$Q05-R7-CG) M(2K$W5UAN6OMNF5R D2#\A5\@:.\[ MQ1_U<-DJX2A<>EEQZS&H8A02Z;20+V&Q!> V&13"!T$I<55("=Y!Z7!(]4%FUR>ZJ',*R\$"$">9!B1Q>O,7)J/D49-R$;2^GTLH3U 45 M=P?;EXCM"5J+TJI@NLL(!^T!WDJ"_G?,&RH(&HH)%Y"IK?HW3>-10.%;<>4= MU&9'&0/8T*-V%FCC'G7%N'H0O^(HN\@D1#8=93E+VWBNU+4+_[]ED<#E,9(E MT126GB$*_1Y&P73U_2^J:[C-(%AUWHT(9RYP.13B/D:]5"#+,!J)X0LSKQ/V MA66<\,^TD?:0* O62C.,>J.*VK3;Y \_1_!5?AL\!_I/B];;7>HY4EGOP7V6 M^'DK\A,X1*5?XH@:S,=A2(%@<9^_C_PQ@#^6KCLMPKP5)BQ>(4=9G#QLZP:Y MZUK]@3E09+WGVK)A]UW9[<-?3M6 M7[#7[QN#QL-T:4N>.M[9"ML/AI8?GXLK,C2*_&:6XNG\JJSH,2#:^_GK.VMT M8)>#J+/$75MOG'B>+1E'E!R(+)O:U;P F\\K"EY0/G# WSW@[^[I5<^+\7>M M _[N 7_W@+][P-\] %,M@4'T[S!CCX'I"M\,X*[94;2M0'CL$86Z^VSDT#W: M,6]^?_P9)U\I3(@=3-.W!WVH=A3]C0#Z;(+45P/V.5B9QW;1,(CX]23VN7I[ MF\CJ6,9W@KD+AL?:"ECJ=X*.=4#<.ZS*'J_*7KE_>^Q_JUK'5NRWH?*?#X1H MO]X9XQM0]0? O<.Z[/FZ/%%#<)5P)(B?WWNS6G"7Q+1B(QQ5)V!IV]WU/N:4 M:.K[7V1'=[5FGL(+Z*SS[#,LP.FD1XG40W]$Z<]_1',8L.?CY4GV4);"#QD[ M@\6#O_SK#13@S>8)>[)EKCE0AP-]:,CJ$!,6--.1/2S]=C75=$W;TO6N)EKF M'BN*;ILEFYY-6DL=8J]:!%O)@^ MCGNBP_$EMC?V*>W-B\:79;-CK\A5@[4[ MG6#*_BZES1M:IN=9FFSU5$\V^EY?=E':;,TQ!OU>U[2[F.Z@O?_%,)7%\L6- M$]\ CH23>\8^P]@+79[;7L$'_=4/HIUG%_45>ZBK74OV^CU7-ES-D+MVORLK MJF&9_:'K&B",.O+1KN=+O8C$9FY,X_ERZ U#;/;4WL!PX0G%5OJR8;L]N>MV M81,.NT:W9ZF#H6Z_-LR"R/@HZBDX3\B(T%?'TLE"L84HCZ9J%6D$H@GRC F5 M(7S8D69^5J!^S)(8LU@E\F@) C.'9$3,N#B,KQ]$5C7B&S$$QDJ/I;.E(U1? MC0DD:25A$P8I4(JJ=1^(5J+G+F^:O:",<$C[+( MNX2 @L=]?$A&:PPC3%EV$X\EA$X3L"YH5Z8".(I-YB',Y):#P:2( 8(II)-@ MDF&!RP/S$T)?\"I8 N*M?DY12P7,DHJ;HWSD/GN$+SRD=7;?Y=(X>+1P FG]P.Z!&GZ@6PNP:/@U1./.# M!2] :,LJ4_+$?YH\C!E0Q0]J!A!1KAJXF.7:@:- K%9O_X3&6*$*G8#1S@O@ MUWWTE5101(9JK%"$WB#F:8>H5\(6;4JY*J[B.*YCR+K6'\A&UP67IJ>ILQ&=<)$W"3B0!:X6!XOBCYHJ1SK&D3 M^!(/)9 4HCL*!*82-[ 5YM:YS'C_BV/6L\>?IJ1.^>_^/^.D)]P/ 0BVK7QG1QGVACU=!T6C M*;+A*0/9[=J*W,-S@69ZMJ*\NBM7S^+-&4/ZY!\L&L<)@K#A"4V<8TLGC_Y: MCIYURM&Q>=5,[N^EN:(3)76:]K=M>%5\V_E M'):^X#&40P0!N_''4H25-_7BYBI74*EC2G(-_"[)D>5$<=?1NS4P!(XK#"S9 M5Y(A**R@ 88/L+@%.Y?.YNA=O9AQE=F\$MHC K"1%X90V?G>+JR<<,1%[2@6 MTX_(4Z@4G<,8R(OBE^1L DN8C%C0,.@MB3BZ[61F873Q"=GU>81"@H,D\/== M0+435-K/G^8%>^)P4GEQY9B0"@@(6+,0^Y^CZ?XGH>G&17'9.#^5P&,5[&_0 MF:'_D);%Z?!O\!Z3P@LHR.+%::64<)S%3M-5.'HGG(4Y%CUE=W$-.)AH"G"+ M9@B('X?&)I2G2 GOWCF%IP%*NZ\**KR3[:5$3/TBQUH7[N<4J>(OPL83,_ M&.>=3$2]FA>-*;+E%1&!O>.&AIA:IF(^P8Y5Z&M&R>^\HJ[X+(DC^'/$*JBD M6W-"3,]RT&M67;4O&^" R XX);+;=RS;,VT;_.O]>DMB-04M>8 M_937B5/E-:]"QI&%T:4S'Y;?$=:!@)8LU'4'Z\J)#RN6DQMP JH7*%7Y*/!A MN;'KU=XJ%>JLY!(/SN#IM(0-B=@=NCN"+1A+07,U!96-C626P*$0!G"2VP4R MOCGYUV%\AX2G:BRCB M.*09PCX'.:H*A6PF%&!$M%-,3B,(");<$M0ZC%CZI#A2)/#)\VX4)4(+S8/# MP/(0$&_M037I8GX81A*&F#N7-#MV+T)>O*T'A[U?F(K S@ME&L'<@S!_'LRP'FA&S_28A27$Y<--+ IH!'24B'M>>!VG3$@]BW7U[ M7-NWZ.(N,+A@+TRF#!=7==(T'G.,_X1E25RT>.*3.ZYJ*^D/$;NB6DK^ X)Y MN!.H+KD;.P_YKL"^#:6J8O=!RC>X<*>7("@XG9K: WDLQ*X%K\"GXLP22"(_ MCU0A'@KQ%^I!;"7A.=X&HJ]!B9Z4]V;"^CVAB_C;N?L'I,U @,YSJR"B=2 MQ\]"X1X5-P/B=%K>)7(<9.(:2R98#4C6K1(4S8.,XO Q9JC-A&\?^E>EJL75 M'2=SD&)^3XX*+TB+*:89^%33HK,(05P0M EA2ZL\ DJX8:W'63JADS"/^*T[ MXT,(5@K<$0&?<2-:5A7;&<9^QAZN;V%Z.1U?Q"&ET:VBM)=4UERBV^<0,\ M4JW"@5J3]Z:LJG6_I_1Z+H !83!Y$.H2@T:5IE"PSD4R2^GZ=(2M$V=X7!4) MVY;AL19%!<_)@O6KSK*]?GS-QYMEX_G5(#56R\D@=5Y22*X'VO[R%Z):/EM> M0D_2T2BBQV/W/!7ZF((OM??4_#8:E+M8-"S,C\.HBE$=NMZLV!1R9%HO"H4K8QVWYJBU_/6GF X71[$UUA#(^DK% MK>A*XCJ5%)IA?D" M36#)BK9,$WS&(WJZ?)>C<$ZB*J 2^U0FG2:"FEH#B[!\28K[4V. M"P"QXC3(G2SL>9*WMZN$D)=[+_X5:(!*OZT.QM;R8Q8>@RD FA^RJ!?+A*.( ME9/L MO_X-AXZ?+X3GFG*_(BA\93PR@.^94!?:68'6>\.JN('T),V8-QJ9\1G7?6SL M($*MT/B1J4"C1&D#=4& OYVBHUMU CY'QX-#F6@HFJ<'U%NI452F\7A4'N&S MPCH[/-I612$.(CKQB? MP/-YULFBEUD8CT*T*X&24L_"&#-8 LQ\+VXJ84_4W;-ESA<\W#@*/1K3K5PY MLYISE7=+G>)-IT@OP^4HI@XL>,9RU%Z9J%%\Q6L+MI5BZ%VX.6U:,99NCS$]-Y5_C M>,S/*J0KZ!(SWR.ZB7ND$5Z1+C&3$64T?Q1G#TP.$F3?:B$67%8IC*-KU)\\ MRDB:[N9AADJ5YW,4:1]"<9=A2TQ3X.$"NE01DPB*26 N-@B=/^Y4/BP.0D6; MU"+"3L:SM7- T8U37!'E'1L6N@P?5?LJX#6UB'7.9RAK2PYA8I=SUM=/8>1K M/!8":=_W/-S@KG:6*C-LT(U**]S(-\U$&'\RZRJRM$M-"+S/%#D1&)[DWJ9;QT <-^ES%]1B FD"QZJ2VS;U!77+M1Z(2JE=8;5Y(>E8YG%1Z:1<8=L^6>Z9FR89AZK(W<, 6Z&ZWZUB6:@S<#?177'#+EZ+I;K:# MX9GWZT#NG@^\_Y%/OER<] <;:F.H;J:-(9X(\P#*(^-MKXOAH\/@;1 M#N-9IYJPW,E;.5,^-68(CP/_.HI3.%#4DL;QP#?#[<*\T^D\BL'5QM1NG&'>\+DXF('+ M#X8IB2N)C)4Q,8DBY1<=E*).H.&1>'=.#L:9'V88 <1D[3;R^818OY<]7>4:2;'$QF.6:R!NUX[NM;G2A$4@F[D[5Y\S#J) MP7['6!5'\11!8T[%5B?^R+Q_._G'RN\.(OD&W+9%POD-V:TH^Y@7+>;PU H/ MT.KBT6N.53"4A),O)QBA;-6?M]+)7CX!7=ND^K!!H MBHF,G*:L.RY3>:D)GE4"0B^L=U3 =/PGA' M\V]0570=1&D;]&"&4>\4V!0R<;MPS2*,A)2A+%S^:0P#S4,_R7.J\I2P0@+$ M8Q@*&(5!1*&4_#/)'_EC-H5!TD,I<*F\H^6-/X M%MNV3;")$E@J5-9?@4I@#)U#KAZD4?* #L@UPPV/N2()8_^F!+/3:G4,5>C& MH;B9P,'_P$KLL43.3"I4166!0XI-(>@_)@OF[,.TM%S!D.Z_B=-9 &=.NJ/# MW^ ?,:KW('L0]WYQQ<6BHI79_"H$-MTP/\1 :.WK8CDX8_-%PINO()L70Q3 M S&FCE_CCHQX*3(LPHBF-KMY2&&Y0+2J5R# S ERNL,OK:9X_\$#3_".\1Q' MQ1Q$D1O1R;6($(W\0G$*MHL$@O"$8#*4P4XAL;B0O[2 ,1"L9=DJP9U->Z1+ MNEF)S3&$ M>CHYI]@M.K(7['I#AWHQTI.(2T-=4S4;3CJJYV&M<-^6NTY/@S./:77[GN,, M+%$KK%68L'3B3P0P@&W B^SA+/2C##;7 #Z=[;SJ?=7X#A#MV,[C08RE%-4Y M00DH-V -0$<-*&D"[\>W>9A5NZH&2VK#.19WO*4ILN-IFFQKNCK0';UK#[4- M'&:_NPXR*QVUUX,N7>F4;6[FE%T5Q*J1QIPGDLO7.7N__091UKXUB"JS$6#% M10:;1WDE]?+%0V?@?5U"..?QK)^4EI"[]B(UJ,0&.DW\"SS@7-8B1."T89H% M3WRD99?01'6HK_N4@R[\V*SOXK_&W]6.S)1P5 R&7XO[W+1M9ICN(?+74L0" MR% )TODA@5,H81Q0U6:$Y2$^ 28D(HY4Q07PQ[=@T@E4@,;%@!==Z6.:[)7@ M#-ZC%XRH3"\/P?QK[H>4^$M7W%C>B[??-&F)WR>GV+0[*G[7_([^*?*$&4*W M4463 (A#6*4D&&4%[9U:U5*>+4D1/Q$H6V 7G>;+(M-:4E^.$L:K%:HSRQ$& M\M?S[_(\09ZS45T',8ER"7"(.A*<"+85YR?*G$CAP)I75.$IDN=HYWFG^+I5 MYE]F(O$Q<@X)1BS0@3Y=*HF3;(3Y ?/I3*3FB/S<.XS&S4IX4I@2\T5[>QA4Q&V"SR<3G@Q9)D:.,DE$/<&UD#CDBXP"J,/E/HQ9FRZ,F.IQ(\/ M*.JMZ=H:DQKY'L3MG6>_B.]XAB,"641YI2@1]FFP(-H-)2*CJ6@"T5#7%[$8Z0X3<^XH?,Y$E_4%P:_-BFXYP+;]X'8, M\;H?E/5QA.RC=\54.XUI>2F&@0NXQJQR"U5+X^5E:X]TC9=F,0?Q1(LB8=01 M$P#+]'K1E!U)\E-1_X:11\(&JNKVG!NI-)XG(BTJ+9*:7UC[_NWMN_N]VG?; MP1!X^PNU;_US\;:YZ'4LB8#'? KOE*NKUDG9<=?OI&P>FAEOJD/*#IKWGLY*Y,ZGPY:'!KT[ M:IUX.L\H=UY4KBTKE%R\-MW[1H.&^6J-!K_I#K?Z>@+V*X_,O3D!4EWU&Q"? MMZ"QUA2H@3@0OSV1^E'M&);V7*GZ:8_$ZAL0HAGB);\]$=*>W35RG^3G&U1+ MPSB9L. M6KH?U6>WZ7RQ3'T#?3H/S7\/-F@31Z\EEQ5O3IT8'54_]/U]_IX] M])<]9)B]Q3OFWL+M,O6[,TUQ"ZRZU>OF:C8"SRJXHS*V(GED7+GO7.-N5^2V MM-SM%I'(AL319R<$C1^)XKN\&2,,5 %E6IPR$K;TMEK,_^C=,R@0\T?@7YP3)4OB*G9 M=0YA@:#(0!'PRT#2-(B"Z7PJ0,IP8$P7S6$@2^)+3.9#+LA^[],G[CK;\\AJ M-YYKB_3ASO-PYWFX\VS>>;K*^G>>UN'.\PW=>7((H-++V,01[!"I>^FY^T3 M#Q.,-?IW;-SY=BX^;5-YK(F*(4711A\4)5#E!?U))6^Z2<5:K!R[O% MC3.I:%W&"\WSPG6\O]OXNXIFMC,F6CV)TO5CZ63"KVDV_DY1&X_5[Z*&GJ\7 MRBU=$0+=\.^(KD[%)5%E59Y>$9IW0\H6V-D4*;_RS!&OQ8_GA Q(?0VND_@N MN^&M>E!<:LTW!$A?I9MKSKSJ1);1/8H3O$6->2(/[=Z"!^("^0DNX"/4!($Z MN6>$^H@5V:+:'N?">QH@K'Q^R8P\XS[8,6_?RX<41D8P%H8<&^'PSRGAGDEBP2W5*K M"\PW&=7-MV2+Y/ICI:OI8^E+O B,?HO>$XD1 M( $+==^U=4?%=LB".&1!'+(@ULJ"T Z5WYN-;:T5!MI!%@0"71^2(-Y"+/>; M28(XU'[OQ9WCFTV"T%ZM@.4[TUK[GP2Q[B(_/<*BO)7>)VA;8V=3/:BSMY!" M\9T+X#=P.7I(P3@8P$,*QM-NE^68!RVS)UD.>SVY]59\C12,[P BUSE Y+Z) MA=J[\'A8[2 BG;,"%?XLB:\3?TK+=^@CLO=]1$XCR9M?S].LW'DF.@R*TZ$T M@VZ,];[Q1.J7+3KRKI\^3TJ@Z]%B_6=\_;%4/9UC#@(E"&!SCCN6]W.=!IFX M3/5YIRQI/L-[VECZ03,[BJ)0EP-X>UP!1^G35^?)'RDXG@S0+II1[ MM*G>>I[9'9H./*&H?5MAJ48\; @N7&/^9T M(\?A2@I6D/3-"]-=_)C^."X_HQ2)&:A^GW>PY+EIM5RZ2=X2%?L+BYZHU,0X MCC#5#W,G.#K)B'HW4K/W@E4%DJ) UHNYF"%2U**?NLW'!0F7\1\-00 M#PMN*>&!]^1%ME"SX04&SK. =RW!E-SIS \2Y#R:=9'3C+8KB,"<7P8:IUMC::,E*-[(=DTK&:2E<9:P4>\%<889G?91_SL?4 143O'\O9;+,>\3< M\.6222V]X#^O8[X_* FR(\U39.I-@ VZJ6DUT@4K0^W%8 C>50S!>Z@I,_E@ M1^^JF^**A9B023F<5Y@SZ6-[;5R;LG':*$A&\RDZ8:)+,Y>:W#4:S9.$:($U MP2;=X![=!DE,S9]Y,W+*TY32.;U\.9%WF".,DQ4MX*JOA0TRPGV._#L)PP"V M-_P"7*H@RYM[=Z3;&&4%YL[(--(H( @LN([$+$"SH71=P8](-H$]R$>^J^:1J!> ^001 M+ >.C[!*3W"#.@]Q5204$6]F?<."1&*D9BCSU8^B&)<1IIFA5XUS('U*#>E2 MZC8@/A$&2C9/%&^N@^.I=X-;%G.@NPFKG[' M74X8E[8W/CPJ&AM+H^ICK%5":OWOA*06Z<()FV!K^E+E+S$FJ&%H6H)A2WLA M+7I4=1>@X3;Y8(#.N2K]%?132CVJ]K M]_M?=-5P&KY1R^0;Y(UN8 .$#!LU MS;&GNE>-/X,FNOZ4FU98B"/>8]X5-Q M2(M864D@73V 1Y,SCQL4OU.:%!1RX&!AA[F"Y2OQTG31]<.L:Z0Y+K!L:?[B MRHF$MO7"%C+/@%,RMIU(^(JO?E8.X\*ZGGF_#N3N^<#['S@N7YST!_N;M/@? M"OW/2AF+5EO&HG@!92E>8@2HG,;O% HJ_SW F%#EZX7@$,U[E_F.W^]:/IY] M6MR$;FPQ]I]@:^?2MXJ)6"I^N[^G7V;QGW4G7PM,[/S2_8?GW;5K2LHX3F M[\8PG%*4(V'71>/#M[1!G(YI;0429_](U3N*\6J&XJVFGI4>ZYYEMVYE8KL7 MZKT@>V\G]MJFZ7%#M,=>L:YU3&,KU7%[0Z+F=A3GT(+HF=MT__*(MS.SMZ/1 M#RO2MOM>EM;=N.*Y7V&ZV[IA4M:\8 KCZ%H. \K'Y!D55WC/7=XST2W3X?IH MO>LCZY'6&LON<%3U]>Z/MO_NPZ7#LV/P+?=!Q3^^NPN)/ANQZ15+EO/C<%]Q MN*]XPJ=7S8[C?-O'%B#Q%4&HOYO[BIX?^6-_YW+_TABET='TK;1FV4M2M[/5 M#X;A&[ZO4+<2P?]>Z/P>(EN'R/AA/?9O/0XW%=8:*K'F]H6P,5$_N&CWXCZ'=<[N]0=\<]/>K6CQG$54D%OPA M.5ZE9KSV.,L?/^+%M537-T8T#,2V.):\\3@0-; )UA0C[ @O^Z,&*?XLR'RJ M.<;"U+N;@-^/^4'"ZR6Q.U#&(FHH0P_<8$,2*M,4-<#'4I]1K2357!WQ@FE_ M&B=9\&]>AD6()?#> %$_>,DMEF6E6>*CG,E8'8J-BF[BL80UI$>\4TQ>(HG/ ML,D\E/"&+LV+NO):9GYA=RQUYT$XILX]'$YEG$^*\4&E[(YA#2E,?!(C\ZAW M3$>0C,7-(-M)R4YDQQ3;K40L:7":E[5.Y@EL2:R6I'\%]QDO/D]8]=TPBGA[ M3(TO6,1?7$YX<5$$\UB5&UBTVLJ/8^E/+/O-*\%1 N)PW,D14SJP[,B-(!WY MR3COL),S;U9(DBA]Q^<37M(\KK:ARLO9.>E^]"!=8]LH$*DP3JFY%G;QP!?D ME:95# ,8H%)N"@L81,!PD!QO-)I/YWPNXXH4X6]F%2F' 0KN8UT[?+T$HH_F MUWH_0N RV' $!OM!MSJ.:=&/\6_%LCM/(+\L6IA5%5U=/0IK=,Z;GB"QHM 4 MQ">"_$67&P8)]5/=UHSVQNX0UO5%-G43174J=N3'L-NK]_K]84Z MU72S9C:>0]JRBEHR,E356>U?J M;/6&)J*3#&37M539L\RA-K 40U-Z^U936^FZLM!7C]HZU1JQ'+U;#[/IQ8U8 MWEIJQ(M;=#RCLO:1;(K-?'[(3GCVA3QWB>G5ASOWW5RM?-OM-FSS4&:WM@1] M+[TTG*W<6G]O^F;_&V5L0EA^U-QG)\#\=% E>]W'8B/R\>SKH!=+QUN_+#E< MMGZ/9N/07J+BI;Y>[T7W^MM/D2X+!@Y$,(KQ;.6$(O[?II,(*1 MQ878EN*,JJX:^E!UY*'F#&7#\[HR?./)GNJ9KN4.=<6P7SO.R.]-?''!-"%< MU1%'_>2\D9C@706 G?X?P_ \2IE^;]'#EQ96V>X>-OA]Q56A6D= MPU"W<7+9&Q*1PE\_?F4JUYG43QI=V+Z@NCP:;5<;6M@(3M(:UFQS"WXD)^ MVRK>7&\C4( UN&6B80^J=J'3\WYAU+^KGM#XYC:.VG&,K92L[1^IEO9JN2MO M_51RN&X^K,?^K$K?CUT^ MK,B^KM5?>Q5C7&LI*. MD^B615F>+9L]!Q3[NJ6)1M]P^[K0Z?OV?H6 M:CB(\_^:Q]FGAFDLO_@D_?G;R>5 OCCS>C!(%"=3/X0/03+HLY,OOXI&/V0I M+\^]+Q?#T_/?\:<1$^_[7(*?%?/(!:L:;)BG?L:NO02;C MJLEIEL1?F4SU!^+["2RH?.LG@1\AX-BU3VA=Y8BU[T?^K/@JE_U<8 *!\57B MK"%43AC?L81G'J49W4I'+),2!MOSWRA9, !LU3E"@V4LF081@GM%DE_?(CB) M?-$;JU.8M$F0I)D<1#S%'I]8W&JKCQ//LR7C8"4/OU\GV+=X.DN"%&<]$9!@ M!<302\MWOC')5?9,<#=3!K7:NBPNP=)JJ66KLX3#FV+HH?O5J[W[654\*\G= M%2C:KZ 3TV#,]K>HI]0MAWY8&^?'&VF)]6QQWGT4?Z6ION1*ZMR_DQ#/%$Q7 M^&:Z9ID=1?NV$?3-CNZ^6C;$!G?,F]\??\;)5T33G27QB*5OL'U01]'-M[%5 M-D'JJP4I#U;F46BN( K2&SBX7L?Q^.UM(JMC&=])DSHP/-:A9G7-Z&W-B=ZS MA.1MS6WWHKTOE._SW/;,E#UNN/;8_U:UCJUL!5=M?TA4._;KG3&^ 56_?[>( M6YOO@QV]R'^TOTFV"!WI)@C/ )B[=A_(G9_X#?N1AHXPSEDSP[B$:\>$3I"# M0V,/F'ML(L-NOR>;5G<@&X.!(WJLAIP/6R?=LM ZM3BKWL,Y64AF^!^6Q?T'1-U?R\@K1RG6Z M5F\LLJF;YM"V[:%L*)8A&[IIRUW%MF7+A@!1<[S6,V\V*?%"/3'83W1'$F7>.)$=NX MPX 2*:(4.\C'\T0:B9>F%#[%;NRS)![/1UE'8O)QCN#!\ZTAV3;OQ;+"TI>LG[4='U'@M/F)!7 MP9446\'[\ \D772-OT[B% /(>TJV6">8,^VG%//[8)5@PK"%R)'Q.8XE_!=N M8D(SYNCZQ]+E39"6_$C8) 1NI.)Y^ ZKDT9^**4DBLBL)& @?R@VP#$_"%%D M4#3Q97,4H ZR\(Z%(6_($V)DA\TU>[@TRA+P2T+'XZEDPG>2,S+ MJ1(=?+1Q,)D 4_),9:!ZDL13VEOY%/QI/(]@\\%, A@)'L[+O$A/(_.F_E@P M*<-5%*\ISRON)WP3 IE>S>F9NW@>(AE7##]'!1M$Z%Z!P-S=Q"&CET72S$\R MZ>I!&K$$%BTJUYF8!+_%_41C21&#QV'%_/$_07]4"3B6+F[H)\A7P8@0)#2$ M58+'&\L'%CAYD%(PPL$$Y"W*JBS)Q1/>S^4R!BD$+D37Q/P)L"0:H4S J^=A MAJ8#7PQ45ACL$]HK&Q\OVMP%(_FX9:I;L1PQW.. X5_F*%_"NJ:G)4PX590^ MVZC-___VOK2Y;21)]+LC_!\0?IZ([@A"C8LX^HK@V:U9=]MCV=VQ^\4!$44) M8Q+@X+#-^?4O,ZL*!P^)E$0*E#"[,Y8HHE"5=V;E =N@AW@_\E= #!. R2S] MY95JKNL\V[)[YL#VU)'K=56KV]= YW7[JC%TX%_/M UG##K/T%_]VK4]PX/7 MEJ??ZT0K=Z$E E$,YTA@5^] !$U"EA[@TG+[^/EY:..A@/ M77ML##6CZVY3[6V=VO;+05W3_K'U.E#";+\$*;FT55X[SM@TJU]"&9PY;[^! MHA6W+G-!]$+5 <5@E1*BH0%)5'>],);C.MG74MM-ZTB= C1,N9GQZ MPZ PA5 1HMKH4S$R*:-WJ+,B/G)P5[NZ-"'XS,**I54H)%BZ8G7!=F8Y:6Q4 MB$2+M#4P*R_0W/G )M=1/(NO0M1TY]'D#)[_KE3G@Y_$-\N/AC]]SRTI6 DU M^&RIQE^Q#CS-+X$O0^""CC+\LX>710P< /:9+UQ?%K[P6VW-,_0S%)X^ [XA M.@,9> ZI3R8Q&G7XTDM_QDTAM+!!VX)EP&8A&2B@9L%M 1.'\2_ #V!'9'$M MG#KXZ2OK5-];^UN>;O\;6 'U/_*$CY75!WSKM2_.&9C_$N 2,9B-_U-S MC>-.2^0G/!;O1(40!)B&Y 8Y[)9<196'\1:(W!'H0D@0G413] M+Y*-KRQ"%,5)\AGJ%CS)V<;HZ[:(;"NNFBJNUNV7CRD1QD@ZO[<8)G5$TX8A#M4I!BB&$N?^9E:X^[Q*3IOE<3F6YC/,,*!\! MB_R&";J%[*H_E@,O)C,2^K45^+P7SFD\O$([@^\P+JR46>A?AC,0IA3Y08F$ M]TT8*YG%&)(2V^!@1'#@WC<_WQ'2F"]2?9^,TPDS"KD[2AF.4K47 ML=%/(?VE\ M'J@*35HG:)8W$!(@'809*D_4'%LP73D?0A.D+*V(:J0DKGI [!)66%GEWWEP MA5]$>_N/DB89!SIB(DMOH$Q2O/"_5S'G#^IRU%'R%(%:":%6@J>X!(^+%@'1 MK]?AY!J>KC#%)9C30"L4HN?Z-XTCPC51.!'&)$PF^1Q#,J!9T&+E5$-)TOAG MGK^N,,!)/ \GH*>^A$D;%<'>ZFN!02;(YPB_ M\]DL!/:&;R0,["@X3O(9R*BC?(F15F#OR/T@5RAR%X-?\)KE"Y<).18JL35X1RQ MQ:V0*Y!6&/>'"8>"#=\M[&:('^U+T*NP(!9TO M0&LB7\+/7.2C68DJC$,CCWB?0^RQ /)9NI)@A:7X';P1BY:=TKP*Q6#6ZW@& M9)5657ZA<%*Z14/D $-'F;"D\GG.#1K@GT3+R;9XT5Y2C<"#O^(;T@1MB18J(]9'$AU5VE?G@X,!'*.2* M%J]588D2ZK6.4]-LGF6@ZQW=UE82#5JR/S$[:HP1W;\D@L>%U7P>P?OS.QI5 M-V:_B$C#;=DOJ+,I:D+4QX>>^^DU=_C@!W2)0)?"7W&/G?(2JXQ"<*^L^,/" M7_+8Q&*1Q-_(*2%W /VDDHAYC%N\M'#@^;=*XU")"/8MO3>;WL<%+O&R#8-F M1WR=P[P7R -YAJ5BFC M_5'Y&/%8%R!>.![.N _&[(3,IPQ83)45=X$*Z4_=/:N>TN1=HZ-;!O=A7;/C:);PB^G5Z#"7USMSP,12 M4A+>]90)*O@+O]&I1HE7%ZAZ]6+2R*HQ ,\4KE9+H\VFT;_10,=B"1\!\)_< MGW%3/L#TPH1")Y6[X\7,C\@@$Q=[Z++"6\E^8_/%+%XR01=S(ME49E/U8S^A M>/V0-&XL;IPK!AS7KO0"I*EK-BMNOB)_7K@1(NL0N<8G\1LF@8H5%$5\\%HP(7"2;@0\EOIZ)O:0L(=O%<5CZC*Z;B&*R)F'<]="9CQ$,57G]_0\AP&O)%(Y9WYIFN) MFG$E=TG PL(%$[K<$R M+')(N*]+]J7X6Y&XER+M>99BJ636.%*KDN\2TJQG+,F$-B<0M:3N7&8P8 MYY>!+>XE\"@]CY)M2;1?T0<@<=(8]L64/T')*DZE8,-$](+%, ^S(GL%IB4[W)"4 MTM8=M_,QV_F8QVJ0W,[';.=CWIF7X7=@T2V&J8ILHCN^.F!:S^Y MXJ57HH_/F3)DU.^D:+WY\H6L?!4?85<0>&\8U/+P .@^JB\5.[PH;[B,E2V.<%GV#2?*;/P2YDI(?L1\7RW,Z6?A[. 9SP2' *Y*287_Q.?9A*,")O7;F_N0:]I:L0)IG&$[S) HSV6=R&G[+> .I MA%7?#:N(M\>4D,\B_N)RP^M(*:=WT7]?)!&NY UN[D[?J_1G"*I4A)F.%2I_^:)*Y[T2_3^0"OF '=CBA-G*=VMK5]O\HN>E5FPY>ERM;A#"*O+H8WBIV<&\I M]L8B@1I.,U9(-EBERM><4^4B[I7NM:QS2=HE?$#:^$,[_V.H[CW2*,0MZ3AC?IHG8/ M-KP "U*K0!&*E&\>U@RC39W3J$,S[\?'>^:T,JKY,JIN /XF^BSN;/(5*VQ( MGY.+H;G&VP>GTG#Z-J&FUJ+Z0F31\DH'RJOUPY+#-]1K1(Q2\ HNQ<:35/\\ M#2FY:0,'2^$HVCA5:@JHK5[9#GA%O&%K^$482!Z+XH9-+Q5 M;YP(SJ\LP+Z%:$4/1)_%CV<79YNZHFYKH+K U,0,)&?1 =57J,8IXYV!65GI MR1N@<@S.PL^PO^LXYBW&"F@4^Z+Q,U_)RI)-1&F6#HV-B9-BC:5H+!9G+S.F%((P6IP;\" M$KG"FK9Z'KMLF(X?2*HE4N5D7?_R1NI#V<6"5'@IXD\O7] ?RUQR;/1:[IT7 M"W LS4*SI\O'Q1='\#2!-_;6L]O75G'7Z!*IF1/A+ $#KR/\.J*)5P84T]D)08G+[EM,%^G:FQ% M<<74>DGUK&NF5BN=&BV=ZCYTH8^$ ^UV',\4/O&-[C/&X.#;GJ/OX$%7_.>; M_>*6>)I-/.L>L9C$J%1&,>Y_'_(WH^@S//]?MC8M%;T./3\!OJY:0[*0_ BF(X5;[RSGIA+^O)%,;^71GSR MH1.HUBYYEP)R?+B*+:><0QF2%\X#%'#F ^$]".DY4!I/5AR*C3BW'(?/HQ >LKX3];ED-G M?R_&.\RH'35]C#HT"=.B+KAX+,1I]M5Y:6$D P\\BC*7N?DB2%H;9"S#@*N[ M0 D);A5*O'8J6<,EW%NP,'F5JN#F@I.!*@M>1)H^,4XL@HRP@0RL13DS6QZT MH] @/92A4E;QKC8KX[?Y]47EYJ4R?TC200MIUI*SK M""^8V\V7_N2SZ)ER\P[(I"AGA/.+9I#)/*/Y"*&/JYQ)_4DH4>+0*VM\\8;T52HT72WY(*E/0Z7"SD5&V@ MQ& FYL0D2).78,<7CF9%/]*%^8I5)G Q(3*+ENFJ'R U9[A4AR@-7Z:XFSV<1Y'BG_S".&OI[%C2#JQH+2!Z?.@UN88L0(C&2P].;*!4N^A!,Y M6FU_93>(55AJ'A=^QKK&ZUTEC#L %.OI75[^%3*E[U_[<]Z;* O.@/*VC>.E M47C\F4T3?OF?RD^&/WT/OD.\_TDFL;J@DVS3W,C$A[8Q?A\(ZV#34$"ZA>'H MK?CU6M$XDHE^8!SX]*^(!A8:;[&['!1W"AB7#3?,]QK>$W*]86^H^" M[G+YCESZ*[7!$0E0_#(P2^^!GNV$%E\2P_#X8'EM$E)7U_*/")5 ^#]',!L1 MI>_]11@H'SAB\2;O>IF&$^!A"ME-^1@?KD/P>A8SX?@$L:+_8>5LN/\\Y;/H M****5Y,Q6$&)_)8<*BC:/#*)BFG%B^,0X+@4[6>K#4"GV,X==YJ#;\^J;KRX M$J%>=ZC'0-G-_0G+J9DWOY^)0B:N9WEW6YY>@ZQU)*>YA'DORL++.%A*X LK MD6Z=:^YBD)=W>'2W*.*V2-@4-T,7.0Q$ %OH?PP:2 4NY,Z?E??4X%(AJ$<@.X%'.T=*UC:9H84DA^JY@N6>2V M4O246J77HK71KBE M"S;!&%8Q]OL=3>UE0<1]Y@!G48./F58L [Q0ZH= H0%)JE[P!9T^^B;#6'G1 MZ? +F\4\,;8G+.AE?9?]WOMAK[[/M5NE0XNXT64\\RM"[@HCLIBJ(9KPTD . M%?,'.V 6S+)07?#.?QREHFTI.>XAAHFY[!:MY#@_O]8[+N":1J\NREG>G!(P M+B$2X>'1UV['AJ]BYF(>!95>PCALE,#-9Y%RD(,I9Y[T$%I>+2\M'0@V'*N1P" M5- ,12@X9E:##)OD\,L7MT<1J&4NI;^6REV.B$&]7=R(KWJ>(I>66N*+&.D- M.B6VYQFHO89XO7@^+P&$B$6@6^182'*TV:;8V.:]F&MJ; M5(@,I=6TB$WB8IL6(>Y?$:E*0KST?^%GOV"D#W=)^TK#;UPL;K&T:L*RV+R4 ME^0G;Y:8*(VTW>0E"E>O)C%IH'!]9GDIT:3-SJ)K5%G$Z!WNL>\D8,<"N'SJ M& N*:=ATAU:><4\#<$L1RDV"9UWLO'RQE^!9-MMY8C?">#RR M&%?O3>FZM10%Y=4.LE>3^5BN>OB_MN M$7I'^"4A3Y*(Q44\$[6A^+($:BZ.,M,NMCGG)7 M257V10H)SX44J9>8RL)?4W<:JR5A/#L?5KID_ *5)P62PL$ -N-3R&B"".4K MB\;A!9Z+/'_463S37T1J^25G]0!GRL4U?46H4P3$#'T9[I^MH$_Y@NYP95Y5 M%21%)F5'T*6X%!9W5V6@429K3NC%EZP*8)E1W>K/4].?0SF?1J2'W3DE+*G, M$5JYZ193;+C[RNW,11*B$RYSCHJ,M,IPF+)@4RR'L:/Z"^X[XJ:(=117_@N, M%BT+0?Y:[YB:+1;"7URW+5X^;8(O#$:4;G^Q** HX2".L"UOPB]2]F>"MY$8 M&K1RH<]KU?#*',C=,/XAO[)AWO-M@]-!"4?Q2H)*;7F]*Y=_^6+["VZ\Q_L; M3;R WQQ5YQM.:N!!-8:95S4+J#"0RN@:'_U+ SO NHG09-QZMK<16P-?>0QQ MPLJX#E Z>@G.K;L1.9QT)[GK;MK!-0UG:J#2,D.LJ+F5!E61#$-V,V:YR.M' M %9Q)8544WR3C"$@'J;B0$Y8] O)A536T\'JXA/28GDD,M(PAA-A4CY%(F)% M/,UUFBC/K+RXTDU UJD4QE2:7_Z;QL]AW<8$LY?+N$<45(?5@IJ=^AE4 M#),55C%/0,C1OA5S$38JM@]!XU81-J: M/%$QE7D)F.J)I[G$+@LLY;&OPC^B/Y4&+)84AD4)EC1G$6CQYB_+>4-[?]]-P4HYQ!&I0TFO>VBA,9;\BRJ(+PB\A!4Q1 MX8B@)I\-"32'D2$6J$"PB7_%E"A'+Q!*R-)R'X.M3,1J>:_/3(C95E!;*W2OU MW7-9*7=?V2V?ARC$%)=95!LOOEI<^8J6!)A3B(XF/$EIPOSNCL:+X1DQO:B< M4E>F)%:!19ZI2.')Y<3;RA0M^I+HV,)#R7Q8%@$:ZP])..01Y4[+ F0>VT:Y M*O?!TYJ+T_-3BK1)?CA!%>6XRTM>8B*JWOVL!BB!:!'UQQN0E2EK=2JT6]9\"BIN)6JC)2H5&9(<$;8]8)[D!A%4P"70)@E"_^7V-<;M MTG:,5CM&JQVC5?0^E<][^X_1ZC[>%*V#O[H=HK77T"C[QJ%1'S"B46[C#PIM MT&:*,5&7B?)#95_T^0AC'Y7'UD=QU98XPJ2I%N6[S@E[CK/1VN%GS1M+\V?A M_ZZ9$TUMVF]T+$O?Z=E3G4N )VPGT#2EPWRC-W=\FF[,T1N]N89IKI/74W^O MQC5OC\2N!S(./GGLL;[7Z#VW1MH:\9O[$3_=:QR?FO=Z8L,9KM3 MLW8[5O<@1NFS5Q3=_7AE*.^AY,7R=.7J1MP9UZZ;3HZW](YKF<^#M6SC('-' MGXDKU(Y];+'28*RTMN%];4.16W)R&JSK=AS'>!XJ#"QAS6GGC#8E-M/HS9V4 M'FOQTOII=PSHC=8RD=IX73/VW-IDIQFON^-EHW9FG(@9=N<#:E9K>S5$C39Z MU\GU9#-4C8-'ISK89JYN;VX\0?J%+CB,JBT14V MC2NE&E<;#:C4:$ 4P=W2_:!LD/GR1:UXL)ZBM%OUX\L7Y1>JI8.\9+"8+8/+ MVS:U-E$LO!46F5&KH]P[O$RP/OHAJQ>-%76=^_,.%EHFG1+:DM>6%3>4)Q$B]8'LLQ@H.Q%A!Y4,Y5)"0N5*Z+>8,B>'G M:S//1<\#.:RP+.6G D4YL%!.N< .U+! @-5GV,PADXTDD,#YJ$4QU*<8'G7I MSWCI[35CF8+=122;E6/DHF(JR]IK<=B=2#U<>05O3UVM]WY/+0FHDK:$B>C^ MQ5L2\1Y*U*Z-CO22.J3D2>+Y[ \3\_2:=6"RZK2'?9 8*,YPNE1"HDBM),96EKAPD M;2/;?"\ZF8"9%M$Q10> = )_E4.^J]I&:D:Y^HUK2ZTSPSG"Q)+5I0(V#2 N6WF[]'-=^&&@AMM&I0!^0NSC471.ND7E84\2:=^N<;PX/:Z"ED'+ MA\WFP[]%\V*D-!PCAN)WX$=^ $\(>U"V)R\56JDNBIYAQ3.5!EJB?1:?1$\M M5XJ&M[+%E!@U=;MU*FW3BLE6:ZM2U;'"0AW09*4E-Y1?6UTQ8<'HN+:SHO"X M28E\7#$JBW[.Q9!Z;*=>TTUKDQS6O$0\SPRG&Q;]S^0<<5)T%7NV:%%8@+( M2Y4'T[KEG:Z#J&6Y9K/MH$4!6C> M5R>-#6J[0#Z3^UAUJH&CQ( *A%P$%)\*,)'8B;%%5A)_H>&YE3;0LL$3[TL^ M1[TNFO[!2A(<5[/X$EM#GXD.0XF8[ Z++&;%V*;J^ZC!IQ@3M^0=T.6@^1+& M*+IDIS.RV@.V"*G7H90R4]ZWZRK&L!MV&A<#I6#%E]59Y-@S+1*-P/E211]T M'MZBNSLNETHG1%A0N$/>[CX5.V78' M7,0ACG\$]PLD+^\\'B^R&J;V$;K?ZD*W^/U)R=QOS9*Y;6#T)-IQ(?NCVN%# M#WC756(VE#9S!H(#N)@/X[F/YCC;HCG^OHG%\08AE?W\JGIR'@?A-.0#/I)8 M6G]BNV=5#:I\%'.$2+CP+_ 14"CI_+)+;C[C T$!#!7UR;Z%O%FD;(G]3Q\$ M7;*LB"^27M2,O53%('Y+P4=S%:)J[SJ_;O@6,E:XH67Q'_XD%)00YJ(Q+6_^ M2:L4(YB$@XSX%]J0OYV;_C22CGT)X[QH!LY7D,!NK=B&6[$?%W$YUJL2K#@->F9(6,+0]7O(FRS/_LC2,D ^")+^BF3] G6)NC=PB )7Y MB\"4$*%FU%VO1CK80A3CB^Q[R M;XOXH^U0."#>.+RLM'8K<5U> "SB5273=Y3+/).CHO .$PQ<^(Z(8Q<'*?MA M%ZVL)3E$]3[51?"Z%0T-%PWG.#!W1MYG5WB?J-*%\WA7NNVJNGZKQWH_ 8UTI<]C,'>XBXB_S#" M.4M\?)0_"_]+O5!1-&%GY23-A3B1S+W?X$62K O M*K93(1_X;7"YX\J;N(2>@L@!H8$#*M?\NY>;IMP(#\_>.97B;[$=$H'WH=XM MN(-3;K'C'#F;N"KW:>Q6X2*+">LW"]&7*U/9]I'CK;!MO+ =L\L$R4"^P5;WZ79ABA8-RM*0^S/$H"*RSAT9F;]2RUZA@-V,EE9B>?== MBWN+?O1 /T4 DOM0LS26+Z^.ZMGNG/B7(%:Y42*FWV7A7,;Q, 1+XU,R<=X.7+E=H27"L)@HU^*2^"\(']R?89E M@SBF3HJ7D++3YF&&,^O00*69",*X%RJ5'TK:[O^6OJ'V'!& M.+,I-X[#PGW&> O#+#R<"L2C]G+.8'E%1$_2*2YIJHF8 UAWN\'=XSE"/-Y$ M&0Z9_XUX%X0Q#F^%KXCTB]H&:.XY)1:RD+(E1(X!O+6J$?CD[OKC9;J"D -D M9A8"F@LP;KD= K8WVFT7(4^"D,.!?66:@U(H!Y874UT5G]+2LF)@6S$N$@"( M "(5V5GS_^MV(&)I=5XD/<[%-2$VD .'.3DP2:,B&9DC@M_58!R#Z[LJQ?.Y M6Y4[0O>GKV$43.$L]7O"+58I6O(UYWXOJQ035"NB7;F K?\99TRQ*]%8\R>1 M**1\\+\AS='U676.?!A16 A_KXV+W8J?2W[1EJ0R_VV:4QJ05,X;$;-NF8#* MIQ%>2!7S&"?4Q!A=E5/!:.9L82\@[U 28L _,15!;F+O(9Z4@#'(0]^^5EE ME%!23AB:5OFX9#T>G>41,3[3&_'!31J>P$12)!5C4.XI>+'$3Q(ZNKV-;6O=?NJ,73@7\^T#6<,!W-> M_6IX#KQ8*S%SXR%6STM9 N]+CWXHH@(RI_6A$&5X0]WINZ8Z[%MP'JL'*'-A M@9%AZY[6&PU,=\ 1A>0FJ.W^5LV*;%@W&+9G2TM(* (4NU8"H=SE-P]EB$5D M8U"F)Z.:O4!6DU+J*J8WA7$BDT]6(RR\ C<&*&F1J(LN@8C$T M4X3T+2_%'Q5C?(_)F*.1/AB,=$OU!JZN6KK;5UW'\533]D9=L^\-'+<+A&R8 MKW[U+-VI<>:M)ZD?_&)RS8)\QMY.0<(F8#"^*2.5'_"FO!"S#\:F VTX')G] M@>IXM@EL.AB"V($%M)&NP>>CX<#SUM@4?[Q,N&?TRZO>8C%C*MDY/"%+C=C7 M61BQ5[59B.W8T\.-/;6=_<>>ZOKCS3T]_+O;*9@/.!%RP\C2XI?G."%SHT*M M@:0=H-FP/L;O_&42\WA(X:A>LHA-0Q%!/8$&>V;'T[H[/7JJ'?:Y(3/ MOO7DGNQR7ERU8P*EOZ1&:,=FD_V>V#2?5;-.A%_N>]3OS#O/K?B^07SS!!7/ M^WCIS]"!.SGVL=V#3/1JWD$]]R"=U5N=LZ>)EL13O*Z@3-HI.TF..<@X\.8= MU-&?@I7V!+4-7?2>'-\8'=,^D=;A]SVJWO&<1QM ^P2:B+.. M?RU19^OE_;R.U_W[4^Q]PH"[.AZ/;=:E"'/[E1^MN'69/F:O8I640#G%XHO"HIM><;C9)3?F5-DE9_W-1&M1 M1GFCE_(HH@H9>V[Q9%I.)?R Z8^BDT!9=S3X"7/WJI5?Q5HR^U@D[Q=UA4&9 M]X;)LK#+?.I/BJ[*J<_;1@2A?Q7%:19.L$@"J]9@15=)EB%VA8(TYJI\*VM3>>:I&$MW:^&$LNI[,\#*H;$MM^^:)LO)ZGHAJ$?ZN#N;PHB/XKX)5A M(5D*>YWQF0]7+,+T;=J'J%[ 3.?R_$4O(T1=951#@KA)9,8;/]U+T9%:H@#- M\Z(;[LI.!2_@3_$\SDF@"V+0K4XN?*C\+^^J#1=@-X RKAF_@SK0>I_#$(< M_G*9PQNHP>A5_ 5VQ3%PQ;OTPPK7RS2QU)=H9='@KM1DLY@/;3V25ZMP'5IKS'"O8#/8Y%8L0'J,TISZ;N"W>XXG MAAT-""74P("C0HX3D%CJT$9DE2V-GDG#+YC17V0"(K)1BNQ2KS")5<#L/"X$ MEJQ94,@ZYJ>1_=$!X-B_7+1%$!11IV],-"3(G%'CYY*X>-NFER\J?+.1KD22 M907XO%<,Y[J7+VK<5G8L9=$58#80G68)O)(/"K*B AWQH>2!CL1CNEI$*)Z0L">[F$W\ M@,&:"!O*"19'W20WY5<0"S7F 2;!LM2R0+K@I@^D!C)2 MS%O"E0*63D!(E+V]@6KF6 [$:^++#/J-;_DNE97'QO=4S2%[MN'VJUWGIMN@ MP"OIJ;>=2 \F 5%^LS8D@-XA.ZGQ,APA-ABU$L&O1)7\B$0.0,?I.C"J!>25844[S2Q9G5C"6^.GU&>KNNRMV>*;<\5? M4OF1O3[Y?6_@[9X_H3]\[*M>^0E:L]8E;NP=]]IZS<-=#D^SC M$NB>L^TIPG=LNKSC59ZA=UQ+V^G94[VM-(R.[MTYA;@5U'?F XH)'UT^WS>) M2>LXVC-)=;0[KG<0WG_*U_BEY=BPO*"#;.SX1-V(8S=V8X^MDAY7 77W4T ? M<)3(J5ABIM'I6B>B>.YJB7D=S7TT2^S4%4[SDI,.L[/343DM1IZG'[1OX%>*IZYLV3-)B MI)D8>6YNT)Z!JR%;) P;=V\;2[1-AW M[]O8RNSG%;IR7/,T6.'>!WV\YG*G[D6T49(6'\W#Q].VOIYTU*IC'>9NK4$G M-+MMEZY&!"*:N[/343@M1IZG [1GT&K@4S\/WC8A"/GRU!Z2J+Z.<2JO!/AA/NG6.F'*4=Y#MY#&QQI\=$\ M?#QM\^LI!ZM0:Z GH.R:0,C+4::B9&=N"];X;YKAF+AEU>ZO9WS M*M\I^W19#_3]MOO;VP!GO7F/9QW(JKGKF?4G(YGMNGSC0C\-7=GIZ-T6HQLXKZC M#7>LSC-ZFR?U 60T76V1A-$D7-!@OFT3_.#A49[$"]:<04P)5NVF-&TJHXA7 M5!F8H%PNE2L67X%8O*:9AW!:OU,.U\)#TK0L+/D5 RCEV+AV1M)^,Y+<&V8. MK:FL<@[KMD<>ZO-'>W5[K]).2'H6N&PG)*T>N+WH.N9%5\U*.1D?5NNXARE7 M:\X1C8[N/-K C=,-W>Q)_MP@/SK=WS>D;G;T4^D(=Y> ME)R41&\QLHG[]KBZ^E8W^_'WE2N>;SML]U W3-J>%TRS.+I29^$7%HCL:N5R M"<^6]TQTR]1>'^UW?63;^U\?Z?KCW1\=_MWMI4-;F-,6YCR]L-1)WE?@U OW M:;LM<$3'/,G&."=%_@,_\@/_Z'1_WQBEU3',$^E*\ !'/0RKMXKA"=]7Z"=2 M'=?,,%NYJS*'O/%CCR+;H:ANED%J=YPCZP;UE_%D\^ M_PH/*S\7#TRN69#/V-OIZJ/GT31.YE12TE^*/Q:+*),XRN"7]VSZRRL6SSZ] M&SFVZ]BJJNJ.KJG_ ECIGRX^##]YVB>,5()XTC]IKY0P^.55&'S2==>U=5ZJ3Y M?.XGX7]AA7C!$A^AI:0<0DI8@@T>3& )+,;)L Q F5/VO\(PZ5]9C^TJ""B: MV(>QS Z?W8L!TSD/IGI02X;7W7C#T_[3NP)]SZSM [[F&R\YMS1*.C M>VV%3MOX;L<+H(ZCG4@JQ'W/:G=BQ=@TCCQAS1Z-B/=X5XZOJF#9.T&&DF1IZ;&[1G MX&J(S7$FH[6&G1"\S!#:)Z# MNFE#)"U&FHF1Y^8 [=V!G[:U](1C58[[M%M% M6=9)MH9MFJA^#K$J[T0XX?XI5OIARE&>@_?0!D=:?#0/'T_;_'K*P2K7>>JA MJJ[7=NIL1/BAN3L['7738F0/[LM6N.^:H5CXY95N;^>\RG?*/EW6 WV_[?[6 MCF9J1S.=0+AAS\@P67QBJE\;$6[&GI^V2_*$(\*ZK7<<\T3*#>]2>B>NX\S&:;/M^(P%]S=W8Z2J?%R";NVV6T-\G"+V&V_(!;>_AI3ZZF&=I0'ZK:>.BIUF#DJGW; M]53'Z0YZMMT?6Z9U[&E/%53?,NP)!SFE""PE7O!"80$M'/2$?X4EIF&29EO' M/744.:;IN4UALMW[36%RO?VG,'7;04B-O3$0\H;>W=X*'*D[9YZEF1\A:RH@ MO?[I1[F?+$N "M%T=%?@WA&:CM4]R3GOCTL]>P8J?TM\8./@Y*A#?[SV>4]) MUNQ)+:-O+)F$Z0G2RW=ZQ[I[;/O&;JNM/*E1R"),3I$^C#L74#PJ<9RX0!G' MR92%IZB OCM0[^;G$,MKKRN>OMZXGQ>S90SVR4D)JZ,_7A>I4Q<3;8#Y_@'F M.\:&5V+-&U?I)> [7C&,4?>7Y5?>^4O\J/?53P+Q#G(RT_/H'4O"./@MB=/T MSL'G/ KY0RF^,7VE!&P2SOU9^LLKU5R/39N#GC9V[;%J]_N&:CFVH?9'0U?M M]0V]UQW9FFEKG[KX+N/5K^!4PFLK<'SX<]>0?:9[)\ M^!B]I_7[NNW!Z7M>5[6,;E?U-,=1^X9C]HW>2!]8SK%C]!CSKK)A* 52CC\( MV"@5X!"UYX78*KY//YR5GRE_,R7AC_V7*8LD#O))!B^14Y>5K]#9A?AKC TO,Z\W! M**(OIOX,'HFGN$J>*&\3_U]Y./F,T$OSQ:9@=___?FC(LT(*;=&'"6P B$ ?YD"Z'?S_]28.<9O(0@G;#,#V=*EO@!Z\"VOS(0OK!*IEPA@PE, M )HS 5@XY:( 8I8GD4(:.<4%X/,MD$E4&5I> M$B/ 6I(38:K)Q)1@,^ 4<9%1'OT5BN.*4.@H<)"4>%YR%E$%XF4"'JK$1X=P M*0D(B:'.B),XYO.R@ K\X M+,J*53LF='3ST!S>%UY\PY0 M<, VX5 A$A3*I12-@C %M:]<+A7 IL]E5D>Y1-VDY M %=%0E*&L^0(,A6(* MG@W+.V=^-%P]^#><#YX#ADG8% 66\AD@'>%601PB1+OFJN #-O#A-^1JXO$IQZ#$ M'\H%E.J%W ]PCRCA8&WRZ7P\$ J(\@0S?)Y9H_#57_+LRGI=;A8H#C!,P-\ M@QG^PHDB52Y#4!B!$%T5P>4C\2[JNH)6X")S1L>50L5'@PN8 ,XL'DG1T0U0 M$'WPOR&\04>1F@+ZN8J!;".$$M:;Y-DUR, L1'I-\\DU+B:X'LD?S.J3J+,?/2$:N[#-]')"?1\H_\XBA*VEQF8M7F$0I %X?O$X@^@05 M,"B6N7+!DB_AA-.BV.4N8F@0J[#"/"XLED(6]:X2)DV)KV%VK?0N+_\*F=+W MK_TY0/5-%IP!]("0P4A8JL!O2+'Y91H&H9\L$7OBB?-H@JC[3DA,.-#@)_ZG M\I/A3]]WD&QVW?T[Q4)>C@KX?>!D,V%-/D883!0NH>%'+_4C7 D>GOO) M9\:M.<$KPJ \,*317HRR\#(.E@1TP3'*Q[.+L[HE&>2))%B>M?2?W$]0JI'% MCRXBV<^ /#2@A09"YT&J$)+7I,'O3[4%?YPIPV)?+U^L[4SP]&NS8]H&GHVT M1\K3L.3&@+4JVAT-+\""_%":"(3$XI%;+0 BWL>S =;DFVZ0?.N2?/N*_JF/ M\00\FW!VD.*!OH 67^M:Q](T. "*/;)IISF/H H<"OH8L@4 FJ0@@/IWYL^ MVA%XO^>PNT+-K>J3WW^_J"D3Y2WQM91]O30-,62;P0(3=-$2RIB#5=XE^$(6 M1-R>#L"%3\'^3"NZR?LI5?HAP#T@'NL%7] @I&\R#/T*E3L$/,[B!6V])^R0 M97V7_=[[8:^^3VG\%-[>89AS=!G/_!I[7F%4 ;B3&_&4+J@NX3P=4%6S+%1! MLJ"%Q1')A3@)**)"D%9O]8X+&$88\N3$M()_]%2"@ (C_@R6>.UV M;/AR%A,9*!/P/'Q@@ D(1 (RKI*PJQR $P.N2A%Y!N8$/'\!?C I0T&!!%G@ M1''EC^\3&9(H19,80R7*:Z=C2!HL=U,2(D^A!,E<(A+.=3B3XB:D].8\.%*A M#Y)S'!^KSH94!SO+$CD=V>%#-5D<#G;M$A;M_ M@]1,A=AT:!TA/RV#$\MKRS70RTP7W,ZA$(.P3*KN$1PF$C$34H$E.![-0._E M5^#BE$;>BA"4CF)-#MI$^-OD(*?CNE )Q/ME_\+/_LEQ^YAXZ?A-\[9=7U7 M9?.*5UOE]6V<[G2T=4Y'JVB=UY777HW3D8@8NF&%;5J3"]+W8M$U"EDB5Q'$ MN%TTX!V] ":0#@O1J(7?*: 8II43WJ"&2;S=E7F0(6"!AV4>R3O ,K9EK5@6 MVQ@#%MG"&NLW,+<&]E%/Q!!B;\/!*>^[WO2<(TM@S=^?3Q8GC; M98EMV3US8'OJR,5+@FY?4_M:MZ\:0P?^]< V<\:?]$_NJU]A"T[]JF3K"1[V M*DDDC&!39'FOTKRKI"Y>)3WH3=*&8^\"UZ-2SVBD#P8CW5*]@:NKEN[V5: 2 M3S5M;]0U^][ <;M /28 IZN[.X#G82F',M.XO]E_6HX#THY&XY=A^N? M<33QT^NWR3L0C>*7WN0_>9B2W!KC[5:/>L[0IR!9]4:2E0&@\^JPN\/1.&SB M-$]^' C=)F1Y.@9C8B T)LBY]X6^[)7*ZIB T2RC.[",OMK5/0#,T!NKO=$8 MJ&HT<,?6T#1[ ^N3@20%.H[@4/01J8SLH!SQ@.U9X) 6EA M]49FU]3UP2>]A(I^%ZB@#QZ$LQS9Z8*!;4XB922NATCZ@&++,Y_SW\A/(C > M4UB/]!IWVN\#/ML <%FFIF/SQ#TU]U@?][WQ>*CV]*$&=&-:JML#XO&Z>+OIN:YUKYLUQWIXY$YME1]S+..4#N9NNH9>M?K M.K9I]HTJ@1G="OAV/6L=0N^2>,)80&JMFN=6E*[< S3 $"2G#5OW[J:K!N98 MUST/ *+W@<\X M9(QE&4/50Q#UNK8SLO5N=ZBY!6#<;CU/\1Z'?B ?:P3F<[8LN36EG(\/UWXD M2/0OAODD]W2\;@#U;N)\V+<&8!8/5&]LC%1KW+74GFV8JFT8WECWK)X[,+@C M9JY[$\<"SK%04M3>G Y6P)>QCH23->@<"RWUI.'FXP3];G>7<,[# ^>29PG=X%4[D+EK/5 MTVW;Z ^Z-MG+!H*H"IX]#G<4I@$O MS2NS&-U[?UGJV9JF-H8]7J XGT1^"Z M6X/AL*<-1_K U=2C9.U,HQ;P/'&UJCPLII#9PF(<0Z$D*>BG5S<(2@=6,\T%W> :R;'=Y*_X,,6.B! M^T2'JF#'Z)!C>CP8Z3J; HR&.]0=RU'M@0U:S 7'OX^!M.' LISNP!@-3+,0 MY>_T_WT (&\X[BD!TM*<[H;RO5T!:1 @S:, N^<- M1K .AX93@<8N>UZ+)RY8DBW?S8 WP:Y")J8\M@<_)%*!IHF;($/7-X13^TYW M:!@#U>T-0&SU![;J=GM !4.M[W6'(TL;V85Y^,[XWUKD\+93-.'8CM;U[GAL M0Q*_H9W==CA]$7$&P_GM,_^(5S M*@1*,[Q0>-"#>CJQLU:[>]KI[L31>D.KYX 'Y/;!778M (/1UU1G8)MCQ\:B M[4'A+N.5I>'^_,.-!WL4\\DOH55T#T!^8VG?#CY32A]IY^ (%L]]_T$ M.$>X=7KGOJ< )S?C%/%]3PE. 8@[GOO0(KP\Z8%%>)E]HVF6M9,(/W)Z&H+% M&[QZD=.- W M4-A@>9AWH^WN:-QUX6FU/Q@!)"P;S)F^/58]W3*[W=Y@T+,T#@G[U:^V4;_G MV>5T&]L&W8.?CWIFI'+=M;3:J>49ZB=[RUMGX"0$+ =Y<_=.4<<^I(GII2M9 M_QM.LZ*T>;PE_1"+!.2MZN]$H."]^M5QZU?TNY_Q$9C>[-J:TST@5$B[.P@5 MLRE,?YPS@\B'!S3[D9C^.(>TX)"VYFF-Y?HCX9J2%1^$ZQ^ RKUNEXP6_,\= MTS8L;S"T^F.UBUZ+-0:;IM?O 0SL@=,SAVC=685A@R;Q#D3^< QT,NEJNUW;V>%@ RP7B@+\!ZGUBS]#BN9W(<#; MV+N/#1G_=X_#HUL)4N/0%2_&)P/TCF774;C/F>K0&%'3G+?3T3?> PS=T;?1 MYO4:"0T;,XKKHGJ?,]6A\1N+0,JC^]D+YN"*IAEO^;9_V>[] ;!3V:Z!MIG= MM>HIU;<<8]4BFS*LK!ZS !^B)DWPY)L8_/ /_C?Q3!^6G(;[J*[](+ QTN+U M/:<['!FJ-1P!^\.K5'],B? M0%M^6L]FV'#)OB/Z=9=B3%:%^C<=XJ!&^-&8'0TSU60 M/ :>O=OP+(ZQ6KPV!_!< \4#^W/+]4\&HA$8X:@([HWM;J]G&ZH]T'O O[VA MZB&"'<.U1L-!O^OT[4]T]=_Q7&07L2SA\7G PEK(&"@ M:WOE?+5MKQ4?4I TE7V3CXJT72*!)'Y-..#*H>K[7KFDC!,67D4#ZEPZ67Y( M_"CUJ2_';WX8H6O59U/XSK&I5.M9IC4:6>K8P/M+#PC4TS5==?H&:"+=&G=M MD7ZBFE8=BWL<:5]8?(S ;IM1#Y,&RF2P1E7=TO<$1GFFS<9(J:@?HN+O 4R1 MG4K<5A.X]SC-9C!P<7<\*^P>=. B';@KJOG&4]S;WSR:V*:R,R%GP)O0OP]F^=Y1'HUB=>D>8 M3EUV[7*:%:<1&U:_2^)C,^:.^.UBS&?5J*KL>0V9G%=Y74X3\6:"D%VYC5C9 M]99 M*#>1HH8'2/KCJW7S[6V]94F/RR[4W#]>*>R@?BL%5.IMNM-U(>?\SX* M$9P]A^,+.(#"Y%94!=^C;V!H4J-9VR>8DL@-#]CZETF\RP:"1YL#-75 MG VT?! 8K%$/!L/>\9Z?07_Y,45=S?,4L.M;D7>Q:1--E R&CJH,X+M*;_Y]S!!*.VN.^IO2=V56DD9-"5 M-JP5T.QRFLUWKT"$9;WLVRF0ZES,16OBZ0T+[QG=E6XPMQYE5]3#2HW%._@< M3M?=$>OB(+>=FW@G#*37*4PF8",26[PC8".!82 3V+< 8Y?3W08AE!\1CKYJ MJ$.&ZMM;R;NX\10;#LSGVPAVH0!\+\N2\#*G 8L?XO6RN.K(B'M#9;=*57VD M&:.AUU-[_4$74ZF[JMNUANIXI'FV9O>]/E::8-S!-C9PR;W.^)!9.L>SE-$< ML;T]$_&V6'YC/JWD)"UZAZ^B&LC^6G70-:Z6MUH;-UX_W-\/2%!;TO@ E7+$_=,VW-J:NW/<^T$T#6GGJ@+*B'!0<00;=KK73,W.M$J]>/?$05 ML$=E/%6#K^TCG=\$''6JJJ_UZR'!Q]K<#18=.E.OBR6?<2Q!M4S?[JE@7]9;7JPL0:6 M[)-XIM]IK,&Q&]>O@>\8C>LI1\URK;IA>(#.]0_9EWT54L?K2[Z:0G[LCNR/ M>7(0NHYI[JUSCM.1?0M@CM"[EP#379G:=.".["<"&. 59Z=!:$=M:KPC1!ZV MJ3%I(F]#F^PF-C7>#*%#-S4V>>,/\T':&N_TY%_^[,Y!VAO@L@NZYR@]%Q[SS%BT#>)HI^SS![O-/?8A3>JY4->DC]-RX3&A MX&$$9',^T",W6MD,E6,THJ!0IZ,_0G>EQSRSCM.85U)ACL?SQSDCEO-JGMY8 MGC\2IO$.3U_)D3]BHY75LQ^OT0I1N>DZNVBVASO8$1JM2)WM[,*_#W:R8S1: MX,/ M/WS]^O4L99.SJ_C+#X/S_P%_ MZDZ]B,_^C_$R^JK+XSS\(Q#T,%@6?G1H6*>,X6?[X\>*YX8L+_%/# M5]$-(T<%^C"8^)OV%17-*<#!Y7KG; J0=S9OXL42=N9D\! M=97TRBK7/4^T\:244T+;:+Z8Q4O&*ID\SPQUM9RS9J+N?JEI_>7F!2JBMU) M+;*Y/E(%V)HR[46!_$M%[:**?6:!G/TR/1M)5FMIH?UEGT63Z[F??*X+B972 ML5LP?9\-K NH09YF8(DG:U]^J%W\X?\[3N1;:DPA/GL;/2<_X."T>G+0N;%S M>R,YNVF!>&#NM-/Q9\37BVIG M(RFG;%6SP7=D";Y@ E!*WTZ';!&G![T+:" &VTNY4T?@C=.9&XK0AV7)G5_\ M'@5V_7U_^-_">7[(6Z33H)G*[/)&TLS6%-Y-,<%QGD1AEB?8X7$=,/O:UG2"IYC$% S":9%U0JJ-!W[.K<.SIXT$T8MS;0.3DM##T=# MK8/3$M$]B:AU<%JZN1/=M Y.2T![$U S":9%5:TXP$386I1787IX/6]I3E,3 M".]09O50#/Z7F#M83T#>V/",[S*!'5VS#U_CEJJ0JDS7=1J:('=Z5'78U.^F M4]5SH:*GB<.VC/=IX+$MXSU9U+5EO*>)MK:,]_10!]Z4B:AS7=.@>A'3-S@?TDQ!&H[P$5*V^+HR".S@'T MR:4??7X[G3(<@PC?>W/>?_O,LN?;@O#F%X0WDFPV%X2;KFV[IY&1*U M2.7O<:)=>K#*\#9#8X=>!RTI'[^WP1.E+\,V;?NI]]+H3:AX&TANPL(O:(^= M!,F=2CN-II%WL]II- ZG,5U6S>:!YZ=NXWHQL' (WJQN(V$CKM;+Q;W8- A MUNIJ'OS0,.AT5PH<7 MX;>,L>C_6!+_&=ZJ?_:(J,QR?F94RA)PB=>5[_KWBXD>.,MC MX"?)$EQH#/$UPWOF7SLRJ;:D^;31+E3_;89_,\G@R1OZ]^ME)PRCQ[.?=&X@ M (TUT$# @^]@(/"O'4[J&F .4'^*F M4!E'PTW;&;(16#!TUVZHO-L!"X/>B6.A[=W80'2T'1F;@0[#<2R/"CG,;D.Y M8\BF+,%<'G[!6>EIN.XQ?ER,P4S+Q'35RE>?!*[:Q/9F8Z;-E6T$,@Q T7D M/(6S(?L,EOAY=]R'T0JN+)!V3^DVBWD*=(/,+=%OWN&V]2L M-S^][D4!_H/5RE_\66FN%$D-<<26?_C)9Y:-\^C6RYE&T6[SZ>;1X[3'/'.W M>6?N'OK,[?"4^P0ES>/BI@U\-0(+;>#K4;'0!KX:B(XV\-40=+07QX^-@A,H M)SI6^ZO1!B'PDA32+"@Y_9T;J:U:PS ^-U5C.IX\7P^)(<^8#A[)?Q=]^A+_]_(/\D"^& MSZ^LE&(GJW1M$?[Q#L]7=O()-OYI9;T@_ (P*L^/S_V9S[%:-RZ%TRZ[Y[#9 M_#PM.V11/ ^C;0MO.E&YYOK#/_]0V?O&HX,09&N PP]W !M:B)_. ?%)CI)Q M;1D>:J]_:1=T7.0+D+TLV;R@_.LN"W&1O64=_L'-D[5U;<^*X M$G[?JOT/.KSL;-42($PR)ZEDM@B9S*8J$U) MO;LRY2P&U"-+;&2G,#Y]4>2 M+QAL%!O(#*GCEXEM]=?J5G_6S:+GXO>Y[Z$GX((P>EEK'35K"*C#7$(GE[7' M0;TSZ-[>UG[_^/-/%_^JU]'US0#]Y8 ''$M 0SQGE/D+-'"FX&-41U,I9^>- MQO/S\Y$[%@X[;9L-D\/VF>'[?_3DNSV8*3R52B=\ZO M1AA=,TK!\V"!;F*K?D-W=]TCU/$\U-?" O5!&PKN4:1+A.ZIIJ+BLI;R\;E] MQ/BD<=QLMAI_?;D+FZ'V\T\HE#V?C[A'5A#Z28QI-P@54AD!*8A'Z#<+0A>/ ML$@CYAE(9%;K[.RL84I3TH&H3S">)?)C+$9&.BI0U;1.Z\U6O=U:1JTV0:/2?*P+)!^F M"C3B?08!:#]$E^;40^@1"YJ/",HUK9W 4$T?DPTR11K4R*$&*,5#U:CY0><.X?PUC''BJ.?X)L$?&!-P:PE)R M,@HDK @$="GR46NYP)0R:3HIMJ$%&]?,";29F+J?J"1R<:M4<]]46$/$O:Q9)1(C8C-<4-TS,>:VFBW5 MA$W@&>*?N(W D80/.N.J.J=P" MN;1L,RYZ&D=C/T$:*&L-F7KC9)AY8,*8TO6P$!&G=+CZ"O"U(, >O;8*6:(( MZ>&/"N81/52ZZ I[>J1!@RF %%7H=@O= U8]MIR")*IM2L?1H%\(YOOBP43O M5LSYM0IN@>#>JEFN#_FAB\KL 3JQ!2@I$(B-4:BO"DN!L/04BWF7^N.Q9W%+7<+!D?D1S(K90_>A1.B4:F1T M5P';%+![)D$,63)6+5NPQR>8DO\:9Y:-K&XZU'U(.9H:Z);@:R(<3Z_]8 AS M>>4QYULJ_-^Q4CN9_JWGN E*W0RG8-YX3!<59\IS9D F5$UP'$QEQS$+8D(G M#RJ(#E&(4DPHJ,H>W[/U^ X"W\=\H7N'5 5H60.*JZC"7S[\43.*![S (P_4 M.ZN>\ #<.X)'Q%/&PM8]P[:ZK01I-=<)$BE%G^8S->17--B&!M1/6 M'L;6>AB['%PBT0UV-#6JOGR;OERJ=I\RSP4N/OT3J%;4LMO&M;@V>Z2/,SUZ M2O$O*%1=A;M\N,.5S1#/MXVP58$]J.WUH(:Z].>EJ@?>)IAJ"NL3&8Z;U%43 M:3VU >KL,/Z65&D/^/M,?[W4;O::5_17#-BB]X:)_MN'&>.Z);?NMPOHL[JB\+W6'3%#_:X^$I4V@EPNOTB#+V+KZH][5=CQE"OI_;) MBTBAG14?=F%%6$/%B>^W1B]!DMUJL+,FLV&WOEZON/$]EGQENHR2.NWQSV[H MY2S_*@Z\[L2Q3/0+:[/&_3BS3V>;1%;Q?_D04=*6T;#;&UO']H[K&C.QESUM MM!=5]O!G]O=*3!;4&)'4N,J2:Y"85*E*^,)PN._:BR MLR2[-UB&)7&-X7F-I,Z*)GNGB?[ &H0>BM[X"@OBJ$GB-?$"">XGS*F2%0_ M!U/,83OZE*O"3JO,[F0I6J4MT0ACB]GCBJQ!L3E(V8.,017G2G N6@'$"X!E MQ[%6L$ZDPC@[.S);F9D5R6K7DEVP5+$N'.OPLU[\5:_0I*0(Q![AS ;FVL?% M:H:QEZ$CLTXL-NLK.+\*G%.1O3HX%6X9=";F6-?CB1/2N;E ML!?28F=!=DLRGP6I\3^J[!<1RJ*P/A176#%C/\SH@Y"<.&JV9(0ZSYB[6U## MJL;.C-?S(:]V8ZGX1Z[R(9_::/JQJJ0 M@@*-%FAI&-*6_3]14?^CLZCT88Q,@I1SG2#DLB:(/_.@%CW#W-%X>VJ5QHPS M]:[K4RV-6&VL((->S>5BZ+W6?I%5L88IA_%E39.A'N>J^*H01W/?BT4DD;J6 M[E(/THK$;PA[7JUQN)ZOAK& XPJ0X_AUHN:-^.WA$7@%75:R.2[?:0UOQ-OU MU[R TPJ2X_1*5Y?C^T4CG6=%W:WF8;E0KC,N$NNXWFX=S84;F5C&@F5+E[,@QI6UP)K.:9,-IO[<_%$-\*1(=-67 MNLHW1V[6IT*MDD;>AT#=+&>Z65JGNUBRG17;F9";DZHH*V* KO2D-!'6TX'M MP /]I"P-7DJO934G#Q??[&9(3K*N8I:D@NY MQ K5GH#,U4[.9[.2%;(@!8NNZTL5Y:W()#DK9,02%5[6EPK*F["6,ZV0 3%& M7^Q6^5KVM6*UQR!SM:'^*!V;,>"RUAF-_B3P!?P1\'"UIN<,7U#D.-! 9V+#W!6/,YVF9/C,AE,6"/5P0.82 M@/X-G-VK55[6N^UU'%13))MH>GM55QPM3F\X\[MJRJ*S5JFE@7#^"+Z M>I(<'PQ;8R87VJ?20WJGX%?@TGY%0[8.I:L7U32)I-L16;;^21B:GPA@CEV'\ \R]8!IS(A5H*@[8]KU&* M0],MHM\+.OGAU'[!>/,CC_(^1[#O[*\KSZ<*R9U@9%I\@^>!D$RM$GLY512[>(:=Y(2E:9'"B)W]3P:N MUW/_"Y[KV<5.%-E!QYN@2#PQ&4X)UQG,]6G:V'-(B8/-KU"&YD]I@N<(BLQ63<:R@_!MR4>\KE74S MC3DD5_N@J]=]_B[=YTY:WD0'&O[G4IT)!_-TN2UWK>:NZ9:PRZULWJDG/V[C MSK"R#[. .U/%UP>NSY/Y&5K;Q7X@DR\:X<&UL[5W=;^,V$G\O MT/_!Y[[< >?82:[;VV#3PODJ F1CP_:VQ;T4C#2V>2N+/E)*XO[U-Y1DR[)% MB8HE4TK[E-CFQ_R&P^',<$A^^NEUX;2>@0O*W,OVZ4FOW0+78C9U9Y?M+^-. M?WQ]?]_^Z<=OO_GTMTZG=7,W;OUF@0.<>-":D%?FLL6J=4T(AXVT'JC[ M]8D(:'5:<\];7G2[+R\O)_946.S$8HONE+K$M2AQ.@+X,[5 =%N=SKJ#7T)2 M+EH?3L[.3SYL_3)BOFM?M,ZVOKKF$/9I(S7X4^_TAT[O^T[OXZ37N_B^=W%V M_I_MTFRYXG0V]UI_M_X1%&[=,-<%QX%5ZVY-U3];#P_7)ZV^X[1&LK!HC4 2 M"O9)U):S!HBL<\5E>POEZQ-W3AB?=<]ZO?/NNF#[VV]:8>&+5T$3%5[.U\5/ MN[]]?AA;?OSXL1O\&I86]$($K3PP*V".!H$M90GY MJ;,NUI%?=4[/.N>G)Z_";O\H._S$F0,CF+8"&BZ\U1(NVX(NE@ZTH^_F'*:7 M;29\WI%<[YV'];^[89:_ !>AVK>N1[W5O3ME?!%0W6[)=K^,[A/D,TZP%0CD MR(N$KRL+=C/;ZAY*Z0AK_C[V4,ID'X/I1EJ&3%#9Q;5#A*!3"G91PC5;/2:$ M(>%0> *-.W-P:,6<E='IT['*!L7T'I*0_XX PCE]6C3V]TZ-C MEW/%]P+&B\'TB@AJ]5W[ACJ^!_8MX2Z6%4/@XSDJJ:IY4HR8$GF%I' ?NWA= MHM+8'IN='][. .T>2D2%EB#.KSMB40?7_I)GN$[C94JSQZRO<^;8: K?_L\O M'X]N!Y5BVDP3.1.(NQ)!D<%2]MRW//J,9%Q, _'7RJ%N-U^B8A"DPK]W-+-AMR6R]2.;+&@GC3 !"XRURQ8B=#- M+]\8*MQ3B2BO?$%=$&(,,TG 5B\E@RS:T5$P;F;"8"F#,\CVJ R.0U\(\"J& M7JC_HW!DR$'(B(#\?S"=,(\XC^"- $U0'Z1X/C!W]H!^4TB?N%K]#&S&R7*. MMA@'4@67#J:I'.?ND7D@)FSCJ&\<-#'@,^+2/P("&O^FW'FR8D"?G^$R(>JV: M!1$%8DA6LD.Y$(0>X ,E3]*70IHJ51EO):"FC"E;6 XCHVHFW<"35ZETJ#JH M7#/L>3&R;*50];NL#?C2-6/!CJMFQ,;_JW3@,WNI&F*&,U@IZ(+]5B[RH1

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end